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SUMMARY 
 
 
 
Nitrogen is an essential component of living organism.  Protein synthesis and 
biosynthesis of nitrogen containing molecules essential for growth, such as 
amino acids and NAD, strictly depend on the availability of the nitrogen source.  
Limiting amount of nitrogen limit cell growth.  Exogenous amino acids and other 
nitrogenous compounds such as ammonium constitute the nitrogen source.  
The budding yeast S. cerevisiae can sense and utilize a total of 21 different 
nitrogenous compounds to sustain growth.  The uptake and utilization of 
different nitrogen sources is hierarchical and subject to strict and complex 
regulation at the transcriptional, translation and post-translational level.  In 
general, preferred nitrogen sources inhibit the uptake and catabolism of non-
preferred nitrogen sources. 
The target of rapamycin (TOR) is a conserved Ser/Thr protein kinase 
among eukaryotes controlling growth in response to nutrients and growth 
factors.  TOR is found in two essential conserved multiprotein complexes 
named TOR complex 1 (TORC1) and TORC2.  In yeast, TORC1 signaling is 
sensitive to nutrients, particularly to availability of the nitrogen source.  Thus, 
TORC1 by promoting anabolic processes, such as protein synthesis and 
ribosome biogenesis, couples growth to the availability of the nitrogen source.   
The sensing mechanism activating TORC1 in response to nitrogen 
source sufficiency is only poorly understood.  Recent studies identified the EGO 
complex as intermediary component of the amino acid sensing pathway.  In the 
presence of amino acids, particularly leucine, the EGO complex is activated and 
promotes TORC1 activity.  The small GTP binding proteins Gtr1 and Gtr2 are 
part of the EGO complex.  Gtr1 and Gtr2 form a heterodimeric complex.  In 
response to amino acids Gtr1 is loaded with GTP and Gtr2 with GDP, leading to 
activation of the EGO complex.  Several factors determine EGO complex 
activation by dictating the Gtr1/2 guanosine loading.  Vam6 was proposed to act 
as guanosine exchange factor (GEF) towards Gtr1.  The Npr2/Npr3/Iml1 
complex was reported to act as GTPase activating protein (GAP) for Gtr1.  
Therefore, amino acid stimulation of TORC1 is decreased in the absence of 
Vam6 and increased in the absence of Iml1.  Several observations point out 
that EGO complex signaling, alone, is not sufficient to explain TORC1 activation 
by the nitrogen source.  For instance, 1) components of the EGO complex 
signaling are not essential; 2) ammonium starvation down-regulates growth 
even in cells where EGO complex signaling is hyperactivated.  Therefore, 
nitrogen source and amino acids sufficiency might signal to TORC1 via distinct 
mechanisms. 
In this study we analyze the effect of different nitrogen sources on 
TORC1 activity.  We use the phosphorylation state of the direct TORC1 target 
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Sch9 as readout for TORC1 activity.  We describe that preferred nitrogen 
sources activate TORC1 signaling stronger and better than non-preferred 
nitrogen source.  TORC1 activation by preferred nitrogen sources is paralleled 
by an increase in glutamine synthesis and accumulation.  Growth is increased 
in the presence of preferred nitrogen sources in a glutamine synthesis 
dependent way.  Therefore, glutamine constitutes a metabolic input linking 
TORC1 activation in response to the quality of the nitrogen source to growth 
capacity.  We find that EGO complex signaling is dispensable when a preferred 
nitrogen source is provided.  TORC1 activation and growth increase are still 
induced in cells compromised for EGO complex signaling.  Taken together, we 
demonstrate that nitrogen source and amino acid sufficiency act via discrete 
mechanisms to activate TORC1. 
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NOVEL FINDINGS 
 
 
 
• TORC1 activity is rapidly induced by the quality of the nitrogen source 
• TORC1-dependent phosphorylation sites on Sch9 are differently 
phosphorylated in vivo according to the quality of the nitrogen source 
• Preferred nitrogen sources better sustain TORC1 activity over time than 
non-preferred nitrogen sources  
• The ability of preferred nitrogen sources to induce and sustain TORC1 
activity depends on their capacity to induce glutamine synthesis and 
accumulation 
• Glutamine synthesis and accumulation constitute a metabolic input 
bridging the quality of the nitrogen source to TORC1 activation and 
growth capacity 
• The metabolic input activates TORC1 independently of the EGO 
complex   
• Amino acids and the nitrogen source activate TORC1 via independent 
mechanisms 
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1  INTRODUCTION 
 
 
 
1.1 TOR DISCOVERY AND EARLY STEPS 
 
 
1.1.1 Rapamycin and TOR  
 
The history of TOR starts with the discovery of rapamycin in 1965.  Rapamycin 
is a macrolide isolated from a culture of Streptomyces hygroscopicus found in 
a soil sample from Easter Island (also known as Rapa Nui, therefore the name 
rapamycin).  Rapamycin was initially identified for its ability to inhibit growth of 
the fungus Candida albicans, while it showed no inhibitory effect on the growth 
of gram-positive or gram-negative bacteria (Sehgal et al., 1975; Vézina et al., 
1975).  Later on, rapamycin immunosuppressive and cytostatic properties in 
higher eukaryotes were uncovered (Calne et al., 1989; Collier, 1989; Thomson 
and Woo, 1989; Tocci et al., 1989).  Therefore rapamycin had to target a 
cellular component involved in cell growth and conserved among eukaryotes. 
For more than 20 years rapamycin remained an orphan drug.  Only in 
1991 the target of rapamycin (TOR) was identified in a genetic screen in the 
budding yeast Saccharomyces cerevisiae (Heitman et al., 1991).  The 
rapamycin resistant mutants found in the genetic screen led to the isolation of 
three genes: FPR1, TOR1 and TOR2.  FPR1 encodes for FKB1, a peptidyl-
prolyl cis-trans isomerase.  FKB1 is the yeast homolog of FKBP12, highly 
conserved among eukaryotes.  TOR1 and TOR2 encode for two related 
Ser/Thr protein kinases that share 67% of identity.  Yeast TOR1 and TOR2 
probably arose from an ancient Saccharomyces genus-specific whole genome 
duplication, since only one TOR gene is found in higher eukaryotes (Wolfe and 
Shields, 1997).  TOR1 and TOR2 are the founder members of the 
phosphatidylinositol 3-kinase-related kinases (PIKK) family.  This class of 
kinases shares similarities with lipid kinases, but members of the PIKK class 
were shown to be not active towards lipids.   
To inhibit TOR activity, rapamycin has first to form a complex with 
FKBP12.  This mechanism of inhibition is analogous to inhibition of calcineurin 
by FKBP12 in complex with FK506, an immunosuppressive compound similar 
in structure to rapamycin (Schreiber, 1991).  In the absence of FKB12, 
rapamycin no longer inhibits TOR.  Organisms such as Arabidopsis thaliana 
and Caenorhabditis elegans, which lack FKBP12, are rapamycin resistant.  
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Thus, mutations in FPR1 affecting rapamycin binding, and mutations in the 
rapamycin-FKBP12 binding site of TOR1 and TOR2 (Ser1972Arg and 
Ser1975Ile) could explain the rapamycin resistance strains found in the original 
genetic screen by Heitman and colleagues. 
Genetic evidence collected in the early years of TOR discovery 
suggested the existence of two discrete TOR signaling branches: one 
rapamycin-sensitive, the other rapamycin-insensitive.  This conclusion is 
based on the evidence that TOR1 and TOR2 deletion mutants displayed 
different phenotypes, despite the high identity shared at the gene level.  
Disruption of TOR1 slightly reduces cell growth, while TOR2 deletion is lethal 
and not rescued by TOR1 overexpression.  Cells depleted of TOR2 arrest 
randomly in the cell cycle with a depolarized actin cytoskeleton, while 
rapamycin treated cells or cells lacking both TOR1 and TOR2 arrest in G1 
phase as unbudded cells.  Thus, TOR appears to exert two different functions.  
The first function is rapamycin-sensitive, redundant between TOR1 and TOR2 
and required for G1 progression.  The second function is rapamycin-
insensitive, unique for TOR2 and required for actin cytoskeleton dynamics 
(Cafferkey et al., 1993; Helliwell et al., 1998a; Kunz et al., 1993; Zheng et al., 
1995).  The elucidation of TOR domains and their function was essential for 
understanding the regulation of the two distinct TOR signaling branches. 
 
 
1.1.2 From TOR domains to TOR complexes 
 
TOR is a large kinase of 300 KDa circa.  In the TOR N-terminal region are 
found several HEAT repeats (Huntingtin, EF3, PP2A and the yeast kinase 
TOR1).  HEAT repeats are units of 40-50 amino acids each, forming 
antiparallel α-helices.  In general, tandem HEAT repeats form a very flexible 
superhelical structure required for protein-protein interaction (Andrade and 
Bork, 1995; Groves et al., 1999).  In the C-terminal part of TOR, conserved 
among the other PIKK members (ATM, ATR, DNA-PK, SMG1, and TRRAP) 
are found several other domains.  In order from N- to C-terminus are the FAT, 
FRB, kinase, FIT and FATC domains.  The FAT (FRAP, ATM and TRRAP) 
domain, assembled from multiple HEAT repeats, is circa 600 amino acids long.  
Following the FAT domain is the FRB domain (FKBP12-rapamycin binding 
domain), important for the binding of the rapamycin-FKBP12 complex (Choi et 
al., 1996) and unique for TOR among the PIKK members.  The FRB domain 
(100 amino acids) contains the original rare missense mutations conferring 
rapamycin resistance to TOR1-1 and TOR2-1 mutants (Heitman et al., 1991).  
Immediately C-terminal to the FRB domain is the TOR kinase domain (300 
amino acids).  After the kinase domain is the circa 100 residues long FIT 
domain (Found in TOR), not highly conserved in other species.  The FIT 
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domain is spatially close to the kinase active site, subjected to 
phosphorylation, and may act as repressor domain (Banaszynski et al., 2005; 
Chiang and Abraham, 2005; Holz and Blenis, 2005; Peterson et al., 2000; 
Sturgill and Hall, 2009).  At the extreme C-terminus is the FATC domain (FAT 
C-terminal).  Even though only 33 amino acids long, this domain is essential 
for TOR activity (Dames et al., 2005). 
Early genetic studies in budding yeast predicted that the two TOR 
signaling branches could be dependent on the non-interchangeable HEAT 
domains of TOR1 and TOR2 and not on the interchangeable kinase domains 
(Helliwell et al., 1994).  A breakthrough discovery in the TOR field came with 
the biochemical characterization of two distinct TOR multiprotein complexes.  
These two complexes, termed TOR complex 1 (TORC1) and TORC2, are 
essential and highly conserved in eukaryotes (Loewith et al., 2002).  Indeed, 
TOR HEAT repeats resulted indispensable in TOR complexes formation, 
biochemically confirming the early genetic evidence.   
The rapamycin sensitive TORC1 mediates temporal growth of the cell in 
response to nutrients.  TORC1 positively regulates anabolic processes such as 
translation initiation, transcription, ribosome biogenesis, nutrient uptake and 
cell size.  At the same time, TORC1 negatively regulates catabolic processes 
such as autophagy and ubiquitin-mediated proteolysis, and down-regulates 
stress response.  TORC2 is rapamycin insensitive and controls the spatial 
growth of the cell by regulating actin cytoskeleton dynamics, cell wall integrity 
pathway, and sphingolipid biosynthesis.  The nutritional cue associated with 
TORC2 activation is still elusive.  In mammals, mTORC1 and mTORC2 are 
both activated by growth factors in a PI3K dependent manner.  Additionally, 
mTORC1 responds to amino acid availability, cellular energy and oxygen 
levels.  Thus, TOR couples growth to nutrient availability in eukaryotes.   
Here the focus is on TOR signaling in budding yeast and to some extent 
on the parallelisms existing between yeast and mammalian cells.  Following is 
a list of exhausting reviews about TOR signaling in yeast and other model 
organisms. 
 
• (Jacinto and Hall, 2003)  TOR in yeast, mammalian and flies 
• (De Virgilio and Loewith, 2006) TOR in budding yeast 
• (Blagosklonny and Hall, 2009) TOR and aging 
• (Grewal, 2009)   TOR in flies 
• (Soulard et al., 2009)  TOR in invertebrates 
• (Hall and Tamanoi, 2010)  TOR signaling 
• (John et al., 2011)   TOR in plants 
• (Loewith and Hall, 2011)  TOR history 
• (Wei and Zheng, 2011)  TOR and longevity 
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• (Robaglia et al., 2012)  TOR in plants 
• (Laplante and Sabatini, 2012) Mammalian TOR signaling  
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1.1.3 TORCs composition and localization 
 
The discovery of the two TOR complexes finally explained TOR signaling 
branching.  Two discrete TOR complexes exist, each one with its essential 
function and exclusive binding partners (Loewith et al., 2002).  The core 
components of TORC1, in budding yeast, are TOR1 or TOR2, Lst8 and Kog1.  
TORC2 core components are TOR2, Lst8, Avo1 and Avo3.  The finding that 
TOR2 could substitute for TOR1 in the TORC1 context helped explaining the 
different phenotypes associated with TOR genes deletions.  In fact, TOR2 is 
an essential gene, while TOR1 is not.  Therefore, in the absence of TOR1, a 
still functional TORC1 containing TOR2 supports cell growth.  On the other 
hand, when TOR2 is depleted, TORC2 essential function is missing, given that 
TOR1 cannot substitute for TOR2 in TORC2.  Exclusive binding partners 
confer specificity to the TOR complexes.   
 
 
TOR complex 1 
 
Kog1 (kontroller of growth) is the homolog of raptor in mammals.  Kog1 has a 
molecular weight of 176 KDa and contains an N-terminal RNC domain (raptor 
N-terminal conserved), four internal HEAT repeats and seven C-terminal WD-
40 repeats.  Kog1 and raptor are required for TORC1 activity (Loewith et al., 
2002; Wedaman et al., 2003), and play a positive role in TOR signaling by 
functioning as scaffold protein to recruit substrates to TORC1 (Kim et al., 2002; 
Nojima et al., 2003; Schalm et al., 2003; Yonezawa et al., 2004).  Substrates 
of mammalian TORC1 (mTORC1) such as S6K and 4E-BP1 contain a TOS 
motif (TOR signaling) recognized by the RNC domain of raptor, greatly 
enhancing TOR-mediated substrate phosphorylation.  Additionally, raptor acts 
to stabilize TOR and confers the capacity to respond to upstream signals (Kim 
and Sabatini, 2004).  From a low resolution electron microscopy of the TOR-
Kog1 complex, Kog1 was shown to interact with the N-terminal HEAT 
containing region of TOR, and with some other regions encompassing parts of 
the helical repeats and FAT domain, and the FAT, FRB, and kinase domain 
(Adami et al., 2007).   
Lst8 (yeast lethal with sec thirteen) is a 34 KDa Gβ-like propeller protein 
structurally defined by seven WD-40 repeats.  Lst8 binds to the kinase domain 
of both TOR complexes (Loewith et al., 2002; Wullschleger et al., 2005).  In 
yeast Lst8 is required for integrity and activity of TORC2.  Mammalian Lst8 
(mLST8) strongly stimulates the catalytic activity of mTOR, but it appears to be 
more important for TORC2 signaling (Guertin et al., 2006; Kim et al., 2003).  
Another non-conserved protein found in TORC1 is Tco89 (TOR complex one 
89 KDa subunit) (Reinke et al., 2004).  Following rapamycin treatment, all 
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components of TORC1 can be co-precipitated with FKBP12.  Thus, contrary to 
mammalian TORC1 (Yip et al., 2010), the structural integrity	
  of yeast TORC1 
is not compromised by rapamycin.   
TOR complex 2 
 
Avo1 and Avo3 (adheres voraciously to TOR2) are both essential proteins and 
exclusive binding partners of TORC2.  Both proteins bind to the N-terminal 
HEAT repeats of TOR2 and are required for complex stability and function.  
Avo1 is required for Avo3 binding to TOR2, but not for TOR2 binding to Lst8.  
Avo1 is thought to mask the FRB site of TOR2 when TORC2 is assembled, 
explaining TORC2 insensitivity to rapamycin (Wullschleger et al., 2005).  
Moreover, Avo1 contains a C-terminal PH-like domain (pleckstrin homology) 
required for TORC2 membrane localization (Berchtold and Walther, 2009).  
The mammalian homologues of Avo3 and Avo1 are rictor and mSin1 
respectively.  As for Avo3, rictor specific function in mTORC2 is unknown.  
mSin1 undergoes alternative splicing.  Five mSin1 splice variants are known 
(mSin1.1-5).  Only TORC2 containing mSin1.1 and mSin1.2 is stimulated by 
insulin.  A TORC2 containing mSin1.5 is insulin resistant (Frias et al., 2006).  
Notably, mSin1.5 is the only isoform lacking the PH and the Raf-like Ras-
binding (RBD) domains.  Both PH and RBD domains target mSin1 to 
membranes.  These findings imply that insulin stimulation of TORC2 requires a 
membrane bound TORC2.  Other non-conserved proteins found in yeast 
TORC2 are Avo2 and Bit61 (Binding partner of TOR2). 
PRAS40, Deptor, PRR5 and PRR5L are components of the TOR 
complexes found only in mammals.  PRAS40 is found only in mTORC1 and 
was shown to negatively regulate mTORC1 activity (Sancak et al., 2007; 
Vander Haar et al., 2007).  Deptor binds to both complexes and regulates 
positively and negatively mTORC1 activity (Peterson et al., 2009).  Deptor is in 
turn regulated at the translational level by both mTORC1 and mTORC2.  
PRR5 and PRR5L are found in mTORC2 where they bind rictor.  Both are not 
required for rictor and mSin1 binding to mTOR. 
 
 
TOR complexes dimerization and localization 
 
Both complexes are thought to exist as multimers, likely as homo-dimers 
(TORC1-TORC1 and TORC2-TORC2).  Dimerization is mediated by HEAT-
FAT interactions between TOR proteins (Loewith et al., 2002; Takahara et al., 
2006; Wang et al., 2006; Wullschleger et al., 2005; Zhang et al., 2006).  In 
yeast, TOR dimerization is not influenced by nutrients, while in mammalian 
cells presence of amino acids stimulates mTOR dimerization.  Rapamycin and 
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growth factors do not affect multimerization events.  Thus, it is not yet clear 
whether TOR dimerization reflects kinase activation. 
The cellular localization of the two complexes is different, consistent 
with the two essential distinct functions carried out by TORC1 and TORC2.  
Yeast TORC1 localizes at the vacuolar membrane (Berchtold and Walther, 
2009; Binda et al., 2009; Chen and Kaiser, 2003; Reinke et al., 2004; Sturgill 
et al., 2008; Urban et al., 2007).  At this location TORC1 is catalytically active.  
Rapamycin or nutrient starvation does not alter TORC1 localization.  In yeast, 
the vacuole is the storage compartment for nutrients.  Thus, TORC1 vacuolar 
localization might be linked to its ability to sense nutrients.  Others reported a 
nucleolar localization for a fraction of TORC1, where it actively controls 35S 
rRNA transcription (Li et al., 2006).  mTORC1 localizes on endosomal 
membranes upon nutrient stimulation and is diffuse in the cytoplasm during 
starvation (Long et al., 2005b; Sancak et al., 2008).   
Yeast TORC2 is localized at or near the plasma membrane (Aronova et 
al., 2007; Kunz et al., 2000; Sturgill et al., 2008; Wedaman et al., 2003) where 
it defines a TORC2-specific domain (Berchtold and Walther, 2009).  The PH 
domains of Avo1 mediate the anchoring of TORC2 to the plasma membrane.  
Also mTORC2 localizes at the plasma membrane, and at the interface 
between ER and mitochondria (MAM) (Betz et al., 2013).   
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1.1.4 Perspective in TOR signaling research 
 
Following the initial discovery of TOR, many efforts were made in 
understanding the role played by TOR in controlling cell growth.  TOR 
signaling was (and still is) studied in different model organisms such as yeast, 
slime mold, plants, worms, flies, mammalian tissue culture cells and mice.  In 
general TOR is activated by nutrients and growth factors, and inhibited by 
noxious stresses.  In yeast several line of evidence suggest that TORC1 is 
activated in response to the availability of nutrients, particularly of the nitrogen 
source (amino acid and other nitrogenous compounds).  Hence, TOR signaling 
ensures proper growth only in conditions that allow growth itself.  In other 
words, TOR couples growth to nutrient availability.  Proper control of growth 
required a further developmental step with the event of multicellularity in higher 
eukaryotes.  Thus, another dimension of control acting at the tissue and whole 
organism level was required in addition to the “simple” single cell level.  
Therefore, growth factors signaling, which coordinate events affecting multiple 
tissues, engrafted on mTOR nutrient sensing and regulation.  Importantly, 
deregulation of mTOR signaling leads to uncontrolled growth and metabolic 
homeostasis, leading to diabetes and cancer onset.  Altered mTOR signaling 
is one of the most common hallmarks in human cancers.  Rapamycin and 
rapamycin derivatives (rapalogs) were proven unsuccessful in cancer 
treatment.  Thus, knowing the exact molecular mechanisms controlling mTOR 
activation and signaling might lead to development of promising new 
anticancer drugs.  In the next sections the focus is on the upstream and 
downstream regulation of TOR complexes.  Following is a list of reviews 
treating mTOR signaling in cancer and disease. 
 
• (Benjamin et al., 2011)   mTOR inhibitors 
• (Dazert and Hall, 2011)   mTOR and disease 
• (Cantor and Sabatini, 2012)  Cancer metabolism 
• (Alayev and Holz, 2013)   mTOR and cancer 
• (Lamming et al., 2013)   mTOR and aging 
• (Vinayak and Carlson, 2013)  mTOR and breast cancer 
• (Zhang et al., 2013)    Cancer metabolism 
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1.3 TORC2 SIGNALING 
 
 
1.3.1 Downstream targets of TORC2 
 
The impossibility to directly inhibit TORC2 with specific drugs left no choice to 
researchers to investigate TORC2 signaling by genetic means.  Over the years 
many downstream functions of TORC2 were uncovered in this way.  TOR2 
(and later on TORC2) was shown to regulate cytoskeleton organization, cell 
wall integrity pathway and sphingolipids biosynthesis.  
 
 
 
 
Figure 1: TORC2 signaling 
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Cytoskeleton organization 
 
One of the earliest observations made on tor2 mutants was that the 
cytoskeleton organization in these cells was compromised (Schmidt et al., 
1996).  Budding yeast growth is polarized towards the bud (daughter cell).  In a 
cell cycle dependent way, from late G1 until mid G2 phase, the actin cables 
and patches are polarized to ensure transport of nutrients and organelles from 
the mother to the daughter cell.  TOR2 control over cytoskeleton organization 
was later shown to be dependent on the activation of the small GTPase Rho1 
(Schmidt et al., 1997).  Deletion of SAC7, encoding for Rho1 GAP, suppressed 
the growth defect of tor2.  Consistently, overexpression of RHO1, RHO2, and 
of the GEF for Rho1 ROM2, restored the growth defect of tor2 cells.  Thus, 
TOR2 control over Rho1 is mediated by activation of Rom2.  The molecular 
mechanism at the basis of Rom2 activation by TOR2 is still unknown. 
 
 
Cell wall integrity pathway 
 
Further genetic studies showed that PKC1 was another downstream effector of 
Rho1 able to restore the growth defect of a tor2 mutant (Helliwell et al., 
1998b).  PKC1 controls a mitogen-activated protein kinase (MAPK) cascade 
pathway called the cell wall integrity (CWI) pathway.  CWI is activated in 
response to stresses leading to the up-regulation of genes involved in cell wall 
biosynthesis (Heinisch et al., 1999).  Similar to PKC1, overexpression of CWI 
component pathway such as BCK1, MKK2 and MPK1 restored the actin 
cytoskeleton depolarization of tor2 mutants.  Therefore, TOR2 via Rom2-
dependent activation of Rho1 and PKC1 controls cytoskeleton polarization and 
CWI. 
 
 
Sphingolipid biosynthesis 
 
Sphingolipids are essential components of eukaryotic membranes.  They are 
involved in actin cytoskeleton dynamics, endocytosis and membrane rafts 
organization.  Sphingolipids biosynthesis steps take place at the ER and are 
well conserved among eukaryotes.  Complex sphingolipids biosynthesis 
requires the production of relevant intermediates such as long-chain bases 
(LCB) and ceramides.  Ceramides are then transported to the Golgi where 
they are further modified to complex sphingolipids.  One of the final steps in 
ceramide biosynthesis, catalyzed by Csg1 or Csg2, converts inositol 
phosphoceramide (IPC) to mannose inositol phosphoceramide (MIPC).  csg2 
mutants were shown to accumulate IPC and be hypersensitive (lethal) at low 
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calcium doses (Beeler et al., 1994).  In the subsequent genetic screen aimed 
to uncover thermo-sensitive suppressors of CSG2 deletion (TSC) TOR2 and 
TSC11 were identified (Beeler et al., 1998).  TSC11, also known as AVO3, 
was later shown being an essential component of TORC2 (Loewith et al., 
2002).  These early genetic data implied an involvement for TORC2 in 
sphingolipid biosynthesis. 
 MSS4 was another gene identified in the csg2 suppressor screen along 
with TOR2 and AVO3.  MSS4 encodes for the yeast PI4,5-kinase, which 
catalyzes the formation of PI4,5P2 from PI4P.  Proteins possessing a PH 
domain can bind PI4,5P2 and localize in this way to membranes.  Some of 
these proteins in turn are involved in actin cytoskeleton, CWI and endocytosis 
regulation.  Another genetic screen aiming to the identification of synthetic 
lethal genes in combination with a hypomorphic temperature-sensitive allele of 
MSS4, identified several genes.  Among these genes was AVO2, component 
of TORC2 (Audhya et al., 2004).  Other synthetic lethal with MSS4 (SLM) 
genes were identified, such as SLM1 and SLM2.  Slm1/2 share overlapping 
functions and were shown to be direct TORC2 targets in two independent 
studies (Audhya et al., 2004; Fadri et al., 2005).  Slm1/2 were lately involved in 
sphingolipids biosynthesis given that Slm1/2 mutants showed negative genetic 
interactions with component of the sphingolipids biosynthetic pathway and 
were hypersensitive to myriocin, a drug that inhibits the first step in 
sphingolipids biosynthesis (Daquinag et al., 2007). 
 The identification of other TORC2 downstream targets, the AGC 
kinases Ypk1 and Ypk2, helped in the further characterization of TORC2 
involvement in sphingolipids biosynthesis.  Ypk1/2 are phosphorylated by Pkh1 
(yeast PDK1) in response to increasing levels of LCBs and further 
phosphorylated and activated by TORC2 (acting as PDK2) (Aronova et al., 
2008; Kamada et al., 2005; Mulet et al., 2006).  Overexpression of the 
hyperactive allele of YPK2 (YPK2D239A) is the only known suppressor of the 
lethality induced by TOR2 loss.  YPK2D239A also restores the levels of 
ceramide which are drastically decreased when TORC2 is compromised 
(Aronova et al., 2008).  Therefore, TORC2 positively regulates de novo 
ceramide biosynthesis via Ypk1/2. 
 A connection between TORC2, Slm1/2 and Ypk1/2 comes from a recent 
paper in which the author demonstrated that Ypk1 recruitment and activation 
by TORC2 is dependent on Slm1/2 which act as scaffold protein through their 
PH domain (Niles et al., 2012).  Another publication showed that upon plasma 
membrane mechanical stress, Slm1/2 relocalized to the plasma membrane to 
activate TORC2 and Ypk1 to promote sphingolipids biosynthesis (Berchtold et 
al., 2012).  This publication is more debatable since it inverts the classical role 
for TORC2 upstream of Slm1/2 activation. 
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 More recently another set of proteins was shown to be important for 
sphingolipid biosynthesis.  ORM are conserved ER membrane proteins which 
bind to and inhibit the first enzyme in sphingolipid biosynthesis, the serine-
palmytoyl-coenzyme A transferase (SPT) (Han et al., 2010).  Orm1/2 are 
inactivated by phosphorylation in response to compromised sphingolipid 
synthesis, leading to SPT activation restoring sphingolipids production 
(Breslow et al., 2010; Sun et al., 2012).  TORC2 was shown to regulate Orm 
phosphorylation via Ypk1.  Reduction in sphingolipids stimulated Ypk1 via 
TORC2-dependent phosphorylation.  Ypk1 then phosphorylated Orm1/2 to 
restore sphingolipids biosynthesis.  Thus, Ypk1 is both a sensor and effector of 
sphingolipid levels (Roelants et al., 2011). 
 
 
Calcineurin signaling 
 
A complex interplay exists between TORC2 and calcineurin signaling.  
Calcineurin is a conserved Ca2+/calmodulin Ser/Thr protein phosphatase 
activated following stress conditions that increase the cytoplasmic 
concentration of Ca2+.  Active calcineurin dephosphorylates several targets, 
one of which is the transcription factor Crz1.  Dephosphorylated Crz1 enters 
the nucleus and drives the transcription of several genes involved in survival 
following stress (Matheos et al., 1997). 
 TORC2 negatively regulates calcineurin signaling and Crz1 
transcription, probably by modulating the interaction of Slm1/2 with the 
catalytic subunits of calcineurin.  In this way, TORC2 suppresses stress 
response during optimal growth conditions (Mulet et al., 2006).  Conversely, 
calcineurin interacts and dephosphorylates Slm1/2 leading to stress-induced 
changes in actin polarization and nutrient-regulated permease endocytosis and 
turnover.  Therefore, calcineurin prevents TOR-mediated growth during stress 
conditions (Bultynck et al., 2006).   
 
 
Eisosome assembly and disassembly 
 
Eisosomes are the endocytosis entry sites at the plasma membrane. Pkh1/2, 
Ypk1/2 and LCB levels were involved in eisosome assembly and disassembly 
(Luo et al., 2008; Walther et al., 2007; 2006).  Whether TORC2 is also directly 
involved in the regulation of eisosome formation and endocytosis remains to 
be confirmed.  TORC2 localization at plasma membrane foci adjacent to 
eisosomes suggests for a direct involvement of TORC2 in endocytosis (Sturgill 
et al., 2008).  On the other hand, TORC2 was shown to localize to a defined 
plasma membrane domain distinct to eisosomes (Berchtold and Walther, 
	
   13	
  
2009).  Thus, TORC2 involvement in eisosome formation and endocytosis has 
to be further investigated. 
 
 
Overlap between TORC1 and TORC2 signaling 
 
The strict division of substrates and function between the two TOR complexes, 
apparently so clear during the early genetic studies, started to be looser in the 
last years.  Accumulated evidence suggests that a role for TORC1 in TORC2 
signaling has to be considered.  More specifically, rapamycin treatment was 
shown to trigger actin depolarization (Aronova et al., 2007).  CWI is affected by 
deletion of non-essential components of TORC1 and mutations in the Tap42-
phosphatase complex (Angeles de la Torre-Ruiz et al., 2002; Reinke et al., 
2004; 2006; Torres et al., 2002; Wang and Jiang, 2003).  Finally, TORC1 was 
shown to control ORM phosphorylation, and consequently sphingolipid 
biosynthesis, independently of TORC2, as a part of an adaptive response to 
nutrient stress.  The mechanism involves activation of Npr1 when TORC1 is 
inhibited by rapamycin, leading to increase de novo synthesis specifically of 
complex sphingolipids (Shimobayashi et al., 2013).  
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1.3.2 TORC2 upstream signaling 
 
 
Both in yeast and higher eukaryotes TORC2 activity is not stimulated by 
nutrients.  In higher eukaryotes growth factors, particularly insulin, stimulate in 
a PI3K dependent way mTORC2 activity, leading to phosphorylation of 
mTORC2 targets such as Akt, SGK1 (the homolog of Ypk2), PKC, Rho1 and 
Rac1 to drive metabolism, survival, actin organization and cytoskeleton 
dynamics.  mTORC2 activation by amino acids is controversial	
   (Hernández-
Negrete et al., 2007; Nobukuni et al., 2005; Tato et al., 2011). 
 Recent finding enabled a better understanding of the upstream 
regulation of TORC2.  Once more, yeast genetics resulted essential in the 
process.  An elegant yeast reverse suppressor screen identified NIP7 as 
upstream regulator of TORC2.  The genetic screen was based on the fact that 
mutants defective in TORC2 signaling require overexpressed hyperactive 
YPK2 for survival.  Following random mutagenesis, those mutants unable to 
lose a high copy number plasmid harboring YPK2D239A were most probably 
defective in TORC2 signaling and potentially defective in upstream regulators 
of TORC2.  Among genes encoding for core components of TORC2 such as 
TOR2, AVO1 and AVO3, a gene involved in 60S ribosome maturation, NIP7, 
was discovered.  The thermo-sensitive mutant identified, nip7-1, perfectly 
phenocopied loss of TOR2 at non-permissive temperature, including actin 
depolarization, failure to induce CWI pathway, impaired sphingolipids 
biosynthesis, restoration of growth of a csg2 strain in the presence of Ca2+, 
decreased TORC2 and Ypk2 kinase activity (Zinzalla et al., 2011).  Nip7 is 
conserved among eukaryotes and is required for ribosome biogenesis also in 
mammalian cells.  Further characterization led to the discovery that the growth 
factor stimulated physical association of mTORC2 with the ribosome, 
independently of translation, is required for mTORC2 activation.  Moreover, 
mTORC2-ribosome association, mediating PI3K-mTORC2-Akt signaling and 
cell survival, was functionally important in cancer cells.  If TORC2-ribosome 
physical association is conserved also in yeast, and how the ribosome 
stimulates TORC2 activity are still unanswered questions.  
 In a follow-up study aimed to better understand the physiology of 
mTORC2-ribosome association, an essential role for mTORC2 in 
mitochondria-associated endoplasmic reticulum membranes (MAM) was 
uncovered.  mTORC2 was shown to localize at MAM in a PI3K and ribosome 
association dependent manner.  MAM-associated mTORC2 activates Akt and 
thereby controls MAM integrity, mitochondrial metabolism, and cell survival 
(Betz et al., 2013).  
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1.3 TORC1 SIGNALING 
 
 
1.3.1 Downstream targets of TORC1  
 
The possibility to chemically inhibit TORC1 signaling with rapamycin helped 
researchers to uncover the many cellular processes regulated by TORC1.  In 
this section the focus is on TORC1 downstream targets, divided in proximal 
effectors and distal readouts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: TORC1 signaling 
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PROXIMAL EFFECTORS OF TORC1 SIGNALING 
 
A clear bifurcation in TORC1 signaling was highlighted by phosphoproteomic 
studies in response to rapamycin treatment (Huber et al., 2009).  The protein 
kinase Sch9 on one side and the Tap42/phosphatase complex on the other, 
mediate these two effector branches.  Many proteins exhibited phosphorylation 
changes dependent only on one or the other activity, highlighting the 
independence of the two downstream pathways.  Some rapamycin-induced 
changes in phosphorylation occurred were dependent on both Sch9 and 
Tap42.  More interestingly, some other phosphorylation events happened 
independently of Sch9 and Tap42, suggesting the existence of other TORC1 
downstream pathways. 
 
 
The AGC kinase Sch9 
 
The AGC kinase Sch9, homolog to mammalian S6 kinase and Akt, is probably 
the best-characterized direct substrate of TORC1.  As all AGC kinases, Sch9 
activity is stimulated by phosphorylation events (Arencibia et al., 2013; Jacinto 
and Lorberg, 2008; Pearce et al., 2010).  Phosphorylation on the activation- or 
T-loop by PDK1 is required for Sch9 activity.  The yeast PDK1 is Pkh1, a 
kinase positively regulated by sphingolipid levels.  Further phosphorylation 
events, thought to enhance or confer specificity to the AGC kinase activity, 
take place in the hydrophobic (HM) and turn motif (TM).  Phosphorylation at 
these sites is dependent on PDK2.  In the past years, mTOR importance as 
regulator of mammalian AGC kinases has emerged (Jacinto and Lorberg, 
2008).  mTOR, in the mTORC2 context, phosphorylates Akt Ser473 within the 
hydrophoibic motif of Akt.  Thus, mTORC2 acts as PDK2 for Akt.  The situation 
is similar in yeast, where it was shown that TORC1 phosphorylates Sch9 on at 
least six residues.  All these residues are localized on Sch9 C-terminus, within 
Sch9 HM, TM and HM-like motives.  TORC1-dependent phosphorylation of at 
least five of the six sites was required for Sch9 activity in vitro and in vivo 
(Urban et al., 2007). 
Sch9 is also regulated by the carbon source, in addition to regulation by 
the nitrogen source via TORC1.  Sch9 levels and phosphorylation were 
regulated by glucose (Jorgensen et al., 2004).  Interestingly, Sch9 was 
originally discovered as multicopy-suppressor in a strain lacking PKA activity 
(Toda et al., 1988).  Sch9 overexpression resulted in the up-regulation of 
several genes, which were also targets of PKA.  PKA is activated in response 
to the carbon source.  In the absence of PKA, a part of the glucose induced 
transcriptional response is due to Sch9 activity (Zaman et al., 2009).  Thus, it 
appears that both carbon (even though only partially) and nitrogen source 
	
   17	
  
converge on Sch9 regulation.  Processes downstream of TORC1 regulated by 
Sch9 are: translation initiation, transcriptional regulation of ribosomal protein 
(RP) and ribosome biogenesis factors (RiBi), entry into G0 phase and 
regulation of G1 progression, transactivation of stress-responsive genes, 
lifespan regulation. 
 
 
The protein phosphatase 2A (PP2A) 
 
The other effector branch downstream of TORC1 involves protein 
phosphatases.  Particularly, TORC1 regulates type 2A (Pph21, Pph22 and 
Pph3) and 2A-related phosphatases (Sit4 and Ppg1).  TORC1 regulation of 
these phosphatases requires the regulatory subunit Tap42.  TORC1 regulates 
directly or indirectly via Tip41, the phosphorylation state of Tap42 (Jacinto et 
al., 2001; Jiang and Broach, 1999).  Phosphorylated Tap42 forms tight 
complexes with the phosphatases (Di Como and Arndt, 1996) and the peptidyl-
prolyl cis/trans isomerases Rrd1 and Rrd2 (Zheng and Jiang, 2005).  The 
Tap42-phosphatase complex is thought to inactivate or redirect towards 
different substrates the phosphatase activity (Düvel et al., 2003; Yan et al., 
2006).  Upon starvation or treatment with rapamycin the Tap42-phosphatase 
complexes are released and result in phosphatase activation or change in 
substrate preference, and Tap42 dephosphorylation over time.  Downstream of 
TORC1, PP2A regulates translation initiation, and the dephosphorylation of 
Gln3 and Gat1, two transcription factors controlling the nitrogen catabolite 
repression (NCR). 
 
 
Other downstream targets 
 
Several other downstream targets of TORC1 were identified over the years.  
Other TORC1 direct targets comprehend the transcriptional activators Gln3 
and Sfp1, respectively involved in NCR and ribosome biogenesis regulation, 
and Atg13, a protein involved in autophagy.  A recent study, focused on 
uncovering the global interaction network of protein kinase and phosphatase in 
yeast, described new potential TORC1 targets (Breitkreutz et al., 2010).  The 
importance in TORC1 signaling of some of these newly identified substrates, 
such as Npr1 and Ksp1 was subsequently proven in more recent studies 
(Panchaud et al., 2013; Umekawa and Klionsky, 2012). 
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TORC1 DISTAL READOUTS 
 
Translation initiation 
 
Rapamycin treatment blocks protein translation leading to decreased protein 
synthesis and arrest in G1 phase of the cell cycle (Barbet et al., 1996).  In both 
yeast and mammalian cells TORC1 controls cap-dependent mRNA translation.   
In yeast, TOR promotes cap-dependent translation acting on the 
phosphorylation of the eIF2α kinase Gcn2 (Gallinetti et al., 2012; Murguía and 
Serrano, 2012).  eIF2α is a component of the met-tRNAi ternary complex.  
eIF2α phosphorylation by Gcn2 inhibits eIF2B GEF activity toward eIF2α 
leading to the formation of the inactive eIF2α-P-GDP-eIF2B complex. The 
eIF2α-P-GDP-eIF2B complex, by sequestering eIF2α, compromises 
translation initiation.  In the presence of unloaded tRNAs Gcn2 is activated and 
phosphorylates eIF2α.  Gcn2 activity is also regulated by phosphorylation on 
Ser577.  TORC1 promotes by two distinct mechanisms the phosphorylation of 
Ser577.  First, TORC1 positively regulates Sch9, which probably in turn 
phosphorylates Ser577.  Second, TORC1 negatively regulates PP2A 
preventing Ser577 dephosphorylation (Cherkasova, 2003). 
In higher eukaryotes TOR promotes cap-dependent translation by 
directly phosphorylating 4E-BP1.  4E-BP1 competes for the binding to eIF4E 
with eIF4G.  When 4E-BP1 is hyperphosphorylated it can no longer bind to 
eIF4E, which then is free to bind eIF4G and drive translation initiation. 
 
 
Ribosome biogenesis 
 
Nutrients fuel cell growth, a process that depends primarily on the biosynthetic 
capacity of the cell, in turn dependent on ribosomes.  Circa 95% of total 
transcription in exponentially growing yeast is dedicated to ribosome 
biogenesis.  Ribosome biogenesis requires not only the action of the three 
RNA polymerases but also protein synthesis itself.  rRNA, tRNA, ribosomal 
proteins and ribosome assembly factors must be transcribed and translated to 
ensure proper ribosome biogenesis.  Thus, ribosome biogenesis is very 
expensive in terms of energy and building blocks consumed.  Therefore, 
ribosome biogenesis has to be down-regulated during times of nutrient 
scarcity, or cells would face energetic failure and certain death.  Therefore, 
ribosome biogenesis is tightly linked to nutrient availability.  TORC1 regulates 
ribosome biogenesis at the transcriptional and translational level by different 
mechanisms (Powers and Walter, 1999). 
RNA Pol I and RNA Pol III transcripts (rRNA and tRNA) are controlled 
by TORC1 via protein synthesis.  In fact, ribosomal RNA processing requires 
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the presence of ribosomal proteins to be incorporated into maturing ribosomes.  
Unprocessed rRNA is rapidly degraded (Warner, 1999).  Thus, a decrease in 
free ribosomal proteins leads to rRNA degradation.  Inhibiting protein 
translation, such as following rapamycin treatment, would produce a decrease 
in rRNA levels (Reiter et al., 2011; Tschochner and Hurt, 2003).  As alternative 
mechanism, TORC1 was proposed to regulate RNA Pol I by affecting the 
polymerase loading at the rDNA locus (Huber et al., 2009).  In the same study, 
it was proposed a role for Sch9 in regulating RNA Pol III transcription via Maf1 
phopshorylation.  Maf1 is a RNA Pol III repressor.  When phosphorylated by 
Sch9, Maf1 binding and repressor activity to RNA Pol III is inhibited, ensuring 
proper tRNA transcription. 
Rna Pol II transcripts (RP and RiBi genes) are promoted via three 
different TORC1-dependent mechanisms, involving Sch9, Sfp1 and Fhl1.  Via 
Sch9, TORC1 ensures that the transcriptional repressors Dot6, Tod6 and Stb3 
are hyperphosphorylated and thus excluded from the nucleus (Huber et al., 
2011).  TORC1 phosphorylation of Sfp1, allows Sfp1 to interact with the RP 
promoters and drive locus transcription (Lempiäinen et al., 2009).  Sfp1 
phosphorylation is intriguingly insensitive to nutrients or stress.  Sfp1 
overexpression also accounts for increased RiBi transcription (Jorgensen et 
al., 2004).  Fhl1 is constitutively bound to RP genes promoters.  TORC1 
influences the binding of the co-activator Ifh1 or of the co-repressor Crf1 to 
Fhl1, determining RP transcription fate.  When TORC1 is active Ifh1 is 
phosphorylated and can interact with Fhl1 activating RP transcription.  
Conversely, when TORC1 is inactive, Crf1 is phosphorylated and thus binds to 
Fhl1 inhibiting RP transcription (Berger et al., 2007; Lee et al., 2002; Martin et 
al., 2004; Rudra et al., 2005; Schawalder et al., 2004; Wade et al., 2004). 
 
 
Cell cycle and cell size 
 
Growth (mass accumulation) and cell cycle are distinct co-regulated 
mechanisms.  Mitosis is an energy demanding process and mitotic 
commitment requires the availability of sufficient nutrients to ensure successful 
duplication.  During the cell cycle, cells are committed to a new mitotic cycle 
following START.  At START converge the inputs deriving from nutrient 
availability.  A critical mass threshold has to be reached before passing 
START.  The mechanism involved in attaining critical mass is still poorly 
understood.  What is known is that the translational machinery, and thus 
protein synthesis, plays a major role.  Possibly, there is a link between 
translation rate and accumulation of the G1 cyclin Cln3.  Cln3 is very unstable 
and thus requires a robust translating machinery to accumulate and drive cell 
cycle progression (Barbet et al., 1996).  Deletion of SFP1 or SCH9 by 
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decreasing ribosome biogenesis, has the effect to reduce the size required for 
passing START (Jorgensen et al., 2004).  Therefore, TORC1 regulates and 
couples nutrient cues to cell cycle progression.  Consistently, rapamycin 
treatment causes arrest in G1 phase by decreasing the levels of the G1 cyclins 
Cln1-3 (Barbet et al., 1996) and up-regulating the Cdk inhibitor Sic1 (Zinzalla 
et al., 2007).  Another interesting observation is that rapamycin treatment 
causes a different phosphorylation status of the G1 transcription repressor 
Whi5 and the G1 transcription activator Msa1 (Ashe et al., 2008; Costanzo et 
al., 2004).  Moreover, rapamycin treatment elicits a paradoxical increase in cell 
size due to increase autophagy in G1 arrested cells.   
Independently of ribosome biogenesis TORC1 appears to control the 
G2/M transition (Nakashima et al., 2008).  The authors showed that TORC1 
regulated the polo-like kinase Cdc5 subcellular localization via the Tap42-
phosphatase branch of TORC1.  Cdc5 proper localization was required for 
phosphorylation and destabilization of Swe1, which negatively regulates 
Cdc28 kinase activity and G2/M progression. 
 
 
Stress responsive genes and autophagy 
 
Rapid response to environmental insults is essential for survival.  Erroneous 
activation of stress response during growth-favoring conditions has negative 
effects on growth itself.  TORC1 negatively regulates stress response during 
growth. 
The environmental stress response (ESR) is elicited by a large number 
of environmental insults, including nutrient deprivation, heat, oxidative stress, 
and high osmolarity (Gasch et al., 2000).  A large transcriptional response 
leading to the up-regulation of more than 300 genes is activated in response to 
ESR.  The redundant	
   Msn2 and Msn4 transcription factors bind to STRE 
elements to activate transcription of a large number of stress responsive 
genes. Nutrient availability impinges on Msn2/4 activity by modulating levels of 
phosphorylation of various sites in turn regulating Msn2/4 nuclear entry, 
nuclear exit, and transcriptional activation.  Msn2/4 phosphorylation is 
regulated by PKA and TORC1.  PKA phosphorylation of Msn2/4 promotes their 
nuclear export and blocks their nuclear import, preventing ESR genes 
transcription.  In a similar fashion, TORC1 prevents Msn2/4 dephosphorylation 
by negatively regulating PP2A.  Moreover, TORC1 negatively regulates 
Msn2/4 activity via the Sch9/Rim15 axis.  Active Sch9 phosphorylates Rim15 
favoring Rim15 interaction, and cytoplasmic anchoring, with 14-3-3 proteins 
(Wanke et al., 2008; 2005).  Rapamycin treatment leads to Rim15 
dephosphorylation, release from 14-3-3 and nuclear localization.  Nuclear 
Rim15 up-regulates the expression of Msn2/4 regulated genes.  Another effect 
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of Rim15 activation is to phosphorylate Igo1/2.  Igo1/2 are α-endusolfine 
paralogs which bind and protect from degradation newly transcribed mRNAs.  
Igo1/2 activation by Rim15 is essential to prevent stress responsive genes 
mRNA degradation and thus, ensure proper translation and activation of ESR 
(Luo et al., 2011; Talarek et al., 2010). 
Autophagy is an essential process that ensures availability of new 
building blocks via degradation of cytoplasmic proteins and organelles.  
Autophagy is especially important to ensure survival during nutrient limitation.  
Two mechanism of autophagy exist in yeast: macro- and micro-autophagy.  
Macro-autophagy describes the packaging of bulk cytoplasmic portions in a 
double membrane structure called autophagosome.  In this way, cytoplasmic 
material and organelles such as peroxisomes or mitochrondria are delivered to 
the vacuole where they are degraded and recycled in amino acids and fatty 
acids.  TORC1 regulates macro-autophagy by dictating the phosphorylation 
state of Atg13 (Kamada et al., 2010).  Phosphorylated Atg13 prevents Atg1 
kinase association in the Atg1-Atg17-Atg29-Atg31 sub-complex.  Upon TORC1 
inhibition, Atg13 is dephosphorylated and allows Atg1 recruitment to the 
complex.  Once complexed, Atg1 is phosphorylated and activated leading to 
macro-autophagy onset.  Atg1 activation is absolutely essential for macro-
autophagy induction, as atg1 mutants display no macro-autophagy.  Moreover, 
dephosphorylation of Atg13 is sufficient to induce macro-autophagy because 
expression of a non-phosphorylatable version of Atg13 yields induction of 
autophagy in cells growing in rich medium (Kamada, 2010).  
In addition to TORC1, also PKA negatively controls macro-autophagy.  
Simultaneous inactivation of PKA and Sch9 yields partial activation of the 
autophagic response without significantly altering the phosphorylation state of 
Atg13.  Moreover, the effect on autophagy of PKA and Sch9 inactivation is 
synergistic with TORC1 inactivation, suggesting that PKA acts in parallel to 
TORC1.  The dominant role of TORC1 over PKA in regulating autophagy may 
reflect the importance of autophagy in protecting cells from nitrogen starvation 
rather than from carbon starvation.  This is based on the fact that the major 
product of macro-autophagy are amino acids and that mutants defective in 
autophagy are much more sensitive to nitrogen or phosphate starvation than to 
glucose starvation (Klosinska et al., 2011). 
In micro-autophagy the cytoplasmic material is directly assimilated in 
the vacuole through invagination of the vacuolar membrane.  TORC1 was also 
shown to negatively regulate micro-autophagy (Dubouloz et al., 2005).  In this 
context micro-autophagy serves to restore cell growth following rapamycin 
treatment, at least in part by reducing the amount of vacuolar membrane that 
accumulates as a result of starvation-induced macro-autophagy. 
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1.3.2 TORC1 and nitrogen metabolism 
 
The response of yeast cells to TOR depletion or rapamycin treatment mimics a 
nutrient stress response, including down-regulation of translation initiation, 
inhibition of ribosome biogenesis (down-regulation of rRNA and ribosomal 
protein transcription), cell cycle arrest in G1 phase, storage carbohydrate 
accumulation (glycogen), increase in amino acid permeases activity and 
autophagy (Barbet et al., 1996; Chan et al., 2001; Noda and Ohsumi, 1998; 
Powers and Walter, 1999; Schmidt et al., 1998; Zaragoza et al., 1998).  In 
addition, genome-wide analysis of genes induced upon rapamycin treatment 
revealed that TOR controls nutrient responsive genes.  Many of these genes 
are involved in the glycolytic pathway and the tricarboxylic acid (TCA) cycle, 
but the most striking set of genes affected by rapamycin treatment is 
composed of genes involved in the assimilation of different nitrogen sources 
(Cardenas et al., 1999; Hardwick et al., 1999; Shamji et al., 2000).  Thus, of 
particular mention for this work is the relationship existing between the 
nitrogen source and TORC1 signaling.  TORC1 is influenced by the nitrogen 
source, and in turn TORC1 controls the transcription of genes required for 
nitrogen source utilization.  In the next section the focus is on the regulatory 
mechanisms that partially explain this synergy.  Following is a list of useful 
reviews treating nitrogen metabolism and regulation in yeast. 
 
• (Cooper, 1982)    Nitrogen metabolism 
• (Magasanik, 1992)    Nitrogen utilization 
• (Hofman-Bang, 1999)   Nitrogen catabolite repression 
• (Schure et al., 2000)   Ammonia metabolism 
• (Cooper, 2002)    TOR and GATA factors 
• (Magasanik and Kaiser, 2002)  Nitrogen regulation 
• (Butow and Avadhani, 2004)  Retrograde response 
• (Wong et al., 2008)    Nitrogen regulation 
• (Ljungdahl, 2009)    SPS sensing pathway 
• (Jazwinski and Kriete, 2012)  Retrograde response 
• (Ljungdahl and Daignan-Fornier, 2012) Nitrogen metabolism regulation 
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ON YEAST METABOLISM 
 
The relation between nutrient availability, metabolism and cell proliferation is 
complex and far from being completely understood.  Unicellular organisms, 
such as yeasts and bacteria, reproduce as quickly as nutrient availability 
allows them to, and enter a quiescent stationary state when nutritional 
conditions become adverse.  Metabolic control systems have evolved to sense 
nutrient supply and channel the required carbon, nitrogen, and free energy into 
generating the building blocks needed for survival and replication.  In general, 
in a rich medium yeast cells are larger and duplicate faster.  Glucose presence 
in the media elicits the best-known control system over metabolism, 
intracellular signaling, growth and proliferation.   
Glucose sustains faster growth compared to all other carbon sources.  
When glucose is provided, yeast cells adopt a fermentative metabolism that 
channels glucose through glycolysis for energy production, even in the 
presence of oxygen.  The pyruvate produced via glycolysis is then converted 
to ethanol.  On one hand, ethanol is then released in the media where it 
inhibits the growth of prokaryotes and other unicellular organism that cannot 
assimilate ethanol, creating an advantageous replicative niche for yeast.  On 
the other hand, alcoholic fermentation yields only 2 molecules of ATP for every 
molecule of glucose metabolized.  Thus, alcoholic fermentation is very 
inefficient compared to oxidative phosphorylation, which produces 36 
molecules of ATP for every molecule of glucose.  Nonetheless, the proliferative 
advantage conferred to yeast by alcoholic fermentation has been evolutionally 
favored over energetic efficiency.  The signaling pathway involving PKA 
ensures that the proper transcriptional program, and thus metabolism, for 
glucose utilization is turned on in the presence of glucose.  Moreover, PKA 
negatively regulates all other transcriptional programs required for utilization of 
other carbon sources.  In this way, energy saving is maximized.  A similar 
mechanism regulating the utilization of the nitrogen source exists and requires 
TORC1 signaling. 
 
 
NITROGEN METABOLISM 
 
When glucose is in excess, the availability and quality of the nitrogen source 
regulates growth.  Yeast cells sense and utilize up to 21 different nitrogenous 
compounds as nitrogen sources.  Among these compounds are amino acids, 
ammonium, urea, citrulline, ornithine and γ-aminobutyric acid.  Yeast exhibits a 
hierarchical preference for nitrogen sources.  The quality of a nitrogen source 
depends on the transcriptional programs activated/repressed in its presence 
and on the ability to sustain fast growth rate.  The nitrogen sources can be 
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divided according to their quality in three groups: preferred, non-preferred and 
intermediate (Godard et al., 2007).  In general, preferred nitrogen sources 
repress the transcriptional programs required for the uptake and catabolism of 
less-preferred nitrogen sources, and down-regulate autophagy.  Preferred 
nitrogen sources, able to sustain a faster cell growth, are always internalized 
and consumed before non-preferred nitrogen sources.  Preferred nitrogen 
sources are: alanine ammonium, arginine, asparagine, aspartate, glutamine, 
glutamate, and serine.  Non-preferred nitrogen sources are: isoleucine, 
leucine, methionine, threonine, tryptophan and tyrosine.  The intermediate 
nitrogen sources are: citrulline, ornithine, phenylalanine, proline, valine, urea 
and γ-aminobutyric acid. 
All of the pathways for the utilization of non-preferred sources of 
nitrogen feed into a common set of reactions for the production of glutamate 
and glutamine. The amino and amide groups of glutamate and glutamine are 
the major nitrogen donors in biosynthetic reactions.  From glutamate and 
glutamine are synthetized all other amino acids and nitrogenous compounds 
such as nitrogen bases and NAD.  The yeast nitrogen metabolism evolves 
around the availability, production and consumption of glutamate and 
glutamine, and requires intracellular ammonium. 
A set of four reactions constitutes the core of nitrogen metabolism.   
1) synthesis of glutamate by combination of ammonium with the citric acid 
cycle intermediate α-ketoglutarate is catalyzed by the NADP+-dependent 
glutamate dehydrogenase, encoded by GDH1 (Grenson et al., 1974).   
2) glutamate can then combine with ammonium in a reaction catalyzed by 
glutamine synthetase (GS), the product of GLN1 (Mitchell, 1985; Mitchell and 
Magasanik, 1983).  These two reactions constitute the anabolic core of 
nitrogen metabolism and also constitute the ammonium assimilation route.   
3) glutamate synthase (GOGAT), the product of GLT1, catalyzes the synthesis 
of two molecules of glutamate from one molecule each of glutamine and α-
ketoglutarate (Cogoni et al., 1995).   
4) finally, glutamate is converted to α-ketoglutarate, resulting in ammonium 
release, by the NAD+-dependent glutamate dehydrogenase, encoded by 
GDH2 (Miller and Magasanik, 1990).  
The regulated combination of these reactions allows for glutamate 
production when glutamine is the sole nitrogen source, and glutamine 
synthesis when glutamate is the only nitrogen source.  When cells are in the 
presence of abundant ammonium concentrations, reactions (1) and (2) ensure 
proper synthesis of glutamate and glutamine.  Non-preferred sources of 
nitrogen are converted through these reactions to glutamate and glutamine, 
which in turn serve as the sources of all cellular nitrogen.  The expression of 
the right set of genes required for nitrogen anabolic and catabolic reactions is 
subject to complex regulation that involves also TORC1 signaling.   
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Intriguingly, glutamine is not only a key intermediate in nitrogen 
metabolism but also an important indicator of the general nutrient status.  
Glutamine was proposed to constitute the intracellular signal activating TORC1 
in response to the nitrogen source (Crespo et al., 2002) (more detailed in 
section 1.3.3).  Inhibition of GS with the specific inhibitor MSX mimicked 
rapamycin treatment leading to activation of only a subset of targets negatively 
regulated by TORC1 (NCR and RTG, explained in detail in the next section).  
Thus, TORC1 and the nitrogen metabolism/regulation are intimately 
interconnected. 
 
 
 
 
Figure 3: Nitrogen metabolism core reactions 
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NITROGEN REGULATION 
 
Depending on the availability of the nitrogen source, yeast cells adapt their 
transcriptional, metabolic, and biosynthetic capabilities to maximize energy 
gain and growth.  Limiting concentrations of nitrogen reduce ribosome 
biogenesis and translation and result in enlarged G1 phase and slower growth 
(Brauer et al., 2006).  Upon complete removal of nitrogen cells enter a 
nitrogen-specific quiescent state (Klosinska et al., 2011).  The mechanisms 
involved in the co-ordination of growth rate to the quality and amount of 
available nitrogen are discussed in the following section. 
 
 
Permease sorting and nutrient uptake 
 
Nitrogenous compounds enter the cell via permease-mediated transport.  The 
permeases are integral membrane proteins, which are sorted through the 
secretory system and delivered to the plasma membrane (André, 1995; 
Regenberg et al., 1999).  More than 270 permeases with different specificity 
are encoded by S. cerevisiae.  For example, the entry of ammonium into the 
cell is facilitated by the three permeases Mep1, Mep2, and Mep3 (Marini et al., 
1997).  A total of 19 amino acid permeases ensure the uptake of amino acids 
required for protein synthesis or to be used as source of nitrogen (Nelissen et 
al., 1997).  In the presence of good nitrogen source, high affinity permeases 
are expressed at the plasma membrane.  In nitrogen poor conditions, more 
broad-spectrum general amino acid permeases are expressed.  Clear 
examples of such regulation are the high affinity tryptophan transporter Tat2 
and the general amino acid permease Gap1.  When cells are shifted from a 
good to a poor nitrogen source, Tat2 is ubiquitinated, internalized and 
degraded, while Gap1 is re-directed to the plasma membrane.  TORC1 
regulates permease sorting via the Tap42-phosphatase branch and possibly 
by Npr1.   
Npr1 is heavily phosphorylated when TORC1 is active and is rapidly 
dephosphorylated and activated following rapamycin treatment (Gander et al., 
2008).  Active Npr1 stabilizes several plasma membrane amino acid 
transporters by antagonizing their ubiquitin-mediated degradation (Beck et al., 
1999; Breitkreutz et al., 2010; de Craene et al., 2001; Jacinto et al., 2001; 
Schmidt et al., 1998; Soetens et al., 2001).   
The Tap42-phosphatase pathway is also involved in permease sorting 
by regulating the stability of the transcription factor Stp1 in response to 
activation of the SPS-sensing pathway (Shin et al., 2009).  The Ssy1-Ptr3-
Ssy5 (SPS) sensor is activated by external amino acids presence.  Upon 
activation of SPS, Ssy5 leads to the cleavage and release of two shortened 
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forms of the transcription factors Spt1 and Spt2.  Shortened active Spt1 and 
Spt2 relocalize to the nucleus where they up-regulate the expression of 
several amino acid permeases.  The other mechanism by which TORC1 
regulates permease sorting is via the nitrogen catabolite repression discussed 
below. 
 
 
Nitrogen catabolite repression 
 
Preferred nitrogen source repress the transcriptional programs required for the 
uptake and catabolism of less-preferred nitrogen sources.  This phenomenon 
is known as nitrogen catabolite repression (NCR).  The GATA factors are 
responsible for NCR regulation.  This group of DNA binding proteins is 
composed by the two transcriptional activators Gln3 and Gat1, and by the two 
transcriptional repressors Dal80 and Gzf3.  The cell controls NCR primarily by 
modulating the nuclear or cytoplasmic localization of the GATA transcriptional 
activators.  This mechanism partially requires Ure2, a cytoplasmic anchoring 
protein for Gln3.  In an ure2 mutant Gln3 localizes to the nucleus and drives 
transcription of NCR genes, regardless of the nitrogen source present.  On the 
contrary, Gat1 does not localize in the nucleus in an ure2 mutant.  Therefore, 
another mechanism different from Ure2 anchoring regulates Gat1 localization.  
In the presence of a good nitrogen source, both Gln3 and Gat1 are 
cytoplasmic, and repression of NCR genes is maximal.  During nitrogen 
starvation or in the presence of a poor nitrogen source Gln3 and Gat1 
relocalize to the nucleus, bind to the GATA sequences of NCR-responsive 
genes promoters and drive their transcription. 
TOR controls the expression of NCR genes by favoring the formation of 
the Ure2-Gln3 complex.  This involves the Tap42-phosphatase branch 
signaling of TORC1.  Mechanistically, TOR-dependent and independent 
events lead to Gln3 and possibly Ure2 phosphorylation favoring their 
association (Beck and Hall, 1999; Cardenas et al., 1999; Carvalho and Zheng, 
2003; Hardwick et al., 1999; Tate et al., 2010; 2009).  
 
 
Retrograde response 
 
The retrograde response is a mitochondrial-to-nucleus signal that drives the 
transcription of nuclear encoded mitochondrial genes to readjust carbohydrate 
and nitrogen metabolism.  Mitochondria are very important biosynthetic and 
energetic hubs for the cell.  Important metabolic processes such as lipid, 
nucleotide and amino acid precursor synthesis take place within the 
mitochondria.  Mitochondrial dysfunctions, possibly sensed by a decrease in 
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the levels of glutamate or glutamine, activate the retrograde response (RTG).  
The mitochondria are also one of the sites for α-ketoglutarate production, 
generated from pyruvate and acetyl-CoA by the first three enzymes of the TCA 
cycle.  Transcription of these three enzymes, including CIT2, is subject to RTG 
regulation.  Thus, growth on nitrogen sources requiring α-ketoglutarate for 
assimilation activates RTG (Liu and Butow, 1999).  
At the core of the retrograde response pathway are Rtg1 and Rtg3.  
Rtg1/3 form a heterodimeric transcriptional activator whose nuclear localization 
is regulated in response to mitochrondrial integrity and nitrogen availability.  
RTG regulatory pathways impinge on Rtg1/3 localization.  Phosphorylated 
Mks1 binds to Rtg1/3 and sequesters the complex in the cytoplasm.  Rtg2 
binding to Rtg1/3 allows nuclear translocation and activation of the RTG 
responsive genes.   
TORC1 negatively regulates RTG dependent transcription (Chen and 
Kaiser, 2003; Komeili et al., 2000; Shamji et al., 2000).  Whether TORC1 
regulates RTG directly or indirectly is still unclear.  TORC1 association with 
Mks1, and the fact that Mks1 is less phosphorylated following rapamycin 
treatment, would suggest a direct role for TORC1 in RTG.  On the contrary, the 
observation that RTG is robustly induced in cells with defective mitochondria 
even in rich medium, and the fact that rapamycin sometimes fails to induce 
CIT2 expression depending on the quality of the nitrogen source present in the 
medium, would speak for an indirect role of TORC1 in RTG control (Tate and 
Cooper, 2003).  
 
 
Another nitrogen regulated pathway 
 
Several line of evidence accumulated in the last years suggest that nitrogen-
source regulation of NCR and RTG genes does not proceed solely through the 
TORC1 pathway.  First, rapamycin induction of CIT2 occurs when cells are 
grown in the presence of ammonium and glutamine, but not in the presence of 
proline or glutamate (Tate and Cooper, 2003).  Second, Gln3 phosphorylation 
is different in rapamycin-treated versus nitrogen starved or MSX treated cells 
(Tate et al., 2009).  Third, Gln3 and Gat1 nuclear localization occurs in 
response to different stimuli, despite their overlapping function in regulating 
NCR.  Gln3 activates NCR predominantly following nitrogen limitation or MSX 
treatment, while Gat1 nuclear localization occurs in response predominantly to 
rapamycin treatment (Tate et al., 2010).  Taken together this data suggest the 
existence of at least one other nitrogen-signaling pathway, the nature of which 
has yet to be uncovered. 
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General amino acid control 
 
Another pathway that controls the transcription of many genes required for 
multiple amino acid biosynthetic pathways in response to starvation is the 
general amino acid control (GAAC).  Gcn4 is the transcriptional regulator at the 
core of GAAC.  GAAC is efficiently activated in response to increased 
unloaded tRNAs.  Gcn4 is controlled at the translational level by a reinitiation 
mechanism involving four short upstream open reading frames (uORFs) 
(Mueller and Hinnebusch, 1986).  In normal growth conditions and in the 
presence of abundant ternary complexes, the four uORFs upstream of GCN4 
ORF are efficiently recognized by the scanning ribosomes and initiate 
translation.  Upon amino acid starvation, multiple tRNAs become deacylated 
(Zaborske et al., 2009; 2010).  Deacylated tRNAs bind to Gcn2 and activate 
the kinase (Dong et al., 2000; Wek et al., 1989).  Active Gcn2 phosphorylates 
eIF2α, leading to reduced levels of ternary complex.  In turn, the scanning 
efficiency of ribosome to reinitiate translation is reduced.  In this way, an 
increasing proportion of ribosomes reinitiate translation at GCN4 bypassing the 
four uORFs.  Gcn4 is then translated and it activates GAAC responsive genes 
transcription, to promote amino acids biosynthesis to restore an efficient 
translation. 
NCR and GAAC also appear interlinked, since expression of GCN4 is 
subject to nitrogen catabolite repression (Godard et al., 2007).  Thus, the 
general amino acid control system is itself a major effector of the TOR 
pathway, with Gcn4 and Gln3 each inducing a similar number of genes during 
rapamycin treatment (Staschke et al., 2010). 
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1.3.3 TORC1 upstream signaling 
 
mTORC1 upstream regulation  
 
The discovery of mammalian TOR (mTOR) and its activation by nutrients 
(amino acids) and growth factors (insulin) strengthened the role of TOR as 
central controller of cell growth in eukaryotes (Brown et al., 1994; Chiu et al., 
1994; Sabatini et al., 1994; Sabers et al., 1995).  Two signaling pathways 
cooperatively converge on mTORC1 activation: the growth factor pathway and 
the amino acid sensing pathway.   
Growth factor stimulation of mTOR requires the PI3K/Akt signaling 
branch.  Upon growth factor stimulation, such as insulin, the activity of 
phosphatidylinositol 3-kinase is increased, leading to the production of 
phosphatidylinositol 3,4,5-triphosphate (PIP3).  PIP3 synthesis is antagonized 
by the lipid phosphatase PTEN.  Increasing levels of PIP3 activate PDK1 (3-
phosphoinositide dependent protein kinase-1), which phosphorylates the 
activation loop of Akt (Thr308).  Active Akt phosphorylates TSC2, inhibiting the 
tuberous sclerosis complex (TSC), which acts as GAP for the small GTP 
binding protein Rheb.  Thus, growth factors stimulation leads to the GTP 
loading and activation of Rheb.  Rheb was shown to localize to 
endomembranes (Buerger et al., 2006; Saito et al., 2005; Sancak et al., 2008; 
Takahashi et al., 2005).  Lysosomal active Rheb could bind to the N-terminal 
portion of the kinase domain of mTOR increasing mTOR activity by enhancing 
substrates recruitment (Long et al., 2005b; 2005a; Sato et al., 2009).  
Interestingly, loss of PTEN and activating mutations in PI3K are one of the 
most frequent genetic mutations in human cancer, underlying the importance 
of tight control over mTOR activation. 
Amino acids dictate mTORC1 lysosomal localization.  In the absence of 
aminoacids, mTORC1 is cytoplasmic and does not interact with Rheb (Long et 
al., 2005b).  Upon restimulation with amino acids mTORC1 punctae appear on 
the lysosomal membrane and mTOR interacts and is activated by Rheb.  
Thus, amino acids sufficiency plays an important role in mTOR activation by 
growth factors.  It is also noteworthy that the amino acids sensing pathway per 
se (in the absence of active Rheb) is unable to activate mTOR (Sancak et al., 
2008).  Thus only the simultaneous presences of growth factors, leading to 
Rheb activation, and amino acids, which tether mTOR to the Rheb-containing 
membranes, achieve mTOR activation.  The mechanism regulating mTORC1 
tethering on the lysosomal surface was lately uncovered and is the subject of 
intensive research.   
At the center of the amino acid sensing pathway are the Rag proteins 
(Sancak et al., 2008; 2010).  The Rags are Ras-related small GTP binding 
proteins.  Four Rag proteins exist: RagA, B, C and D.  RagA with RagB, and 
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RagC with RagD constitute two pair of homologues.  Strikingly, Rag proteins 
activation requires the formation of Rag etherodimers.  Always one of the 
RagA/B pair was found in complex with one of the RagC/D pair.  To add more 
complexity to Rags regulation, only one guanosine nucleotide binding 
combination lead to the active complex conformation.  This happens when 
RagA/B binds GTP and RagC/D binds GDP.  The complex results inactive in 
the RagA/B-GDP and RagC/D-GTP conformation.  Rag complexes 
simultaneously loaded with two GTPs or two GDPs were never observed.  
Only in the active conformation Rags tether mTORC1 to the lysosomal 
membrane.  Amino acid sufficiency leads to formation of the active Rag 
complex.  Different mechanisms explaining Rag activation and hence 
mTORC1 activation by amino acids were proposed.   
The first mechanism described is the so-called “V-ATPase dependent 
inside-out amino acid sensing mechanism” (Zoncu et al., 2011).  In early 
studies, it was shown that the pentameric Ragulator complex formed by p18, 
p14, MP1, HBXIP and C7orf59 (now renamed LAMTOR1-5) was required for 
Rag activation.  Ragulator activated RagA/B acting as GEF (Bar-Peled et al., 
2012).  Ragulator GEF activity did not reside in one single component, but 
rather in the whole complex.  The mechanism leading to Ragulator activation 
required the vacuolar ATPase and luminal amino acid accumulation, but was 
independent of the proton gradient generated. 
The second mechanism proposed for Rags activation involves 
glutaminolysis (Durán et al., 2012).  Glutaminolysis converts in a two-step 
reaction glutamine to α-ketoglutarate.  In the first step, catalyzed by the 
glutaminase (GLS), intracellular glutamine is converted to glutamate.  In the 
second step glutamate dehydrogenase (GDH) converts glutamate to α-
ketoglutarate.  Increasing α-ketoglutarate levels led to GTP loading of RagA/B 
and thus, mTORC1 activation in response to amino acids.  The important 
feature of this model is that it combines glutamine and leucine sensing, the two 
most potent amino acid inducers of mTORC1 activity.  The importance of 
leucine in this model is highlighted by the requirement of leucine as cofactor 
for GDH activity (Carobbio et al., 2009; Li et al., 2003).   
In the last year an octomeric complex interacting with Rags at the 
lysosomal surface was identified.  This complex was shown to posses GAP 
activity towards RagA/B and has therefore renamed GATOR (GTPase-
activating protein activity toward RAGs) (Bar-Peled et al., 2013).  GATOR was 
additionally dissected in two sub-complexes.  GATOR1 components depletion 
promoted constitutive localization of mTORC1 to the lysosomal membrane and 
blocked mTORC1 inactivation following amino acid withdrawal, suggesting that 
GATOR1 inhibits mTORC1 signaling.  On the other hand depletion of 
GATOR2 components prevented mTORC1 translocation to the lysosome and 
impaired amino acid–induced activation of mTORC1.  Taken together these 
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data indicate that the GATOR sub-complexes reciprocally regulate mTORC1-
dependent amino acid sensing.  More specifically GATOR1 functioned 
downstream of GATOR2 and upstream of Rags in the amino acid sensing of 
mTORC1.  Intriguingly, inactivating mutations and truncating deletions in the 
genes encoding the GATOR1 proteins DEPDC5 and nitrogen permease 
regulator-like 2 (NPRL2) were detected in human glioblastoma and ovarian 
tumors.  
 
 
 
Figure 4: mTORC1 upstream signaling 
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Yeast TORC1 upstream regulation  
 
Yeasts are insensitive to growth factor stimulation.  S. cerevisiae does not 
encode TSC homologs, and Rheb is not involved in TORC1 signaling.  The 
more ancient nutrient sensing activation of TORC1 is conserved and partially 
overlaps with mTOR activation by amino acids.  Thus, TOR couples nutrient 
availability (carbon and mostly nitrogen source) to cell growth.  But which is the 
signal impinging on TORC1?  And how does the nitrogen source influence 
TORC1 activity?   
Yeast TORC1 activation by the nitrogen source is still elusive, but 
similarities between yeast and mammalian amino acid sensing arose in the 
last few years.  In a first study, glutamine, the preferred nitrogen source of 
yeast cells, was proposed to constitute the intracellular signal transmitting 
nitrogen sufficiency to TORC1 (Crespo et al., 2002).  Glutamine in yeast is 
synthetized by the essential gene GLN1, encoding for the cytosolic glutamine 
synthetase (GS).  Inhibition of glutamine synthesis with the specific GS 
inhibitor MSX (methionine sulfoximine) led to decrease intracellular glutamine 
levels and arrest in cell cycle equivalent to rapamycin treatment.  Some 
readouts of TORC1, the transcription factors Gln3, Rtg1 and Rtg3 were 
affected by MSX treatment, while other TORC1 readouts such as Gat1, 
Msn2/4 were unaffected.  In mammalian cells, TOR responds to essential 
amino acids used for protein synthesis (Hara et al., 1998; Wang et al., 1998).  
In yeast, TOR may respond to glutamine both as an amino acid required for 
protein synthesis and as a nitrogen source.  The finding that only a portion of 
TORC1 readouts is affected by intracellular glutamine levels confirms the 
hypothesis that TORC1 acts as a multichannel processor to differentially 
regulate gene expression in response to different nutrient conditions (Shamji et 
al., 2000). 
In a more recent paper, the yeast homolog of the Rag proteins, Gtr1 
and Gtr2 were shown to be important for TORC1 activation in response to 
amino acid availability (Binda et al., 2009).  Gtr1 and Gtr2 were found in 
complex with two other proteins, Ego1 and Ego3.  EGO1, EGO3 and GTR2 
deletions were all identified in a selection for mutants that are unable to exit 
from a rapamycin-induced growth arrest (Dubouloz et al., 2005).  All together 
these proteins form the tetrameric EGO complex.  Ego1 and Ego3 act as 
functional homolog of the Ragulator complex and are involved in complex 
stability (Kogan et al., 2010).  The EGO complex (EGOC) was found on the 
vacuolar membrane, the same sub-cellular localization as TORC1.  Active 
EGOC, analogously to Rags, required Gtr1-GTP and Gtr2-GDP binding.  
EGOC signaling to TORC1 was so far studied the most in response to leucine 
starvation and restimulation.  Leucine starvation destabilized the Gtr1-TOR 
interaction leading to decreased phosphorylation of Sch9, a direct target of 
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TORC1.  Expression of a GTP locked version of Gtr1 (Gtr1Q65L) led to delayed 
Sch9 dephosphorylation during leucine starvation.  Cells expressing the 
dominant negative version of Gtr1 locked in a GDP binding conformation 
(Gtr1S20L) were reported to be sick.  In another study, leucyl-tRNA synthetase 
(LeuRS) was proposed to regulate TORC1 activity via the EGOC (Bonfils et 
al., 2012).  The molecular mechanism involved the interaction between the 
editing site of LeuRS and Gtr1.  In the presence of intracellular leucine, the 
interaction LeuRS-Gtr1 protected Gtr1-GTP loading, inhibiting GTP hydrolysis.  
The GEF and GAP for Gtr1 were identified as Vam6 and the Npr2/Npr3/Iml1 
containing complex (Binda et al., 2009; Panchaud et al., 2013).   
Vam6 is a vacuolar protein that plays a critical role in the tethering steps 
of vacuolar membrane fusion by facilitating guanine nucleotide exchange on 
small guanosine triphosphatase Ypt7 (Oka et al., 2004; Raymond et al., 1992; 
Robinson et al., 1988; Rothman et al., 1989; Wurmser et al., 2000).	
    It was 
later demonstrated that Vam6 also functioned as GEF for Gtr1 in vitro and in 
vivo (Binda et al., 2009).  Vam6 loss decreased Gtr1-TORC1 interaction.  
Moreover, unaltered TORC1 signaling was observed in a ypt7 strain, which 
displays the same abnormal vacuolar fragmentation as a vam6 strain.  Thus, in 
addition to its regulatory role in homotypic vacuolar fusion and vacuole protein 
sorting as part of the HOPS complex, Vam6 also controls the activity of 
TORC1 by activating the Gtr1 subunit of the EGOC. 
Early evidence suggested that Npr2 and Npr3 positively regulate non-
nitrogen-starvation (NNS)-induced autophagy by negatively regulating TORC1 
(Neklesa and Davis, 2009; Wu and Tu, 2011).  NNS-autophagy is a particular 
form of autophagy triggered when cells are switched from a rich medium to a 
minimal medium in the complete absence of nitrogen starvation.  Further more, 
Npr2 and Npr3 were found in association with other proteins in the large SEA 
complex.  The SEA is a coatomer-related complex that associates dynamically 
with the vacuole (Dokudovskaya et al., 2011).  In a later study the SEA 
complex was genetically dissected.  It emerged that it could be divided in two 
sub-complexes possessing different effects on TORC1 activation.  The first 
complex, containing Npr2, Npr3 and Iml1 acted as GAP for Gtr1, thus 
downregulating TORC1 activity.  The complex was therefore named SEACIT 
(for SEAC subcomplex inhibiting TORC1 signaling) and is the homolog of 
GATOR1 in mammalian cells.  The second complex, formed by Sea2, Sea3, 
Sea4, Seh1, and Sec13, antagonized the negative regulation of SEACIT.  
Renamed SEACAT (for SEAC subcomplex activating TORC1 signaling) it 
constitutes the homolog of GATOR2 in higher eukaryotes (Panchaud et al., 
2013). 
Overall these data highlight the parallelism existing between Rags and 
EGOC in the signaling of amino acids sufficiency to (m)TORC1.  But few 
considerations on the differences existing between the two upstream signaling 
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pathway should be taken into account.  First, TORC1 activation by the EGOC 
was dependent on the presence of Tco89, a nonessential component of 
TORC1.  If the EGOC were essential for TORC1 activity, one would expect it 
being dependent on essential components of the pathway.  Second, Gtr1 
deletion is not lethal and induces slow growth and decreased Sch9 
phosphorylation.  Third, in Gtr1Q65L expressing cells TORC1 activity was still 
repressed by ammonium starvation.  Fourth, the SEACIT inhibition of TORC1 
likely does not apply during nitrogen starvation, since Npr2 and Npr3 are 
clearly involved in NNS-induced autophagy.  Fifth, the majority of the 
experiments supporting EGO complex signaling to TORC1 were always 
performed in the presence/absence of leucine.  The importance of EGOC 
signaling in the presence/absence of other amino acids was never thoroughly 
examined (e.g. glutamine, the other proposed upstream signal of TORC1).  
Therefore, it appears that EGOC is sufficient to explain, at least partially, 
amino acids sensing signaling to TORC1, but is not sufficient to explain the 
nitrogen sensing signaling to TORC1.  It is tempting to speculate that amino 
acid and nitrogen source sensing are separate and act independently on 
TORC1.  The analysis of this point will be the focus of the results section.   
 
 
Figure 5: TORC1 upstream signaling 
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1.4 AIM OF THE STUDY 
 
 
As outlined in the introduction, the upstream regulation of TORC1 in response 
to the nitrogen source is only partially understood.  The signaling deriving from 
amino acid sufficiency is only partly transmitted to TORC1 by the EGO 
complex.  A unifying model of how the nitrogen source (amino acids and other 
nitrogenous compounds such as ammonium) is sensed and activates TORC1 
is still missing.   
The two major aims of the study are: 1) clarifying possible differences in the 
sensing of nitrogen source versus amino acid sufficiency; 2) determining the 
signaling route leading to TORC1 activation in response to the nitrogen 
source.   
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2  RESULTS 
 
 
 
The following manuscript published on The Journal of Biological Chemistry 
(JBC) forms the basis of my PhD thesis.  The cumulative bibliography from the 
accepted paper and the thesis is given on page 81.   
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2.1 CAPSULE 
 
 
Background: Nutrients, in particular the nitrogen source, activate TORC1 
signaling in yeast. 
Results: The nitrogen source stimulates a rapid, transient activation of 
TORC1.  Preferred nitrogen sources result in sustained TORC1 activity and 
growth, via a mechanism dependent on glutamine accumulation and 
independent of the Gtr/Rag. 
Conclusions: Nutrients activate yeast TORC1 via two distinct mechanisms. 
Significance: Gtr/Rag is not the only mechanism to activate TORC1 in 
response to nutrients. 
 
 
 
 
2.2 ABSTRACT 
 
 
The evolutionary conserved TOR complex 1 (TORC1) activates cell growth in 
response to nutrients.  In yeast, TORC1 responds to the nitrogen source via a 
poorly understood mechanism.  Leucine, and perhaps other amino acids, 
activates TORC1 via the small GTPases Gtr1 and Gtr2, orthologs of the 
mammalian Rag GTPases.  Here we investigate the activation of TORC1 by 
the nitrogen source and how this might be related to TORC1 activation by 
Gtr/Rag.  The quality of the nitrogen source, as defined by its ability to promote 
growth and glutamine accumulation, directly correlates with its ability to 
activate TORC1 as measured by Sch9 phosphorylation.  Preferred nitrogen 
sources stimulate rapid, sustained Sch9 phosphorylation and glutamine 
accumulation.  Inhibition of glutamine synthesis reduces TORC1 activity and 
growth.  Poor nitrogen sources stimulate rapid but transient Sch9 
phosphorylation.  A Gtr1 deficiency prevents the transient stimulation of 
TORC1 but does not affect the sustained TORC1 activity in response to good 
nitrogen sources.  These findings suggest that the nitrogen source must be 
converted to glutamine, the preferred nitrogen source in yeast, to sustain 
TORC1 activity.  Furthermore, sustained TORC1 activity is independent of 
Gtr/Rag.  Thus, the nitrogen source and Gtr/Rag activate TORC1 via different 
mechanisms. 
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2.3 INTRODUCTION 
 
 
To avoid metabolic stress, unicellular organisms possess finely tuned 
regulatory systems to ensure that cell growth and replication are tightly 
coupled to nutrient availability (Smets et al., 2010).  Nitrogen is an essential 
element required for synthesis of amino acids, nucleotides and other cellular 
components.  The budding yeast Saccharomyces cerevisiae can sense, take 
up and assimilate several different nitrogen sources (N-sources) (Magasanik 
and Kaiser, 2002).  Qualitatively better N-sources are assimilated before 
others.  The quality of a N-source is generally defined by its ability i) to sustain 
core nitrogen metabolism and thus growth and ii) to activate or repress specific 
transcriptional programs that mediate selective nitrogen assimilation (Godard 
et al., 2007).  To maintain growth, N-sources must sustain core nitrogen 
metabolism that involves four interconnected enzymatic reactions with α-
ketoglutarate, glutamate, glutamine and ammonia as key metabolites (Cooper, 
1982).  Glutamine is considered the best N-source for yeast cells (Cooper, 
1982).  In the presence of exogenous glutamine as the N-source, yeast cells 
grow and replicate at a high rate, and maximally repress the metabolic 
pathways required for utilization of other N-sources (Hofman-Bang, 1999; 
Magasanik and Kaiser, 2002).  Moreover, glutamine plays an essential role in 
anabolic metabolism, in particular in purine and pyrimidine synthesis, and in 
the biosynthesis of other amino acids following conversion to glutamate.  
Amino acids other than glutamate and glutamine can also serve as nitrogen 
sources, but only by sustaining nitrogen core metabolism indirectly.  These 
amino acids undergo deamination, liberating free ammonia which can then be 
used for glutamate or glutamine synthesis, or generate glutamate via 
transamination (Magasanik, 1992).  Depending on the amino acid, the 
remaining carbon skeleton following deamination or transamination is either 
fed into carbon metabolism or converted through the Ehrlich pathway into fuse 
oils and secreted (Hazelwood et al., 2008). 
Metabolic adaptation to the nutritional environment is achieved via complex 
transcriptional, translational and post-translational regulation which relies on 
nutrient sensing and signal transduction (De Virgilio and Loewith, 2006; 
Ljungdahl and Daignan-Fornier, 2012).  The target of rapamycin (TOR) 
pathway is a central regulator of cell growth in response to nutrients (Loewith 
and Hall, 2011; Wullschleger et al., 2006).  TOR is an evolutionary conserved 
protein kinase found in two highly conserved multi-protein complexes termed 
TOR complex 1 (TORC1) and TORC2.  TORC1 is acutely sensitive to 
rapamycin and is activated by nutrients (Barbet et al., 1996; Beck and Hall, 
1999; Smets et al., 2010). TORC1 couples nutrient sufficiency to growth by 
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activating anabolic processes such as protein synthesis and ribosome 
biogenesis, and repressing catabolic processes such as autophagy.  Despite 
the many cellular functions in which TORC1 is involved, few direct TORC1 
targets are known.  The best-characterized TORC1 direct target in yeast is 
Sch9, a kinase belonging to the AGC kinase family also containing PKA, PKG 
and PKC.  In the presence of nutrients, TORC1 phosphorylates at least six 
residues in the Sch9 C-terminus (C-term) and thereby activates Sch9 in a 
rapamycin sensitive manner (Huber et al., 2009; Magasanik and Kaiser, 2002; 
Soulard et al., 2010; Urban et al., 2007).  Sch9 activates genes encoding 
ribosomal proteins and factors required for ribosome biogenesis (RiBi regulon) 
(Godard et al., 2007; Huber et al., 2011), ultimately controlling cell growth and 
longevity (Cooper, 1982; Fabrizio et al., 2001; Kaeberlein et al., 2005; Toda et 
al., 1988).  
 In yeast, the so-called EGO complex (EGOC) mediates amino-acid-
dependent activation of TORC1 (Binda et al., 2010; Cooper, 1982).  EGOC 
consists of Gtr1, Gtr2, Ego1 and Ego3.  The small GTP binding proteins Gtr1 
and Gtr2 are orthologs of the mammalian RagA/B and RagC/D GTPases, 
respectively (Binda et al., 2009; Hofman-Bang, 1999; Kim et al., 2008; 
Magasanik and Kaiser, 2002; Sancak et al., 2008).  Like their mammalian 
counterparts, Gtr1 and Gtr2 form a heterodimer that is active in the Gtr1GTP-
Gtr2GDP conformation.  Ego1 and Ego3, the functional homologs of the 
mammalian Ragulator complex (Laplante and Sabatini, 2012; Magasanik, 
1992), are also required for activation of Gtr.  The amino acid leucine 
stimulates Gtr1GTP interaction with Ego1, thereby activating EGOC and, in turn, 
TORC1 (Binda et al., 2009; Hazelwood et al., 2008).  Vam6 and the 
Npr2/Npr3/Iml1 complex were identified as the guanine nucleotide exchange 
factor (GEF) and GTPase-activating protein (GAP), respectively, for Gtr1 
(Binda et al., 2009; De Virgilio and Loewith, 2006; Ljungdahl and Daignan-
Fornier, 2012; Panchaud et al., 2013).  The yeast leucyl-tRNA synthetase 
(LeuRS) was reported to positively influence the GTP loading of Gtr1 (Bonfils 
et al., 2012; Loewith and Hall, 2011; Wullschleger et al., 2006).   
 The rapamycin induced response in yeast mimics the response to 
nitrogen starvation (Cardenas et al., 1999; Hardwick et al., 1999; Shamji et al., 
2000).  This early observation led to the conclusion that the N-source activates 
TORC1.  The mechanism by which the N-source, in the form of an amino acid 
or other nitrogenous compound, activates TORC1 is poorly understood.  Early 
studies reported a prominent role for the intracellular level of glutamine in 
TORC1 activation, at least toward the transcription factors Gln3, Rtg1 and 
Rtg3 (Crespo et al., 2002).  Although increasing evidence suggests that 
intracellular leucine stimulates TORC1 via EGOC, it is not yet known if the N-
source, including ammonium or other amino acids, activates TORC1 via 
EGOC.  Cells expressing a constitutively active version of Gtr1 (Gtr1Q65L) still 
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down-regulate TORC1 activity in response to ammonium starvation (Binda et 
al., 2009), suggesting that the N-source signals to TORC1 independently of 
Gtr1. 
 Here we investigate the modulation of TORC1 activity by different N-
sources in vivo, using the phosphorylation state of Sch9 as readout.  We show 
that preferred N-sources sustain TORC1 activity and growth rate by rapidly 
increasing glutamine synthesis.  Moreover, we demonstrate that glutamine 
synthesis does not require Vam6 or Gtr1 for TORC1 activation.  Thus, there 
are distinct molecular mechanisms by which nutrients activate TORC1.  
 
 
2.4 RESULTS 
 
 
TORC1 rapidly phosphorylates Sch9 in response to the nitrogen source.  We 
initially sought to establish a system, using the phosphorylation state of the 
Sch9 C-term as a readout, to monitor changes in TORC1 activity in response 
to nutrients in vivo.  Moreover, we reasoned that signaling events associated 
with nutrient availability would be triggered very rapidly, as in the case of 
glucose-induced cAMP production in yeast cells (Thevelein and De Winde, 
1999; van der Plaat, 1974).  To capture fast acting signaling events, Sch9 
phosphorylation was assayed as early as 20 seconds, and up to 4 hours, after 
stimulation with nutrients.  We used the strain YSBN9 (Canelas et al., 2010) 
which we made prototrophic by transformation with the centromeric plasmid 
pSCH9-3HA containing the selectable marker URA3 in addition to expressing 
C-terminally 3xHA tagged Sch9 under the control of its own promoter.  By 
working with a prototrophic strain, we were able to grow cells in medium 
supplemented with a single nitrogen source, thereby avoiding the confounding 
effect of the simultaneous presence of different N-sources. 
We first validated our system by pharmacologically inhibiting TORC1.  
Rapamycin treatment of yeast cells, grown in the presence of glutamine, 
resulted in an acute decrease in Sch9 C-term phosphorylation.  Compared to 
untreated cells, Sch9 phosphorylation decreased to minimal levels within 5 
minutes and remained low for the remainder of the experiment (Fig. 6A and B).  
We next sought to determine the effect of changes in the nutritional 
environment on TORC1 activity by varying the quality of nutrients from good to 
poor (nutrient downshift) or from poor to good (nutrient upshift).  When 
performing nutrient downshift experiments, cells were grown in the presence of 
the preferred N-source glutamine and switched to medium containing a less 
preferred N-source such as proline.  As observed for rapamycin treatment, 
Sch9 phosphorylation decreased to minimal levels within minutes after nutrient 
downshift (Fig. 6C and D).  These data underscore the similarity between 
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pharmacological and physiological inhibition of TORC1.  In the case of nutrient 
upshift experiments, cells were grown in the presence of proline and 
stimulated with a good N-source.  When using glutamine as the good N-
source, Sch9 phosphorylation levels increased more than two fold already 
within one minute after addition of glutamine (Fig. 6E and F).  Following this 
initial increase, Sch9 phosphorylation decreased to rise again at 15 minutes.  
Pre-treating cells with rapamycin for 10 minutes was sufficient to block the 
increase in Sch9 phosphorylation induced by glutamine (Fig. 6G), 
demonstrating that Sch9 was phosphorylated by TORC1 during the nutrient 
upshift.  To determine whether the increase in Sch9 phosphorylation was 
caused exclusively by the presence of the newly introduced N-source, we 
performed mock upshift experiments without increasing the nitrogen quality.  
As expected, no increase in Sch9 phosphorylation was observed when cells 
were treated with water or the same medium in which they were growing (Fig. 
6H and I).  Overall, these findings indicate that our in vivo system is valid and 
that the N-source rapidly stimulates TORC1 activity.  
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Figure 6: TORC1 rapidly phosphorylates Sch9 in response to the nitrogen 
source. 
(A and B) Sch9 C-term phosphorylation decreases upon rapamycin treatment (200 
nM) and  (C and D) during nutrient downshift (glutamine to proline).  (D and E) Sch9 
C-term phosphorylation increases during nutrient upshift (proline to glutamine).  Sch9 
phosphorylation is unaffected when cells are subjected to either (G) nutrient upshift 
(Pro to Gln) following rapamycin pre-treatment (200 nM, 10 min), or mock treated with 
(H) water or (I) mock treated with the same medium in which they were growing. 
Protein samples were chemically cleaved with NTCB.  Electrophoretic mobility shift 
induced by Sch9 C-term phosphorylation state assessed by Western blot (panel A, C, 
E, G, H and I).  Relative quantification of Sch9 C-term phosphorylation (panel B, D 
and F) is expressed as mean ± SEM of at least 3 independent biological experiments.    
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The quality of the nitrogen source determines TORC1 activity.  To gain 
mechanistic insight into the nutrient-induced activation of TORC1, we 
quantified the extent of TORC1 activity over time in response to different N-
sources.  We determined the dynamics of Sch9 phosphorylation during 
nutrient upshift experiments in response to various nitrogen sources including 
growth-promoting amino acids and ammonium (Fig. 7).  All N-sources tested 
induced a rapid increase in Sch9 phosphorylation within 20 seconds and 
peaking at 2-3 minutes after stimulation, although with different amplitudes.  As 
observed above for glutamine, this rapid increase was transient as Sch9 
phosphorylation then decreased, often to near basal levels.  Upon comparing 
the change in Sch9 phosphorylation at 30 minutes and up to 4 hours after shift, 
the N-sources clustered into two discrete groups.  The first group contained 
the so-called high-end N-sources, able to re-stimulate and sustain high 
TORC1 activity (p < 0.05).  The second group contained the low-end N-
sources where Sch9 phosphorylation remained low (Fig. 7A).  Arginine, 
asparagine, glutamine, and ammonium belonged to the high-end N-sources 
(Fig. 7B).  Serine, threonine, the branched chain amino acids (isoleucine, 
leucine and valine), the negatively charged amino acids (aspartate and 
glutamate), and the hydrophobic amino acids (alanine, methionine, 
phenylalanine and tryptophan) fell in the low-end group (Fig. 7C).  Tyrosine 
was not included in the study because of its low solubility in water.  All the N-
sources belonging to the high-end group were previously characterized as 
preferred N-sources (Godard et al., 2007).  Similarly, the N-sources belonging 
to the low-end group were previously classified as less preferred, with the 
exception of alanine, serine, aspartate and glutamate.  We conclude that 
sustained TORC1 activity after nutrient upshift correlates with the quality of the 
N-source. 
 We next asked whether the quality of the initial N-source would affect 
the extent of TORC1 stimulation upon nutrient upshift.  To this end, we 
compared the ability of glutamine and ammonium, two preferred N-sources, to 
stimulate TORC1 activity in cells initially grown in the presence of proline or 
leucine, an intermediate and a non-preferred N-source, respectively.  We 
observed that the glutamine- or ammonium-induced increase in Sch9 
phosphorylation was equal in cells originally grown in the presence of proline 
or leucine as the only N-source (data not shown).  Therefore, TORC1 activity 
is solely dependent on the quality of the N-source added during nutrient 
upshift.  Collectively, we conclude that the extent of TORC1 stimulation in vivo 
parallels the quality of the N-source.  In general, preferred N-sources stimulate 
and sustain TORC1 activity whereas poor N-sources do not.  
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Figure 7: The quality of the nitrogen source determines TORC1 activity. 
N-sources can be grouped based on the increase in Sch9 C-term phosphorylation 
upon nutrient upshift.  (A).  Classification of the N-sources based on their ability to 
sustain TORC1 activity for up to 4 hours after shift.  The fold change mean value ±SD 
of Sch9 phosphorylation at five different time points (30, 60, 120, 180 and 240 
minutes after shift) for each N-source is shown in the graph.  For statistical analysis, 
we compared in a two-way ANOVA analysis the values of this five time points for 
each N-source to the respective values obtained in mock shift experiments with water.  
In four cases (Arg, Asn, Gln and NH4+) the difference was significant (p < 0.05).  (B) 
Fold change of Sch9 C-term relative phosphorylation following nutrient upshift from 
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proline to individual high-end N-sources (arginine, asparagine, glutamine, and 
ammonium).  Relative quantifications are expressed as mean ± SEM of at least 3 
independent biological experiments.  (C) Fold change of Sch9 C-term relative 
phosphorylation following nutrient upshift from proline to individual low-end N-sources 
(alanine, aspartate, glutamate, isoleucine, leucine, methionine, phenylalanine, serine, 
threonine, tryptophan and valine).  Relative quantifications are expressed as mean ± 
SEM of at least three independent biological experiments. 
 
 
The quality of the nitrogen source couples TORC1 activation to cell growth.  
Phosphorylation of Sch9 influences its kinase activity in vitro and in vivo 
(Huber et al., 2011; Urban et al., 2007).  We next asked whether the Sch9 
phosphorylation increase observed during nutrient upshift would result in 
increased Sch9 kinase activity.  To monitor Sch9 kinase activity in vivo, we 
measured the phosphorylation state of Dot6, a direct target of Sch9 involved in 
ribosome biogenesis (Huber et al., 2011).  As assayed by immunoblotting, 
nutrient upshifts with glutamine, leucine or ammonium resulted in the 
appearance of a slow-migrating form of C-terminally 3xHA tagged Dot6 (Fig. 
8A).  As expected, no detectable change in Dot6 phosphorylation was 
observed when supplementing cells with water (Fig. 8A).  In all three nutrient 
upshift experiments, Dot6 phosphorylation increased already at 2-3 minutes 
following stimulation, consistent with the rapid increase in Sch9 
phosphorylation described above.  Interestingly, Dot6 phosphorylation was 
sustained up to 30 minutes after stimulation with the preferred N-source 
glutamine or ammonium, whereas Dot6 phosphorylation decreased starting at 
8 minutes after shift to the less preferred N-source leucine.  For unknown 
reasons, shift to leucine also caused a decrease in Dot6 protein levels at 30 
minutes after the shift.  These data suggest that nutrient stimulation rapidly 
activates Sch9 downstream of TORC1. 
 Active Sch9 positively regulates ribosome biogenesis thereby 
increasing cell growth potential (Jorgensen et al., 2002; Urban et al., 2007).  
We tested the physiological impact of TORC1 activation upon nutrient upshift 
on cell growth.  Yeast cells grown in the presence of proline were 
supplemented with glutamine, ammonium, leucine or water (Fig. 8B).  
Following glutamine or ammonium stimulation, growth increased within 2-3 
hours after treatment compared to un-stimulated cells.  The observed increase 
in growth rates paralleled sustained Sch9 and Dot6 phosphorylation up to 4 
hours after treatment (Fig. 8C and D).  Conversely, growth rate was unaffected 
when cells were supplemented with leucine or water, and Sch9 and Dot6 
phosphorylation remained low.  Thus, stimulation with preferred N-sources 
confers an increase in TORC1 activity and a corresponding increase in 
proliferation.   
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Figure 8: The quality of the nitrogen source couples TORC1 activation to cell 
growth. 
Sch9 is activated following nutrient upshift.  (A) The phosphorylation of the Sch9 
direct target Dot6 increases during nutrient upshift from proline to glutamine, leucine, 
ammonium, but not when treating cells with water.  A representative Western blot of 
protein extracts is shown.  The red line indicates the fast migrating band of Dot6, 
which corresponds to the hypo-phosphorylated form.  (B) Cell growth is increased 
after glutamine and ammonium upshift, but not when using leucine or in cells treated 
with water.  A representative growth curve of three independent replicates is shown.  
Increased phosphorylation of (C) Sch9 C-term and (D) Dot6 correlate with the N-
source induced increased in cell growth.  
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Intracellular glutamine is a metabolic input to activate TORC1.  As described 
above, prolonged stimulation of TORC1 by preferred N-sources correlates with 
increased growth rate.  These data suggest that the transient TORC1 
activation elicited in the first minutes of nutrient upshift, common to all N-
sources tested, is not sufficient to maintain growth.  We tested this hypothesis 
by titrating the concentration of glutamine used for the nutrient upshift and 
monitoring the effects on Sch9 phosphorylation and growth rate.  Indeed, a 
lower final concentration of glutamine (5 mg/L, Gln 1%) was still able to rapidly 
induce TORC1 activity, but failed to sustain Sch9 phosphorylation over time 
(Fig. 9A and B).  The low glutamine concentration also failed to enhance the 
growth rate of cells grown on proline, while an intermediate concentration of 
glutamine (50 mg/L, Gln 10%) only partially increased growth (Fig. 9C).  In 
conclusion, low concentrations of glutamine, unable to sustain TORC1 activity 
over time and consequently growth, still trigger an early activation wave of 
TORC1.   
The above data suggest two distinct mechanisms for how N-sources stimulate 
TORC1.  The first mechanism, responsible for the rapid, transient activation of 
TORC1, is triggered by all N-sources independent of quality and is unable to 
sustain growth.  The second mechanism, in response to good N-sources, 
mediates sustained TORC1 activity and growth.  The sustained stimulation of 
TORC1 could be dependent on a 'metabolic input' that a poor N-source is not 
able to generate or maintain.  To investigate the nature of a potential 
‘metabolic input’, we measured the changes in relative levels of several 
metabolites by mass spectrometry, focusing on the first 10 minutes after 
nutrient upshift.  We reasoned that if a common metabolic input exists, its 
relative level would increase/decrease within the first minutes after nutrient 
upshift, and upon reaching a certain threshold would sustain TORC1 activity 
and growth.  We consistently found that the intracellular level of glutamine 
increased in cells stimulated with a preferred N-source such as ammonium, 
asparagine or glutamine itself (Fig. 9D, E, G and H).  Interestingly, glutamine 
levels increased two fold already within two minutes after ammonium and 
asparagine addition, but remained below the two-fold threshold for up to 9 
minutes after addition of leucine (Fig. 9F).  When stimulating with a lower 
amount of glutamine (1%), we observed a corresponding smaller and transient 
increase of intracellular glutamine (Fig. 9H).  These data suggest that 
intracellular glutamine may be the common metabolite required for TORC1 
activation.   
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Figure 9: Intracellular glutamine constitutes a metabolic input to activate 
TORC1. 
The increase in cell growth rate following nutrient upshift depends on the quality and 
quantity of the given N-source.  (A and B) Nutrient upshift with 1% glutamine (final 
concentration 5 mg/L) results in low Sch9 C-term phosphorylation at 30 min after shift 
compared with nominal (100%) glutamine concentration (final concentration 0.5 g/L).  
Relative Sch9 C-term phosphorylation quantification is expressed as mean ± SEM.  
(C) Cell growth rate with different N-sources at different concentrations.  Where not 
specified or when 100%, the final concentration of the N-source is 0.5 g/L.  The black 
arrow indicates the time of stimulation.  A representative growth curve of three 
independent replicates is shown. 
Glutamine synthesis and accumulation within the first 10 minutes after nutrient upshift 
are key features of high-end, preferred N-sources.  Intracellular glutamine levels 
measured by LC-MS/MS during nutrient upshifts with (D) ammonium, (E) asparagine, 
(F) leucine, (G) glutamine at the final concentration of 0.5 g/L (100%), and (H) 
glutamine at the final concentration of 5 mg/L (glutamine 1%).  Fold changes of 
relative glutamine levels are expressed as mean ± SEM. 
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 Next, we investigated the role of glutamine synthesis in TORC1 
activation during nutrient upshift.  To this end, we used the drug methionine 
sulfoximine (MSX), a specific inhibitor of glutamine synthetase.  MSX 
treatment of cells growing in glutamine-free media leads to an arrest in cell 
growth, due to decreased intracellular glutamine levels and decreased TORC1 
signaling (Crespo et al., 2002).  As previously reported, MSX treatment 
compromised growth of cells grown in the presence of ammonium or leucine, 
but not in the presence of glutamine (data not shown).  We tested the effect of 
blocking glutamine synthesis on activation of TORC1 by treating cells for one 
hour with MSX before addition of an N-source.  Pre-treatment with MSX 
prevented Sch9 phosphorylation when stimulating with leucine or ammonium 
(Fig 10D and E.).  When stimulating with ammonium, Sch9 phosphorylation 
was significantly impaired in both the initial and delayed phases of TORC1 
activation (p < 0.01) (Fig. 10D).  MSX decreased the transient stimulation 
observed with leucine (p < 0.05) (Fig. 10E).  However, no significant difference 
in the increase in Sch9 phosphorylation was observed in cells stimulated with 
glutamine (Fig. 10F).  These data suggest that ammonium assimilation into 
glutamine is essential for ammonium to be sensed and translated into the 
metabolic input activating TORC1.  We conclude that the intracellular level of 
glutamine is important for TORC1 activation by the N-source.  Intracellular 
accumulation of glutamine constitutes a metabolic input for TORC1 activation 
in response to a good N-source.  
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Figure 10: MSX treatment blocks the metabolic input to TORC1. 
Glutamine synthesis and accumulation constitute a metabolic input signal to TORC1.  
MSX pre-treatment (2 mM, 1 h) reduces the Sch9 C-term phosphorylation increase 
during nutrient upshift with (A) ammonium and (B) leucine, but not when using (C) 
glutamine.  Relative quantifications are expressed as mean ± SEM.  Statistical 
analysis was performed using two-way ANOVA.  
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The metabolic input acts independently of Gtr/Rag in TORC1 activation.  Next, 
we addressed the mechanism by which the N-source activates TORC1, and 
how this is related to amino-acid-dependent activation of TORC1.  Leucine and 
possibly other amino acids activate TORC1 via EGOC (see Introduction), 
whereas the mechanism of TORC1 activation by N-sources such as 
ammonium and glutamine is unknown.  To address the role of EGOC in 
TORC1 signaling during N-source upshift, we examined glutamine stimulation 
in strains lacking GTR1 or VAM6.  Glutamine failed to stimulate rapid Sch9 
phosphorylation in gtr1Δ and vam6Δ strains, but was still able to induce the 
delayed, sustained Sch9 phosphorylation (Fig. 11A and B).  The delayed Sch9 
phosphorylation in the deletion strains was comparable to that observed in a 
wild-type strain (Fig. 11A and B).  We also tested the effect of inhibiting Gtr1 
using 1,3-dihydro-1-hydroxy-2,1-benzoxa-borole (DHBB).  DHBB occupies the 
editing site in LeuRS, inhibiting the interaction of LeuRS with Gtr1 and favoring 
hydrolysis of Gtr1-bound GTP (Bonfils et al., 2012).  DHBB pre-treatment had 
no effect on Sch9 phosphorylation following glutamine stimulation, but 
decreased TORC1 activation upon stimulation with leucine (Fig. 11C, D, E and 
F).  These data are consistent with a positive role for EGOC in the rapid, 
transient activation of TORC1, and at the same time suggest that glutamine 
accumulation is able to stimulate and sustain TORC1 activity even in the 
absence of a functional EGOC.  Moreover, LeuRS appears to play a role in the 
specific activation of TORC1 by leucine, and is dispensable for the N-source 
input. 
To investigate further the requirement of EGOC for growth, we compared 
growth of a wild-type and several EGOC mutant strains on solid YMM media 
supplemented with only one nitrogen source.  We used vam6Δ, gtr1Δ and 
gtr2Δ strains and strains in which we complemented GTR1 loss by ectopically 
expressing wild-type GTR1 or allelic versions of GTR1 encoding inactive GDP-
bound (GTR1S20L) or active GTP-bound Gtr1 (GTR1Q65L).  Strains lacking 
GTR2 grew worse than other EGOC deficient strains (Fig. 11G), indicating a 
dominant role for GTR2 over GTR1 as previously reported (Binda et al., 2009).  
This may be due to a more prominent role of Gtr2 in permease sorting, 
although both GTR2 and GTR1 were reported to be required for the plasma 
membrane sorting of Gap1 and Put4 (Gao and Kaiser, 2006).  Consistent with 
this explanation, we found that the gtr2Δ strain failed to grow on proline as the 
sole N-source.  Conversely, the gtr1Δ strain was viable on proline medium 
(Fig. 11G), indicating that at least in our background (S288c derived 
prototroph) Gtr1 is not required for permease sorting to the plasma membrane.  
Deletion of GTR1 negatively affected growth only when cells were forced to 
use leucine as the sole N-source.  GTR1 was dispensable for growth in the 
presence of the preferred N-source glutamine or ammonium (Fig. 11G).  
Expression of wild-type or constitutively active Gtr1 restored growth of gtr1Δ 
	
  54	
  
cells on leucine.  Expression of inactive GDP-bound Gtr1 further impaired 
growth on leucine, but had no remarkable effect when cells were grown in the 
presence of glutamine or ammonium (Fig. 11G).  Also, growth of a vam6Δ 
strain was rescued in the presence of glutamine or ammonium.  When grown 
on proline or leucine, a vam6Δ strain displayed a phenotype intermediate to 
that exhibited by gtr1Δ or gtr2Δ strains (Fig. 11G), suggesting a role for Vam6 
in growth regulation in addition to its role as a GEF for Gtr1.  We conclude that 
preferred N-sources, such as glutamine and ammonium, sustain growth 
independently of Gtr/Rag, while cells cultured in the presence of leucine as the 
only N-source require functional Gtr/Rag. 
The EGOC components Gtr2, Ego1 and Ego3 were initially identified as 
necessary for restoration of growth after rapamycin treatment (Dubouloz et al., 
2005).  Indeed, we found that vam6Δ, gtr1Δ and gtr2Δ strains, independently 
of the N-source, were unable to resume growth following rapamycin treatment 
(Fig. 11G lower panel).  In the gtr1Δ strain, growth was restored by expression 
of wild-type as well as constitutively active Gtr1.  These data suggest that 
EGOC is essential for restoration of growth following rapamycin treatment, 
independent of the nutritional environment.  Overall, we show that glutamine 
activates TORC1 independently of Gtr/Rag. 
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Figure 11: The metabolic input acts independently of the EGO complex in 
TORC1 activation. 
(A and B) Following glutamine upshift, only the rapid, transient increase in Sch9 C-
term phosphorylation is impaired in the vam6Δ and gtr1Δ strains compared to wild-
type.  DHBB pre-treatment (10 µM, 30 min) has no effect on Sch9 phosphorylation 
following (C and D) glutamine upshift, while it affects TORC1 activation in response to 
(E and F) leucine stimulation.  Western blot of NTCB treated samples (panel A, C and 
E) and relative quantifications expressed as mean ± SEM (panel B, D and F). 
(G) Growth assay on YMM solid media containing the indicated N-sources at the final 
concentration of 2.5 mg/mL.  In the lower panel, cells were plated following rapamycin 
treatment (200 nM, 6 hours).  All the indicated strains were initially grown in YMM 
supplemented with ammonium at the final concentration of 0.5 g/L and spotted on 
solid media following serial dilutions (1:5) starting at OD600 of 0.2. 
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2.5 DISCUSSION 
 
 
Here, we investigated in vivo activation of TORC1 by N-sources and whether 
the underlying molecular mechanism requires Gtr/Rag.  Both high (glutamine 
or ammonium) and low quality (leucine) N-sources stimulated a rapid, transient 
activation of TORC1 in a Gtr/Rag dependent manner.  However, only high 
quality N-sources sustained TORC1 activity and growth.  The preferred N-
sources ultimately sustained TORC1 activity via glutamine synthesis and/or 
accumulation.  Intracellular glutamine sustained TORC1 activity independently 
of Gtr/Rag.  These findings suggest that nutrients activate TORC1 via different 
molecular mechanisms, and explain why Gtr/Rag is not essential for TORC1 
signaling or viability in the presence of preferred N-sources.   
Several observations support our suggestion that Gtr/Rag is not the only 
mechanism of TORC1 activation by nutrients.  First, constitutively active GTP-
bound Gtr1 is unable to sustain TORC1 activity following ammonium starvation 
(Binda et al., 2009).  Second, mutations that likely increase the intracellular 
levels of glutamine suppress the inability of EGOC mutants to resume growth 
after rapamycin treatment (Dubouloz et al., 2005).  Third, we show that 
glutamine but not leucine sustains growth of vam6 and gtr1 strains defective in 
EGOC function.  Fourth, we also show that EGOC is required for an initial, 
transient stimulation of TORC1 in response to all examined nutrients, but is not 
required for sustained TORC1 signaling in response to a good N-source.  
Thus, a good N-source such as glutamine activates TORC1 via a mechanism 
independent of EGOC.  The decrease in Sch9 phosphorylation between the 
transient and sustained peaks of TORC1 activity might reflect the alternate 
onset of the EGO- and the glutamine-dependent mechanisms of TORC1 
activation.  The mechanism by which glutamine activates TORC1 in the 
absence of EGOC remains to be determined. 
In mammalian cells, two models have been proposed to explain how amino 
acids influence the GTP loading of Rags.  In one model, amino acids stimulate 
RagA/BGTP by a so-called lysosomal inside-out mechanism, dependent on the 
vacuolar ATPase but independent of a proton gradient (Zoncu et al., 2011).  In 
a second model, glutamine and leucine stimulate glutaminolysis and thereby 
α-ketoglutarate production that enhances GTP loading of RagA/B which 
ultimately activates mTORC1 (Durán et al., 2013; 2012).  Strikingly, in yeast, 
glutamine synthesis and accumulation, rather than glutaminolysis, positively 
regulate TORC1 activity.  This may reflect the metabolic differences between 
mammalian cells and budding yeast.  In proliferating mammalian cells, ATP is 
produced mainly via mitochondrial oxidative phosphorylation.  In this case, the 
flux through the TCA cycle is required to replenish the NADH pool to maintain 
respiration.  Thus, in mammalian cells, the equilibrium α-ketoglutarate ↔ 
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glutamate ↔ glutamine is pushed to the left, requiring α-ketoglutarate to 
sustain high flux through the TCA cycle (Tennant et al., 2009).  Conversely, 
exponentially growing S. cerevisiae provided with a fermentable sugar, favor 
glycolysis over respiration, even in aerobic conditions and even though 
glycolysis is less efficient at producing ATP (Broach, 2012; Gancedo, 1998).  
Glucose also affects the expression of genes involved in nitrogen metabolism, 
such as the NADP-dependent glutamate dehydrogenase encoding genes 
GDH1 and GDH3 (DeLuna, 2001; Ljungdahl and Daignan-Fornier, 2012).  In 
the presence of glucose, GDH1 is highly expressed and accounts for the 
reductive amination of α-ketoglutarate to glutamate.  Thus, glutamate levels 
are kept high in the presence of glucose, but ammonium is then required to 
convert glutamate to glutamine.  In this situation, ammonium is limiting for 
growth (Schure et al., 1995).  Preferred N-sources such as ammonium or 
glutamine, by favoring glutamine synthesis or accumulation, provide a richer 
nutritional environment leading to increased TORC1 signaling and faster 
growth.  Non-preferred N-sources, unable to drive glutamine synthesis and 
accumulation, result in lower TORC1 activation and slower growth. 
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2.6 MATERIAL AND METHODS 
 
 
Yeast strains, plasmid and media.  Yeast strains and plasmids used in this 
study are listed in Table 1 and 2.  Yeast cultures were grown in flasks at 30°C 
in liquid YMM containing only one source of nitrogen, at a final concentration of 
0.5 g/L.  Detailed composition of 1 L YMM is as follows: 5 g (NH4)2SO4; 3 g 
KH2PO4; 0.5 g MgSO4 · 7H2O; 1.5 mg EDTA; 4.5 mg ZnSO4 · 7H2O; 0.3 mg 
CoCl2 · 6H2O; 1 mg MnCl2 · 4H2O; 0.3 mg CuSO4 · 5H2O; 4.5 mg CaCl2 · 
2H2O; 3 mg FeSO4 · 7H2O; 0.4 mg NaMoO4 · 2H2O; 1 mg H3BO3; 0.1 mg KI; 5 
µg biotin; 100 µg Ca-pantothenate; 100 µg nicotinic acid; 2.5 mg inositol; 100 
µg pyridoxine; 20 µg p-aminobenzoic acid; 100 µg thiamine; 20 g/L glucose; 
0.5 g/L N-source ; to 1 L with 100 mM KH-phthalate-water pH 5.   
 
Growth conditions and cell extracts.  Typically, cells were grown in YMM 
supplemented with the first N-source at a concentration of 0.5 g/L in shaking 
flasks at 30°C until mid log phase (OD600 ≈ 1.0).  In the case of nutrient upshift, 
the second N-source was added at time point 0 at the final concentration of 0.5 
g/L directly in the media.  When performing nutrient downshifts, cells were 
gently pelleted by spinning for 2 min at 1000 g and re-suspended, at time point 
0, in fresh YMM media containing L-glutamine at the final concentration of 0.5 
g/L.  For each time point, 9 mL of culture were taken, quenched with cold 
trichloroacetic acid (10% final concentration), and incubated on ice for 5 min.  
Cells were then pelleted at 3,500 g for 5 min, washed twice with cold acetone 
and dried in a speed-vac.  The cellular pellet was re-suspended in 100 µL urea 
buffer (50 mM Tris-HCl pH 7.5, 5 mM EDTA, 6 M urea, 1% SDS), and mixed 
with 200 µL of glass beads.  Cell lysis was performed using a bead-beater 
(Biospec Products), beating 5 times for 45 seconds at max speed with 3 
minutes intervals on ice.  The extract was collected and heated to 65°C for 10 
min.  Unbroken cells and debris were removed by centrifugation at 13,000 g 
for 5 min.  Protein concentration was determined using the Pierce BCA protein 
assay (Thermo Fisher Scientific, Rockford, IL USA). 
 
Chemical fragmentation and phosphorylation quantification of Sch9.  Cell 
extracts were subjected to NTCB cleavage as described previously (Urban et 
al., 2007).  Further analysis was done by SDS-PAGE and immunoblotting 
using anti-HA antibody (HA-Tag (6E2) Mouse mAb #2367, Cell Signaling 
Technology, Danvers, MA, USA).  To quantify Sch9 phosphorylation, we used 
the software ImageJ (Schneider et al., 2012).  We measured the integrated 
density of the upper-most band (phosphorylated protein) and divided it by the 
sum of the integrated density of the upper-most plus the lower-most band 
(unphosphorylated protein). 
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Metabolite extraction.  All samples were supplemented with 50 µL 13C-labeled 
internal standard and extracted one time with 1 mL 75%(v/v) ethanol buffered 
with 10 mM ammonium acetate pH 7.5, at 78°C for 3 min.  After the extraction 
step, biomass was separated by centrifugation for 3 minutes at 5000 rpm at -
9°C.  The liquid extract of each sample was dried at 10-1 mbar to complete 
dryness in a RapidVac and then stored at -80°C until re-suspension. 
 
Metabolite mass spectrometry.  Liquid chromatography separation of 
compounds was achieved by an ion pairing-reverse phase method developed 
for UHPL (ultra high performance liquid chromatography) Q3 systems 
(Buescher et al., 2010), based on previously published high pressure methods 
(Büscher et al., 2009; Ewald et al., 2009; Luo et al., 2007) and implemented on 
a Waters Acquity UPLC (Waters Corporation, Milford, MA, USA) using a 
Waters Acquity T3 end-capped reverse phase column with dimensions 150 x 
2.1 mm x 1.8 µm (Waters Corporation).  Selective and sensitive detection of 
compounds was achieved by coupling liquid chromatography to a Thermo 
TSQ Quantum Ultra QQQ mass spectrometer from Thermo Fisher Scientific 
(Waltham, MA, USA) using a heated electrospray ionization source.  The mass 
spectrometer was operated in negative mode with selected reaction monitoring 
(SRM).  Fragmentation parameters were optimized individually for all 
compounds (Buescher et al., 2010).  Both acquisition and peak integration 
were performed with the Xcalibur software version 2.07 SP1 (Thermo Fisher 
Scientific).  Peak areas were normalized to fully 13C-labeled internal standards 
(Wu et al., 2005) and the amount of biomass. 
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2.7 TABLES 
 
 
Table 1: Strains used in this study. 
 
Strain Genotype Source 
YSBN9 MATα FY3 ho::Ble ura3-52 Canelas et al., 2010 
YSBN9 vam6Δ MATα FY3 ho::Ble ura3-52 VAM6::KanMX this study 
YSBN9 gtr1Δ MATα FY3 ho::Ble ura3-52 GTR1::KanMX this study 
YSBN9 gtr2Δ MATα FY3 ho::Ble ura3-52 GTR2::KanMX this study 
YSBN9 DOT6-3HA MATα FY3 ho::Ble ura3-52 DOT6-
3xHA::KanMX 
this study 
 
Table 2: Plasmids used in this study. 
 
Plasmid Vector; Insert Source 
pRS416 cen URA3    
pJU733 pRS416; cen URA3 SCH9-3xHA Urban et al., 2007 
pMB1393 YCplac33; cen URA3 Tet-on-GTR1 Binda et al., 2009 
pMB1394 YCplac33; cen URA3 Tet-on-GTR1-Q65L Binda et al., 2009 
pMB1395 YCplac33; cen URA3 Tet-on-GTR1-S20L Binda et al., 2009 
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2.8 ADDITIONAL RESULTS 
 
 
2.8.1 Ser711 and Thr737 are two major TORC1-dependent 
phosphorylation sites of Sch9 
 
INTRODUCTION 
 
In our study, we measured TORC1 activity following perturbation of the 
nitrogen source.  Sch9 is a direct target of TORC1.  Sch9 phosphorylation 
state is used as readout of TORC1 activity.  For this purpose, we measured 
and quantified Sch9 C-terminus phosphorylation state following chemical 
cleavage with NTCB and Western blot.  We also directly measured by mass 
spectrometry the phosphorylation of the six single phosphosites target of 
TORC1.  Previous studies showed that only simultaneous mutation of at least 
five sites to alanine prevented the phosphorylation induced mobility shift of 
Sch9 C-terminus in nutrient rich conditions (Urban et al., 2007).  In our study 
we identified in S711, T737 and S765 the phosphosites subjected the most to 
TORC1 regulation in vivo during nutrient upshift.   
Here, we investigated whether substitution of these residues with the 
non-phosphorylatable alanine would have an impact on the migration pattern 
of Sch9 C-terminus following nutrient upshift.  These data are still preliminary 
and will be the subject of further studies. 
 
 
RESULTS 
 
First of all we obtained the plasmids harboring the Sch9 alanine mutants by 
PCR-based in situ mutagenesis.  We then reintroduce the plasmids in the 
YSBN9 strain.  We tested the electrophoretic mobility shift induced by nutrient 
upshift with glutamine on cells expressing a mutated copy of Sch9.  Single 
substitution of S711 or T737 with alanine did not lead to any significant 
alteration of Sch9 C-terminus phosphorylation (Fig. 12A, B and C).  On the 
other hand, we observed no TORC1-induced increase in Sch9 C-terminus 
phosphorylation when increasing TORC1 activity with glutamine in the double 
mutant S711A/T737A (Fig. 12A and D).  By comparing the levels of Sch9 
phosphorylation, it is clear how single mutations of S711A and T737A only 
partially decrease Sch9 C-terminus phosphorylation by 10-20%, while the 
double alanine substitution S711A/T737A prevents the TORC1-induced 
phosphorylation increase (Fig. 12E).  We conclude that S711 and T737 are 
two major TORC1-dependent phosphorylation sites on Sch9 C-terminus.  
Simultaneous absence of both sites dramatically decreases the TORC1-
	
  62	
  
induced increase in Sch9 phosphorylation following nutrient upshift.  When 
singularly mutated, phosphorylation on one or the other site is still responsible 
for the electrophoretic mobility shift induced by TORC1-dependent 
phosphorylation. 
 
 
 
Figure 12: S711 and T737 are major TORC1-dependent phosphorylation sites of 
Sch9. 
(A) Cells expressing different alanine mutated versions of SCH9 were subjected to 
nutrient upshift with glutamine.  Cell extracts were cleaved with NTCB and loaded on 
Western blot.  (B, C, D and E) Quantification of signal obtained by Western blot. 
  
0 3 6 9 12 15 18 21 24 27 30
0
20
40
60
80
Sch9
Sch9 711A
time (min)
%
 S
ch
9 
ph
os
ph
or
yl
at
io
n
0 3 6 9 12 15 18 21 24 27 30
0
20
40
60
80
Sch9
Sch9 737A
time (min)
%
 S
ch
9 
ph
os
ph
or
yl
at
io
n
Sch9-HA
Sch9-HA 711A/737A
Sch9-HA 711A
Sch9-HA 737A
0 0.3 0.6 1 1.5 2 3 4 5 8 11min 15 30
A
B C
D E
Glutamine upshift
0 3 6 9 12 15 18 21 24 27 30
0
20
40
60
80
WT
711A
737A
711A 737A
time (min)
%
 S
ch
9 
ph
os
ph
or
yl
at
io
n
0 3 6 9 12 15 18 21 24 27 30
0
20
40
60
80
Sch9
Sch9 
711A/737A
time (min)
S
ch
9 
ph
os
ph
or
yl
at
io
n 
%
	
   63	
  
DISCUSSION AND OUTLOOK 
 
Six different residues on Sch9 C-terminus are phosphorylated in a TORC1 
dependent manner.  These sites were shown to be required for Sch9 activity in 
vitro and in vivo (Urban et al., 2007).  We previously determined that the extent 
of phosphorylation of these sites is dependent on the quality of the nitrogen 
source.  By mass spectrometry we identified three sites which phosphorylation 
state changes the most when TORC1 is activated by the quality of the nitrogen 
source: S711, T737 and S765.  Simultaneous mutation of S711 and T737 to 
alanine blocks the phosphorylation increase of Sch9 C-terminus following 
nutrient upshift, indicating that these two sites are major TORC1 targets in 
vivo.   
 We further tested the impact of the alanine substitutions of Sch9 on 
growth.  We used a strain deleted for SCH9 expressing a plasmid harboring a 
wild-type or mutated version of SCH9.  Despite a clear role as major TORC1 
target sites in vivo, alanine substitution of S711 and T737 had no effect on 
growth in vivo (data not shown).  Together with the observation that only the 
mutation to alanine of at least five residues on Sch9 C-terminus decreases 
Sch9 activity in vitro and in vivo (Urban et al., 2007), these data indicate that 
TORC1-dependent phosphorylation of any residue within Sch9 C-terminus can 
sustain Sch9 activity and growth.  Or in alternative, another protein with a 
redundant function with Sch9, such as Sfp1 or Fhl1, could sustain ribosome 
biogenesis and growth when Sch9 activity is slightly compromised by 
interfering with Sch9 C-terminus phosphorylation. 
Alanine substitution of S765, alone and in combination with S711 and 
T737, and its effect on Sch9 phosphorylation will be the subject of further 
studies. 
 
 
MATERIALS AND METHODS 
 
Sch9 immunoprecipitation and proteolysis 
 
Cell lysis was performed using 1 mL of urea buffer and 1 mL glass beads 
starting from 90 mL of mid log-phase culture for each time point.  After Pierce 
BCA protein quantification, same amounts of cell extracts were diluted 10-fold 
with breaking buffer (PBS 1x, 10% glycerol, 0.5% tween-20, PPi, and Pi) and 
pre-cleared with 50 µL of a 50% w/v suspension of Protein A Sepharose (…) 
for 90 minutes at 4°C rocking.  From the pre-cleared extracts, SCH9-HA was 
immunoprecipitated overnight at 4°C rocking with 50 µL of a 50% w/v 
suspension of Protein A Sepharose beads covalently crosslinked with anti-HA 
antibody.  The beads were then collected at 2000 rpm for 2 min, washed twice 
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with PBS, and three times with 100 mM Tris-HCl pH 8.0, 150 mM NaCl.  After 
the final wash, beads were dried and diluted with 100mM Tris-HCl pH 8.0, 
150mM NaCl to a final 50% w/v suspension.  For proteolysis, immuno-
precipitated SCH9-HA was digested with 250 ng endoprotenase LysC (Wako, 
Neuss, Germany) for 2 h at 37°C.  The beads were then centrifuged at 1,500 g 
for 1 min and the supernatant was collected.  One half of the endoproteinase 
LysC digest was acidified with TFA (1% final concentration), while the other 
half was further digested with 100 ng endoproteinase AspN (Roche, Rotkreuz, 
Switzerland) for 2 h at 37°C followed by a second aliquot of 100 ng 
endoproteinase AspN and overnight digestion at 37°C.  The digestion was 
stopped adding TFA. 
 
 
Protein mass spectrometric analysis 
 
Digests were analyzed by capillary liquid chromatography tandem MS using a 
setup of a ProteoCol C18 trap column (0.15 x 10 mm, 3 µm particle size, 300 
Å, SGE Analytical Science, Victoria, AU) and a separating (0.1 x 250 mm) 
column that had been packed with C18 ReproSil-Pur, 3 µm material (Dr. 
Maisch GmbH, Ammerbuch, Germany).  The columns were connected online 
to an Orbitrap FT hybrid instrument (Thermo Scientific, Bremen, Germany).  
The solvents used for separation were 0.1% acetic acid/2% acetonitrile 
(solvent A) and 0.1% acetic acid/80% acetonitrile (solvent B).  Peptides were 
injected via a 2 µL loop onto the trap column with the capillary pump of an 
Agilent 1200 (Agilent Technologies, Basel, Switzerland) system set to 4 
µL/min.  After 10 min, the trap column was switched into the flow path of the 
separating column.  A linear gradient from 2 to 35% Solvent B in solvent A was 
delivered with an Agilent 1200 nano pump set to 300 nL/min.  The eluting 
peptides were ionized at 1.7 kV.  The mass spectrometer was operated in a 
data-dependent fashion.  The precursor scan was done in the Orbitrap set to 
30,000 resolution, while the fragment ions were mass analyzed in the LTQ part 
of the instrument.  A top five method was run so that the five most intense 
precursor ions were selected for fragmentation.  Singly charged ions were 
omitted from fragmentation and previously selected ions were dynamically 
excluded for 25 seconds.  The normalized collision energy was set to 35% and 
for phosphopeptide analysis multistage activation was enabled.  Automatic 
gain control was set to 500,000 and 10,000 for Orbitrap and LTQ, respectively. 
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Peptide identification 
 
The LC/MS/MS data were analyzed with Proteome Discoverer 1.3 (Thermo 
Scientific, San José, CA, USA) against the SwissProt database.  The 
Proteome Discoverer was set to use Mascot (version 2.4.0 (1)) as the search 
engine.  A mass tolerance of 10 ppm was set.  Cysteine carbamidomethylation 
was used as a fixed, and methionine oxidation, and phosphorylation on serine 
and threonine was set to variable modification.  Two missed cleavages were 
allowed.  For peptide identifications an FDR of ≤ 1% was set. 
 
 
Strains and plasmids 
 
A list of plasmids used for the experiments presented is given below in table 3. 
 
For growth conditions, NTCB cleavage and signal quantification please refer to 
section 2.6, pages 58-59.   
 
PCR-based site directed mutagenesis was performed as described before 
(Zheng et al., 2004). 
 
Table 3 
 
 
 
 
 
 
 
 
  
Plasmid Vector; Insert Source 
pRS 416 cen URA3    
pJU 676 pRS 416; SCH9-5xHA Urban et al., 2007 
pDS 1 pRS 416; SCH9 (S711A)-5xHA this study 
pDS 2 pRS 416; SCH9 (T737A)-5xHA this study 
pDS 3 pRS 416; SCH9 (S711A, T737A )-5xHA  this study 
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3  APPENDIX 
 
 
 
3.1 ACTIVATION OF mTORC2 BY ASSOCIATION WITH THE 
RIBOSOME 
 
 
Zinzalla and colleagues made an important step forward in the understanding 
of TORC2 upstream regulation.  The isolation of the nip7-1 thermo-sensitive 
mutant in yeast led to the discovery that mTORC2 activation by growth factors 
requires TORC2 association with the ribosome.  I helped in this work with the 
characterization of the yeast mutant nip7-1.   
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Activation of mTORC2
by Association with the Ribosome
Vittoria Zinzalla,1 Daniele Stracka,1 Wolfgang Oppliger,1 and Michael N. Hall1,*
1Biozentrum, University of Basel, CH-4056 Basel, Switzerland
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SUMMARY
The target of rapamycin (TOR) is a highly conserved
protein kinase and a central controller of growth.
Mammalian TOR complex 2 (mTORC2) regulates
AGC kinase family members and is implicated in
various disorders, including cancer and diabetes.
Here, we investigated the upstream regulation of
mTORC2. A genetic screen in yeast and subsequent
studies in mammalian cells revealed that ribosomes,
but not protein synthesis, are required for mTORC2
signaling. ActivemTORC2was physically associated
with the ribosome, and insulin-stimulated PI3K
signaling promoted mTORC2-ribosome binding,
suggesting that ribosomes activate mTORC2 di-
rectly. Findings with melanoma and colon cancer
cells suggest that mTORC2-ribosome association is
important in oncogenic PI3K signaling. Thus,
TORC2-ribosome interaction is a likely conserved
mechanism of TORC2 activation that is physiologi-
cally relevant in both normal and cancer cells. As
ribosome content determines growth capacity of
a cell, this mechanism of TORC2 regulation ensures
that TORC2 is active only in growing cells.
INTRODUCTION
Target of rapamycin (TOR) is a central controller of cell growth
and metabolism in response to nutrients, growth factors, and
energy status. TOR is found in two structurally and functionally
distinct multiprotein complexes termed TOR complex 1
(TORC1) and TORC2 (Wullschleger et al., 2006). The TOR com-
plexes, originally described in yeast (Loewith et al., 2002), are
conserved across all eukaryotes and regulate a wide spectrum
of cellular processes that mediate cell growth (Laplante and
Sabatini, 2009; Soulard et al., 2009; Wullschleger et al., 2006;
Yang and Guan, 2007). In mammalian cells, mammalian TORC1
(mTORC1) contains mTOR, raptor, and mLST8 and is sensitive
to the immunosuppressant and anticancer drug rapamycin
(Hara et al., 2002; Kim et al., 2002; Loewith et al., 2002). mTORC1
controls transcription, ribosome biogenesis, protein synthesis,
lipid synthesis, nutrient transport, autophagy, and other
growth-related processes. The best-characterized substrates
of mTORC1 are S6K and 4E-BP via which mTORC1 controls
translation (Sonenberg and Hinnebusch, 2009). mTORC2
consists of mTOR, rictor, mSIN1, mLST8, and PRR5/PRR5L
(also known as protor1 and 2) and is insensitive to rapamycin,
although long-term rapamycin treatment can indirectly inhibit
mTORC2 in some cell types (Cybulski and Hall, 2009; Jacinto
et al., 2004; Sarbassov et al., 2004; Sarbassov et al., 2006;
Sparks and Guertin, 2010). mTORC2 directly phosphorylates
and activates the AGC kinases Akt (also known as PKB),
SGK1, and likely PKC (Facchinetti et al., 2008; Garcı´a-Martı´nez
and Alessi, 2008; Hresko and Mueckler, 2005; Ikenoue et al.,
2008; Jacinto and Lorberg, 2008; Sarbassov et al., 2004; Sar-
bassov et al., 2005). mTORC2 promotes cell survival via Akt
and mediates organization of the actin cytoskeleton (Cybulski
and Hall, 2009; Sparks and Guertin, 2010).
Both mTORC1 and mTORC2 are activated by growth factors,
including insulin, IGF-1, and others. Growth factors activate
mTORC1 via phosphatidylinositol 3-kinase (PI3K), PDK1, Akt,
the TSC1-TSC2 complex, and Rheb, a small guanosine triphos-
phate (GTP)-binding protein that binds and activates mTORC1
directly (Avruch et al., 2009; Manning and Cantley, 2003). In
contrast, the mechanism via which growth factors activate
mTORC2 has been elusive. Growth factors activate mTORC2
via PI3K (Frias et al., 2006; Garcı´a-Martı´nez and Alessi, 2008;
Yang et al., 2006), but signaling steps beyond PI3K are distinct
from those upstream of mTORC1 and unknown (Cybulski and
Hall, 2009; Sparks and Guertin, 2010). The nature of the
upstream regulators of TORC2 in unicellular model organisms
such as yeasts, which lack a growth factor signaling pathway,
is completely unknown (Soulard et al., 2009).
Here, we describe a genetic screen in yeast and subsequent
studies in mammalian cells that identify the ribosome as an acti-
vator of TORC2. We demonstrate that the ribosome, indepen-
dent of protein synthesis, is required for mTORC2 signaling
in vivo and mTORC2 kinase activity in vitro. Active mTORC2 is
associated with the ribosome. Insulin stimulates the association
of mTORC2 with the ribosome via PI3K signaling. Findings with
cancer cells suggest that ribosome-dependent mTORC2 activa-
tion is physiologically relevant in tumors with hyperactive PI3K
signaling.
RESULTS
A Genetic Screen Reveals that NIP7 Is Required
for TORC2 Signaling in Yeast
To identify upstream activators of TORC2, we performed
a genetic screen in the budding yeast S. cerevisiae. Furthermore,
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we assumed that whatever activates TORC2 in yeast would also
be upstream of mTORC2 in mammals. In other words, we
assumed that growth factor signaling was grafted onto a hereto-
fore unknown ancestral input controlling TORC2 in unicellular
yeast. This reasoning was supported by the fact that growth
factor signaling was grafted onto the ancestral nutrient input in
the case of TORC1.
mTORC2 phosphorylates the hydrophobic motif in the AGC
kinase SGK1 and thereby activates SGK1. In yeast, TORC2 simi-
larly phosphorylates and activates the SGK1 ortholog YPK2. Our
genetic screen was based on the observation that overexpres-
sion of constitutively active YPK2 (YPK2D239A, hereafter referred
to as YPK2*) suppresses the lethality of a TORC2 defect
(Aronova et al., 2008; Kamada et al., 2005). Assuming that
YPK2* would also suppress lethality caused by a defect in an
upstream activator of TORC2, we performed a so-called reverse
suppressor screen to isolate yeast mutants that depend on
YPK2* for viability (Figure 1A and Experimental Procedures).
This is referred to as a reverse suppressor screen because it
starts with a suppressor mutation (YPK2*) to identify unknown
‘‘suppressee’’ mutations—the reverse order of a normal
(forward) suppressor screen. The screen was predicted to iden-
tify loss-of-function mutations in an essential upstream activator
of TORC2 or in the essential components of TORC2, including
TOR2, AVO1 (mSIN1 ortholog), and AVO3 (rictor ortholog). The
screen yielded a total of 44 independent mutants defective in
TORC2, thereby validating the screen. The 44mutants consisted
of 25, 13, and 6 tor2, avo1, and avo3 mutants, respectively. In
addition, we obtained a temperature-sensitive nip7 mutant that
we hereafter refer to as nip7-1 (Figure 1A and Figures S1A and
S1B). Sequence analysis of the nip7-1 allele identified a point
mutation that converts glycine 71 to aspartic acid. Western
blot analysis of extracts from nip7-1 cells showed that the point
mutation mildly and strongly decreased NIP7 protein levels at
permissive temperature (25!C) and nonpermissive temperature
(37!C), respectively (Figure S1A). YPK2*, but not wild-type
YPK2, suppressed the growth defect of the nip7-1 mutant at
semipermissive temperature (30!C and 34!C) (Figure S1B).
NIP7 is an essential protein required for maturation of rRNA of
the 60S ribosomal subunit (Zanchin et al., 1997). Confirming
this role of NIP7 in ribosomebiogenesis,we observed a reduction
in the amounts of the 60S subunit, the 80S ribosome, and poly-
somes, with a concomitant appearance of halfmer polysomes, in
extracts of the nip7-1 mutant grown at semipermissive temper-
ature (30!C) (Figure S1C).
To examine further whether NIP7 is required for TORC2
signaling, we investigated whether the nip7-1mutant phenocop-
ied TORC2mutants. The nip7-1mutant indeed exhibited several
defects similar to those observed in temperature-sensitive
TORC2 mutants (avo3-1 and tor2-21) (Aronova et al., 2008;
Beeler et al., 1998; Facchinetti et al., 2008; Helliwell et al.,
1998; Kamada et al., 2005; Schmidt et al., 1997). First, the
nip7-1 mutant exhibited reduced signaling through the cell wall
integrity pathway, as evidenced by decreased MPK1 phosphor-
ylation and PKC1 protein levels, depolarization of the actin cyto-
skeleton, and restoration of growth in the presence of the
osmotic stabilizer sorbitol (Figure 1B and Figure S1D). Second,
the nip7-1 mutant showed impaired sphingolipid biosynthesis,
including hypersensitivity to myriocin, an inhibitor of the first
step in the sphingolipid biosynthetic pathway, and restoration
of growth in the presence of Ca2+ in a csg2D background
(Figure S1E). Third, the nip7-1 mutant showed decreased
YPK2 kinase activity, as measured by an in vitro kinase assay
with immunopurified YPK2 and, as a control, kinase-dead
YPK2K373A (Figure 1C and data not shown for kinase dead).
Finally and most importantly, TORC2 kinase activity was
reduced in the nip7-1mutant, as measured by an in vitro kinase
assay with TORC2 immunopurified from wild-type cells and
nip7-1mutant cells grown at 30!C (Figure 1D). The above results
strongly suggest that NIP7 is required, directly or indirectly, for
TORC2 kinase activity and signaling.
mNIP7 Is Required for mTORC2 Activity
and Ribosome Maturation in Mammals
Yeast NIP7 shares 75% identity with an uncharacterized
mammalian protein also termedNIP7 (Figure S2A).We examined
whether mammalian NIP7 (mNIP7) is required for mTORC2
signaling. mTORC2 directly phosphorylates Ser473 in the hydro-
phobicmotif of Akt and Ser422 in the hydrophobicmotif of SGK1
and thereby activates Akt and SGK1 toward substrates such as
FoxO3a (Thr32) and NDRG1 (Thr346), respectively (Garcı´a-
Martı´nez and Alessi, 2008; Sarbassov et al., 2005). mTORC2
also autophosphorylates sites in rictor (Sarbassov et al., 2004;
Jacinto et al., 2004) and is required for phosphorylation of
Thr450 in the turn motif of Akt (Facchinetti et al., 2008; Ikenoue
et al., 2008). Knockdown of mNIP7 in HeLa and HEK293 cells
strongly decreased basal and insulin-stimulated phosphoryla-
tion of Ser473 and Thr450 in Akt, Thr32 in FoxO3a, Thr346 in
NDRG1, and rictor in mTORC2 (Figure 2A, Figure S2B, and
data not shown). mNIP7 knockdown had no effect on Erk phos-
phorylation or mTORC1-dependent S6K phosphorylation (Fig-
ure 2A). These findings suggest that mNIP7 is specifically
required for mTORC2 signaling. Finally, we observed that
mNIP7 knockdown reduced (by 58%) mTORC2 kinase activity
in vitro, with no effect on mTORC2 amount or integrity (Fig-
ure 2B). These findings indicate that mNIP7 is required for
mTORC2 activity and signaling, and not for mTORC2 synthesis,
assembly, or stability. Furthermore, NIP7 is required for TORC2
signaling in both yeast and mammalian cells, suggesting
a conserved mechanism of TORC2 activation.
Is mNIP7 a 60S maturation factor like NIP7 in yeast? Knock-
down of mNIP7 reduced the amounts of the 60S ribosomal
subunit and the 80S ribosome (80S), with no effect on the
amount of the 40S subunit (Figure S2C). Knockdown ofmTORC2
component mSIN1 had no effect on the ribosome profile (Fig-
ure S2C), indicating that the effect of mNIP7 on ribosome matu-
ration was not due to a defect in signaling downstream of
mTORC2. Thus, NIP7 is conserved from yeast to human as
a 60S ribosome maturation factor and a TORC2 activator.
Ribosomes, but Not Protein Synthesis, Are Required
for mTORC2 Signaling
Does mNIP7 control mTORC2 via its role in ribosome matura-
tion? To address this question, we examined whether ribosome
content affects mTORC2 signaling. Knockdown of ribosomal
protein Rpl7 (60S subunit) reduced the amounts of the 60S
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subunit and assembled ribosomes (80S monosomes and
polysomes), whereas knockdown of ribosomal protein Rps16
(40S subunit) reduced the amounts of the 40S subunit and
assembled ribosomes (Figure S2C). We also observed that
knockdown of Rpl7 or Rps16 reduced the amounts of other
proteins in the corresponding ribosomal subunit (Figure 3A and
Figure S3A), consistent with the published finding that ribosomal
subunit assembly determines the level of ribosomal proteins
(Idol et al., 2007). Like knockdown of mNIP7, knockdown of
either Rpl7 or Rps16 decreased basal and insulin-stimulated
Figure 1. NIP7, Identified by a Reverse Suppressor Screen, Is Required for TORC2 Activity In Vivo and In Vitro
(A) Schematic representation of the reverse suppressor screen. A wild-type strain (JK9-3da) overexpressing constitutively active YPK2* (YPK2D239A) on an
URA3-based plasmid was mutagenized with ethyl-methanesulfonate (EMS). Mutants that could not grow on plates containing 5-FOA were chosen for further
analysis. A plasmid-borne NIP7 gene (pNIP7) was isolated by complementation of the nip7-1 mutation.
(B) nip7-1mutant exhibits depolarization of actin cytoskeleton.Wild-type (JK9-3da), avo3-1 (BAS65-2a), and nip7-1 (DS1) cells grown in YPD at 25!Cwere shifted
to 37!C for 6 hr. The actin cytoskeleton was stained with rhodamine-coupled phalloidin. A representative figure of three independent experiments for each strain
is shown.
(C) nip7-1 mutant shows decreased YPK2 activity. Wild-type cells (JK9-3da) (mock) and wild-type, avo3-1, or nip7-1 cells expressing plasmid-borne YPK2-HA
(pYPK2-HA) were grown in YPD at 30!C. YPK2-HA was immunoprecipitated and subjected to in vitro kinase assay using cross-tide as a substrate. Substrate
phosphorylation was quantified, and the average ± standard deviation from the mean based on three independent experiments is shown. Immunoprecipitated
YPK2-HA was detected by western blotting (bottom).
(D) nip7-1 mutant shows decreased TORC2 kinase activity in vitro. Wild-type cells (JK9-3da; mock) and wild-type (DS2; WT) or nip7-1 (DS3; nip7-1) cells
expressing AVO3-HA were grown in YPD at 30!C. AVO3-HA was immunoprecipitated and subjected to a TORC2 kinase assay in vitro using recombinant YPK2
protein as a substrate. Also shown are Coomassie blue-stained total YPK2 protein and immunoblot of immunoprecipitated AVO3-HA.
See also Figure S1.
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phosphorylation of Akt (Ser473 and Thr450), FoxO3a (Thr32),
NDRG1 (Thr346), and rictor, with no effect on Erk or S6K phos-
phorylation (Figure 3A, Figure S2B, and Figure S3A). Finally,
we observed that Rpl7 knockdown reduced mTORC2 kinase
activity, as determined by an in vitro kinase assay with immuno-
purified mTORC2 and recombinant, kinase-dead Akt as a
substrate. Rpl7 knockdown had no effect on mTORC2 amount
or integrity, as determined by unaffected coimmunoprecipitation
of mTOR, mSIN1, or mLST8 with rictor (Figure 3B). Thus, assem-
bled ribosomes (not 60S or 40S ribosomal subunits alone) are
required for mTORC2 kinase activity and signaling. Furthermore,
the above findings suggest that mNIP7 controls mTORC2 via its
role in ribosome maturation.
mTORC2 promotes cell survival via phosphorylation and
activation of Akt, which in turn phosphorylates and inhibits
proapoptotic Bad (Brazil et al., 2004; Datta et al., 1997; Jacinto
et al., 2006; Yang et al., 2006). To investigate further the physio-
logical relevance of ribosome-mediated mTORC2 regulation, we
examined the effect of mNIP7, Rpl7, or Rps16 knockdown on
induction of apoptosis by etoposide or hydrogen peroxide
(H2O2). Both treatments induce cell death in an Akt-sensitive
manner (He et al., 2010; Kim et al., 2001; Wang et al., 2000).
Knockdown of mNIP7, Rpl7, or Rps16 enhanced the induction
of apoptosis by etoposide or hydrogen peroxide, as indicated
by an increase in caspase 3 and PARP cleavage and a decrease
in cell viability (Figure 4A and Figure S4). Knockdown of mSIN1
(mTORC2) similarly enhanced apoptosis. Knockdown of Bad
Figure 2. mNIP7 Is Required for mTORC2 Activity
In Vivo and In Vitro
(A) siRNA-mediated knockdown of mNIP7 inhibits
mTORC2 signaling. HeLa cells, 48 hr after transfection
with the indicated siRNA, were harvested (left) or serum
starved for 3 hr and then restimulated with insulin for the
indicated times before harvesting (right). Phosphorylation
and protein levels were determined by immunoblotting
with the appropriate antibodies, as indicated.
(B) Knockdown of mNIP7 inhibits mTORC2 kinase activity
toward Akt with no effect on mTORC2 integrity. rictor
immunoprecipitates were immunoblotted with the indi-
cated antibodies to determine mTORC2 integrity.
mTORC2 in vitro kinase assay was performed using
immunopurified mTORC2 (rictor) and recombinant,
kinase-dead Akt as a substrate.
See also Figure S2.
blocked the proapoptotic effect of mSIN1,
mNIP7, Rpl7, or Rps16 knockdown (Figure 4B).
Thus, ribosomes appear to regulate mTORC2
signaling in a physiologically relevant manner.
Although ribosomal knockdown reduces
mTORC2 kinase activity and signaling without
affecting mTORC2 synthesis, is the process of
protein synthesis per se required for mTORC2
activation? To address this question, we exam-
ined whether the protein synthesis inhibitors
salubrinal, cycloheximide, anisomycin, or puro-
mycin acutely inhibit mTORC2 signaling. Salu-
brinal blocks translation initiation by selective
inhibition of eIF2a dephosphorylation (Boyce et al., 2005; Cnop
et al., 2007) (Figure S3B). Cycloheximide, anisomycin, and puro-
mycin inhibit translation elongation. Unlike knockdown of
mNIP7, Rpl7, or Rps16, salubrinal, cycloheximide, anisomycin,
and puromycin had no effect on basal or insulin-stimulated Akt
Ser473 phosphorylation (Figures S3B–S3D and Figure S5C). All
drugs were used under conditions known to affect protein
synthesis in the expected manner, as determined by polysome
gradient analysis (Figures S3B–S3D and data not shown).
Thus, ribosomes mediate mTORC2 signaling independently of
protein synthesis.
Active mTORC2 Is Associated with the Ribosome
To investigate the molecular mechanism by which ribosomes
activate mTORC2 signaling, we examined by four unrelated
methods whether ribosomes and mTORC2 physically interact.
First, we determined whether mTORC2 coimmunoprecipitates
with ribosomal protein Rpl26. Endogenous Rpl26 coimmunopre-
cipitated with endogenous mTOR, rictor, mSIN1, and ribosomal
protein Rpl7 (Figure 5A), but not with raptor. This suggests that
mTORC2, but not mTORC1, associates with the ribosome.
Second, we determined whether mTORC2 copurifies with total
ribosomes isolated by sedimentation through a sucrose cushion
(see Experimental Procedures). mTOR and rictor, but not raptor,
cosedimented with Rpl26, Rpl7, and Rps16 (Figure 5B). Third,
although ribosomes activate mTORC2 independently of protein
synthesis, we also determined whether mTORC2 cosediments
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with polysomes in a sucrose gradient. Lysates were fractionated
in a sucrose gradient to separate polysomes from 80S, 60S, and
40S ribosomes. mTOR, rictor, andmSIN1 were found in both the
polysomal and ribosomal fractions, to the same extent as Rpl7,
Rpl26, and Rps16 (Figure S5A). Finally, we determined whether
mTORC2 copurifies with mRNA-bound ribosomes. mRNA-
bound ribosomes were purified by pull-down of poly(A) mRNA
with oligo(dT) cellulose (Figure S5B) (Ceci et al., 2003). In this
experiment, mTOR and rictor copurified with Rpl26, Rpl7, and
the 40S ribosomal protein RACK1. RNase A treatment of a lysate
before pull-down prevented isolation of any of the above
proteins (Figure S5B), confirming interaction of mTORC2 with
mRNA-bound ribosomes. The above data taken together
suggest that mTORC2 physically interacts with translating
(mRNA-bound) and nontranslating 80S ribosomes. An interac-
tion between mTORC2 and the 80S ribosome is also supported
by published mass spectrometry studies that identified several
large and small subunit ribosomal proteins in mTORC2 immuno-
precipitates (Pearce et al., 2007; Thedieck et al., 2007). We also
note that nonionic detergent was required during any of our four
above ribosome purifications to detect copurification of
mTORC2 and that protein synthesis inhibitors had no effect on
the interaction between mTORC2 and Rpl26 (Figure S5C).
To obtainmore insight into themTORC2-ribosome interaction,
we performed coimmunoprecipitation experiments after knock-
down of mTORC2 subunits or ribosomal proteins. First, the
amount of mTOR in Rpl26 immunoprecipitates from rictor or
mSIN1 knockdown cells was significantly reduced compared
to control cells (Figure S6A), suggesting that mTORC2 interacts
Figure 3. Ribosomes Are Required for mTORC2
Activity and Signaling
(A) siRNA-mediated knockdown of Rpl7 inhibits mTORC2
signaling. HeLa cells, 24 hr after transfection with the
indicated siRNA, were harvested (left, basal activity) or
serum starved for 3 hr and then restimulated with insulin
for the indicated times before harvesting (right, insulin-
stimulated activity). Phosphorylation and protein levels
were determined by immunoblotting with the appropriate
antibodies, as indicated.
(B) Knockdown of Rpl7 inhibits mTORC2 kinase activity
toward Akt with no effect on mTORC2 integrity. rictor
immunoprecipitates were immunoblotted with the indi-
cated antibodies. mTORC2 in vitro kinase assay was
performed using immunopurified mTORC2 (rictor) and
recombinant, kinase-dead Akt as a substrate.
See also Figure S3.
with the ribosome via rictor and/or mSIN1. We
could not distinguish a requirement specifically
for rictor or mSIN1 because knockdown of
either rictor or mSIN1 alone also results in loss
of the other. Second, knockdown of Rpl7 (60S
subunit) abolished the interaction between
mTORC2 and Rpl26, whereas knockdown of
Rps16 (40S subunit) only moderately decreased
the interaction between mTORC2 and Rpl26
(60S subunit) (Figure S6B). These results
suggest that mTORC2 associates with the ribosome via rictor
and/or mSIN1 binding to the 60S subunit.
The above findings suggest that ribosomes bind and activate
mTORC2. To test this model further, we investigated whether
ribosome-bound mTORC2 is indeed active. We performed an
mTORC2 kinase assay with ribosomes purified either by Rpl26
immunoprecipitation or by sedimentation through a sucrose
cushion,asdescribedabove. Inbothcases,a ribosome-associated
kinase phosphorylated Ser473 in recombinant, kinase-dead Akt
(Figure 5C). ThemTOR inhibitor PP242 (Feldman et al., 2009) abol-
ished the in vitro phosphorylation of Ser473 (Figure 5C), confirming
that the ribosome-associated Ser473 kinase was mTORC2. Thus,
ribosome-associatedmTORC2 isactive.Furthermore,weanalyzed
whethermTORC2kinaseactivity is required formTORC2-ribosome
interaction. Treatment of HeLa cells with PP242 abolished Ser473
phosphorylation, as expected, but had no effect on mTORC2-
Rpl26 interaction (Figure S6D), suggesting that mTORC2 activity
is not required for mTORC2-ribosome association.
Insulin-PI3K Signaling Stimulates mTORC2-Ribosome
Association
We next investigated whether mTORC2 association with the
ribosome is regulated by insulin. Insulin treatment of serum-
starved cells significantly increased the amount of mTOR and
rictor that coimmunoprecipitated with Rpl26 (Figure 6A). Impor-
tantly, this stimulation of the interaction between mTORC2 and
Rpl26 correlated with phosphorylation of the mTORC2 target
site Ser473 in endogenous Akt. Thus, insulin stimulates
mTORC2-ribosome association.
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Insulin activates mTORC2 via PI3K (Frias et al., 2006; Garcı´a-
Martı´nez and Alessi, 2008; Yang et al., 2006). To investigate
whether PI3K signaling regulates mTORC2 association with
the ribosome, we examined whether the mTORC2-Rpl26 inter-
action was affected upon inhibition or hyperactivation of PI3K
signaling. Inhibition of PI3K strongly decreased mTORC2-
Rpl26 interaction, as determined by a reduction in the amount
of mTOR and rictor that coimmunoprecipitated with Rpl26 in
lysates from cells treated with the PI3K inhibitor LY294002 (Fig-
ure 6B and Figure S6D). In contrast, hyperactivation of PI3K
signaling by knockdown of PTEN, a negative regulator of PI3K
signaling, increased the amount of mTOR and rictor in Rpl26
immunoprecipitates, compared to control cells (Figure 6C).
Again, the change in mTORC2-Rpl26 interaction upon PI3K inhi-
bition or hyperactivation was paralleled by a corresponding
change in phosphorylation of the mTORC2 target site Ser473
Figure 4. Ribosome or mTORC2 Knockdown Enhances Stress-Induced, Bad-Dependent Apoptosis
(A) siRNA-mediated knockdown of mSIN1, mNIP7, Rpl7, or Rps16 increases etoposide-induced apoptosis. HeLa cells were transfected with the various siRNAs
and then treated with 25 mM etoposide for the indicated times (top) or for 24 hr (bottom). Extracts were analyzed by immunoblotting to assess efficiency of siRNA
knockdown and induction of apoptosis with the indicated antibodies (top). Apoptosis was assessed by blotting for cleaved PARP (cPARP) and cleaved caspase 3
(cCaspase 3). Cells were fixed and stained with DAPI and cleaved PARP antibody to detect apoptotic cells (bottom).
(B) Bad is required for enhanced apoptosis in cells with knockdown of mSIN1, mNIP7, Rpl7, or Rps16. HeLa cells were transfected with the indicated siRNA and
then treated with 25 mM etoposide for 24 hr. Extracts were analyzed by immunoblotting to assess the induction of apoptosis with cleaved PARP antibody. The
efficiency of Bad knockdown is shown.
See also Figure S4.
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in endogenous Akt (Figures 6B and 6C). Taken together, the
above data suggest that insulin stimulates mTORC2-ribosome
association in a physiologically relevant manner via PI3K.
mTORC2-Ribosome Interaction Promotes Akt Signaling
in Cancer Cells
PI3K-dependent association of mTORC2 with the ribosome,
ribosome-mediated mTORC2 activation, and the physiological
relevance of mTORC2-ribosome interaction in promoting cell
survival prompted us to analyze mTORC2-ribosome association
in cancer cells with hyperactive PI3K signaling. First, we exam-
ined whether PTEN-deficient metastatic melanoma cells have
elevated mTORC2 activity. Approximately 60% of metastatic
melanomas have reduced PTEN expression and elevated Akt
phosphorylation (Robertson, 2005; Stahl et al., 2004). We
analyzed PTEN expression and Akt Ser473 phosphorylation in
Figure 5. Active mTORC2 Is Associated with the
Ribosome
(A) Endogenous Rpl26 coimmunoprecipitates with
endogenous mTOR, rictor, and mSIN1. Rpl26 and mock
immunoprecipitations were performed with HeLa cell
extracts and analyzed by immunoblotting with the indi-
cated antibodies.
(B) mTORC2 associates with ribosomes. Ribosomes were
purified from HeLa cells by sedimentation through a
sucrose cushion. Ribosomes were probed with the indi-
cated antibodies (left) or were resedimented through a
sucrose gradient to monitor 40S, 60S, and 80S ribosomes
and polysomes. The absorbance profile of the sucrose
gradient was determined at 254nm (right).
(C) Ribosome-associated mTORC2 is active. mTORC2
kinase assays were performed with Rpl26 or mock
immunoprecipitates using recombinant, kinase-dead Akt
as a substrate and in the presence or absence of the
mTOR inhibitor PP242 (left). mTORC2 kinase assay was
performed with ribosomes purified as described in (B),
with recombinant, kinase-dead Akt as a substrate and in
the presence or absence of PP242 (right).
See also Figure S5.
Figure 6. Insulin-PI3K Signaling Stimulates
mTORC2-Ribosome Association
(A) Insulin stimulates mTORC2-ribosome association.
HeLa cells were serum starved and then restimulated with
insulin for the indicated time. Rpl26 immunoprecipitates
(IP: Rpl26) and cell extracts (lysate) were immunoblotted
with the indicated antibodies.
(B) PI3K inhibition decreases mTORC2-ribosome associ-
ation. HeLa cells were treated with LY294002 (50 mM
final concentration) for 30 min before harvesting. Rpl26
immunoprecipitates and cells extracts (lysate) were im-
munoblotted with the indicated antibodies.
(C) siRNA-mediated knockdown of PTEN increases
mTORC2-ribosome association. HeLa cells were trans-
fected with the indicated siRNA and then harvested after
48 hr. Rpl26 immunoprecipitates and cell extracts (lysate)
were analyzed by immunoblotting with the indicated
antibodies.
See also Figure S6.
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six human metastatic melanoma cell lines generated from
different patients (Certa et al., 2001; Deschodt-Lanckman
et al., 1990; Gervois et al., 1996). PTEN expression inversely
correlated with Akt Ser473 phosphorylation (Figure 7A). For
further study, we chose the two cell lines NA8 and ME67 with
low PTEN expression and high Akt Ser473 phosphorylation
(mTORC2 activity) and, as a control, the cell line Juso with the
opposite signaling profile. To examinemTORC2-ribosome asso-
ciation, ribosomes were isolated from the three cell lines and
probed for mTOR, rictor, and mSIN1. In all cases, the total yield
of ribosomes obtained by sedimentation through a sucrose
cushion was similar. However, the PTEN-deficient NA8 and
ME67 cells exhibited significantly increased levels of mTORC2
associated with the ribosomal fraction as compared to the
PTEN-positive Juso cells (Figure 7B), consistent with our PTEN
knockdown studies in HeLa cells described above (Figure 6C).
We also examined mTORC2-ribosome interaction in colon
cancer cells harboring an activating mutation in the PI3K gene
PIK3CA. The PIK3CA mutant cell lines HT29 and HCT116
exhibited both Akt Ser473 hyperphosphorylation (mTORC2
activity) and increased mTORC2-ribosome association as
compared to SW60 colon cells harboring an unaltered PIK3CA
gene (Figure S7A). Thus, mTORC2-ribosome interaction
correlates with mTORC2 activity in both melanoma and colon
cancer cells.
To investigate further the physiological relevance of mTORC2
activation via ribosome association, we examined the effect
of mSIN1 and Rpl7 knockdown on mTORC2 signaling and
cell survival in NA8, ME67, and Juso cells. Knockdown of
either mSIN1 or Rpl7 decreased Akt Ser473 phosphorylation
Figure 7. mTORC2-Ribosome Interaction Pro-
motes Akt Signaling in Cancer Cells
(A) Akt Ser473 phosphorylation inversely correlates with
PTEN expression in human melanoma cells. Cell extracts
from six human melanoma cell lines were analyzed by
immunoblotting with indicated antibodies.
(B) PTEN-deficient cell lines exhibit increased mTORC2-
ribosome association. Ribosomes were purified from
PTEN-deficient (NA8 and ME67) and PTEN-positive
melanoma cell lines (Juso) by sedimentation through a
sucrose cushion. Ribosomes were probed with the indi-
cated antibodies.
(C) Knockdown of mSIN1 or Rpl7 induces apoptosis in
PTEN-deficient (NA8 andME67) melanoma cell lines. Cells
were transfected with the indicated siRNA and harvested
after 72 hr. Extracts were analyzed by immunoblotting to
check the efficiency of the knockdown and the induction
of apoptosis (PARP and caspase 3 cleavage) with the
indicated antibodies.
See also Figure S7.
(Figure 7C), supporting a role for ribosome-
dependent activation of mTORC2 in cancer.
Furthermore, knockdown of either mSIN1 or
Rpl7 enhanced apoptosis both in the presence
and absence of etoposide. Interestingly, the
increase in apoptosis was more pronounced in
the PTEN-deficient NA8 and ME67 cells than
in Juso cells, suggesting that NA8 and ME67 cells are more
‘‘addicted’’ to mTORC2 (Figure 7C and Figure S7B). The above
results taken together suggest that mTORC2-ribosome associa-
tion, mediating PI3K-mTORC2-Akt signaling and cell survival, is
functionally important in cancer cells.
DISCUSSION
We investigated the upstream regulation of TORC2. A genetic
screen in yeast and subsequent studies in mammalian cells
revealed that ribosomes are upstream of TORC2. In particular,
we found the following. First, the genetic screen in yeast revealed
that knocking down ribosome biogenesis inhibits TORC2 kinase
activity in vitro (Figure 1D) and TORC2 signaling in vivo (Figures
1B and 1C and Figure S1). Second, the ribosome is required for
mTORC2 activity in vitro (Figure 2B and Figure 3B) and mTORC2
signaling in vivo in mammalian cells (Figure 2A, Figure 3A, and
Figure S3A). Knockdown of ribosome maturation factor mNIP7
or ribosomal proteins (Rpl7 or Rps16) in mammalian cells
decreased mTORC2 kinase activity and mTORC2 signaling.
Third, the ribosome (translating or nontranslating) interacts
directly with mTORC2 (Figures 5 and Figure S5). mTORC2 cop-
urified with ribosomes isolated by four independent methods.
Furthermore, mTORC2 copurified with ribosomes isolated from
growing cells or cells treated with protein synthesis inhibitors.
Fourth, ribosome-bound mTORC2 is active (Figure 5C), and
ribosome-free mTORC2 is inactive in vitro (Figure 2B, Figure 3B,
and Figure S6B). Fifth, PI3K-dependent insulin signaling stimu-
lates binding of the ribosome to mTORC2 (Figure 6 and Fig-
ure S6D) with the same kinetics that it stimulates mTORC2
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activation (Figure 6A). Finally, the mTORC2-ribosome interaction
correlates with mTORC2 activity in both melanoma and colon
cancer cells (Figure 7 and Figure S7). Melanoma and colon
cancer cells with high PI3K activity (due to loss of PTEN or an
activating mutation in the PI3K gene) exhibited both enhanced
mTORC2-ribosome interaction and increased mTORC2 activity.
Our findings suggest that the translating or nontranslating 80S
ribosome binds and activates mTORC2 in response to growth
factor-stimulated PI3K signaling (Figure S7C). TORC2-ribosome
association is a mechanism of TORC2 activation that is likely
conserved from unicellular yeast to human. The ribosome is
presumably a primordial activator of TORC2 onto which growth
factor signaling was grafted during the evolution of
multicellularity.
In a parallel and complementary study, Oh et al. also showed
that mTORC2 associates with the ribosome (Oh et al., 2010).
Furthermore, they showed that mTORC2 phosphorylates the
Akt turn motif cotranslationally and the Akt hydrophobic motif
posttranslationally. Thus, Oh et al. investigated the role of the
mTORC2-ribosome interaction in downstream signaling by
mTORC2. Our study addresses the separate issue of upstream
regulation of mTORC2. We show that an mTORC2-ribosome
interaction activates mTORC2, and this activation is indepen-
dent of translation. In other words, an mTORC2-ribosome
interaction activates mTORC2 regardless of whether mTORC2
is phosphorylating a substrate co- or posttranslationally. We
note that Oh et al. did not examine a requirement for the ribo-
some in posttranslational phosphorylation.
A connection between ribosomes and TOR signaling is well
established. TORC1 activates ribosome biogenesis and protein
synthesis and inhibits autophagy as key readouts in the control
of cell growth. Why should ribosomes control TORC2? Ribo-
some content determines growth capacity of the cell and
TORC2 regulates growth-related processes. Thus, regulation
of TORC2 by ribosomes ensures that TORC2 is not inappropri-
ately activated in cells that are unable to grow. The above also
implies that TORC1, via activation of ribosome biogenesis and
inhibition of autophagy-mediated ribosome turnover, indirectly
controls TORC2. Indeed, Sarbassov et al. (Sarbassov et al.,
2006) have shown that inhibition of mTORC1 by long-term rapa-
mycin treatment indirectly inhibits mTORC2. Our findings
suggest that the effect of rapamycin on mTORC2 is due, at least
in part, to a reduction in ribosome content. Interestingly, the liter-
ature also indicates that ribosomal defects induce apoptotic cell
death, although the underlying mechanism is not understood
(Warner and McIntosh, 2009). We find that ribosomal defects
inhibit mTORC2 and its downstream effector Akt, which in turn
leads to Bad-dependent apoptosis. Thus, our findings also
provide a mechanism for the induction of apoptosis by a ribo-
somal defect.
Our findings suggest that ribosomes bind and activate
mTORC2 directly. The fraction of total mTORC2 that associates
with ribosomes varies depending on the cell type and the growth
conditions. For example, under normal growth conditions,!20%
of total rictor (mTORC2) was associated with ribosomes in HeLa
cells, whereas !30%–40% of rictor was associated with ribo-
somes in PTEN-deficient cells such as melanoma and PTEN
knockdown cells. Thus, ribosome association appears to be
a major if not the sole mechanism of TORC2 activation. Consid-
eration of the fraction of total ribosomes that associate with
mTORC2 is also potentially informative. Given that ribosomes
are 100- to 1000-fold more abundant than signaling kinases
such as mTORC2, only a small fraction of total ribosomes bind
mTORC2. This excess of ribosomeswould require strong regula-
tion ofmTORC2-ribosome binding by upstreamPI3K signaling to
achieve physiologically relevant regulation of mTORC2. Alterna-
tively, TORC2 could be regulated by a specific subpopulation of
ribosomes. Previous studies have demonstrated that TORC2 is
associated with membranes, including the endoplasmic retic-
ulum (ER) and Golgi apparatus, and that mTORC2 isolated from
ER microsomes phosphorylates Akt Ser473 in vitro (Drenan
et al., 2004; Hresko and Mueckler, 2005; Liu and Zheng, 2007;
Schroder et al., 2007; Sturgill et al., 2008). These findings suggest
that TORC2 might associate specifically with membrane-bound
ribosomes. In support of this notion, we observed that mTORC2
copurifies with ribosomes only when the ribosomes are isolated
in the presence of detergent. Membrane-bound ribosomes con-
stitute!10% of total ribosomes and include both translating and
nontranslating ribosomes (Seiser and Nicchitta, 2000). It is also
interesting to note that Komili et al. (Komili et al., 2007) have
proposed a ribosome code in which there is a specialization of
ribosomes for specific cellular process.
Our findings are consistent with other studies proposing the
ribosome as a kinase platform. The two kinases PKCbII and
Pim-1 are associated with the ribosome via RACK1 and
Rps19, respectively (Ceci et al., 2003; Chiocchetti et al., 2005;
Grosso et al., 2008b). Overall, the ribosome appears to be
a signaling platform for mTORC2 and other kinases. Further-
more, ribosomal proteins have been shown to modulate the
activity of NF-kB, p53, and c-Myc (Lindstro¨m, 2009).
PI3K-Akt signaling is upregulated and contributes to tumori-
genesis in !60% of advanced-stage melanomas (Stahl et al.,
2003, 2004). PTEN expression or Akt inhibition increases
sensitivity of melanoma cells to apoptosis-inducing agents and
prevents tumor development (Madhunapantula and Robertson,
2009; Stahl et al., 2004). Our data, with melanoma, cancer colon,
and HeLa cells, suggest that PI3K signaling promotes Akt
phosphorylation via stimulation of mTORC2-ribosome binding.
Furthermore, disruption of the mTORC2-ribosome supercom-
plex selectively induces apoptosis in PTEN-deficient melanoma
cells (Figure 7C). The extent to which cells of other cancers
require ribosome-dependent mTORC2 activation is unclear,
although we expect that other cancers driven by mutations
promoting PI3K signaling may also depend on mTORC2-ribo-
some association. Disrupting the mTORC2-ribosome interaction
may be a useful strategy in the treatment of melanomas, colon
carcinomas, and possibly other cancers.
Several findings suggest that upregulation of the protein
synthesis machinery contributes to the development of cancer
and other diseases (Ruggero and Pandolfi, 2003). Consistent
with our findings, a ribosomal protein deficiency inhibits Akt-
driven tumorigenesis (Hsieh et al., 2010). Furthermore, the myc
oncogene enhances ribosome biogenesis, and myc oncoge-
nicity in mice can be blocked by mutations in ribosomal protein
genes (Barna et al., 2008; Ruggero, 2009). Our findings and the
observation that mTORC2 is required for tumor progression in
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at least some cancers (Guertin et al., 2009; Gulhati et al., 2009;
Masri et al., 2007) suggest that myc and increased ribosomal
content may promote tumorigenicity via stimulation of mTORC2
and its downstream effector Akt.
Curiously, our genetic screen in yeast yielded 44 TORC2
mutants but only a single mutant (nip7-1) that was defective in
ribosome biogenesis. Why did we not obtain more mutants
that were defective in ribosomal maturation factors or ribosomal
proteins? First, ribosomal genes are duplicated in yeast, thereby
precluding identification of recessive, loss-of-function mutations
in these genes. Second, YPK2 is downstream of the ribosome in
activation of TORC2 but is not downstream of the ribosome in
mediating protein synthesis, precluding full suppression of a ribo-
some biogenesis defect by YPK2*. YPK2* only partly suppresses
the nip7-1 mutation and only at semipermissive temperature.
EXPERIMENTAL PROCEDURES
Detailed protocols for apoptosis assays and statistical analyses can be found
in the Extended Experimental Procedures.
Yeast Strains, Media, Kinase Assays, Actin Staining, and Antibodies
Yeast strains used in this study are listed in the Table S1. All strains are
isogenic derivatives of JK9-3da. Plasmids used in this study are described
in Table S2. Standard techniques and media were used for yeast manipulation
(Kamada et al., 2005; Loewith et al., 2002). Unless indicated otherwise, cells
were grown in rich YPD medium. YPK2 and TORC2 kinase assays were
performed as described previously (Casamayor et al., 1999; Kamada et al.,
2005; Loewith et al., 2002; Wullschleger et al., 2005). Rhodamine phalloidin
staining of polymerized actin was performed as described (Loewith et al.,
2002; Mulet et al., 2006). Immunoprecipitations were performed as described
previously (Loewith et al., 2002; Wullschleger et al., 2005).
Reverse Suppressor Screen
A wild-type strain (JK9-3da) was transformed with an URA3-based plasmid
overexpressing YPK2* (pYPK2*) (Figure 1A). Cells were randomlymutagenized
with 100 mM ethyl-methanesulfonate (EMS) (Sigma) for 15 min in SD-Ura
medium, washed, and then allowed to recover in SD-Ura medium without
mutagen for 2–4 hr. Cells were plated on solid SD-Ura or SD supplemented
with 5-FOA and incubated at 30!C. The SD medium supplemented with
5-FOA counterselected againstURA3 such that only those cells that had spon-
taneously lost the URA3-based pYPK2* plasmid were able to form a colony.
Mutants that were unable to grow on SD 5-FOA (and hence in the absence
of YPK2*) were isolated from the master SD-Ura plate. "45,000 colonies
from mutagenized cells were screened, from which 45 mutants were isolated
and the corresponding mutations were identified. Mutated genes were iso-
lated by complementation with a LEU2 centromeric plasmid-based yeast
genomic library. Complementing members of the genomic library were
selected by growth on SD-Leu medium containing 5-FOA. Genomic inserts
of library-derived plasmids were identified by sequencing. Complementation
with subclones of isolated inserts identified the complementing ORF within
a given insert. Sequencing of the genomic copy of NIP7 and meiotic segrega-
tion studies confirmed that NIP7 was indeed the relevant mutant gene. nip7-1
was found to be temperature sensitive upon subsequent characterization. For
experiments at semipermissive temperature (30!C), nip7-1 cells were grown in
YPD at permissive temperature (25!C), diluted to OD600 = 0.1, and grown at
30!C to approximately OD600 = 0.6–0.8. For experiments at the nonpermissive
temperature (37!C), nip7-1mutant was grown in YPD at 25!C and then shifted
to 37!C for 6 hr.
Cell Culture, Immunoprecipitations, Immunoblotting,
and mTORC2 Kinase Assay
HeLa, melanoma cells, and colon cancer cells were cultured, transfected,
stimulated, and harvested as described previously (Jacinto et al., 2004;
Thedieck et al., 2007). In brief, cells were seeded and grown for 48 hr in
DMEM supplemented with 10% serum (basal conditions). Cells were starved
of serum for 3 hr before restimulation with 100 nM insulin (Sigma).
For mSIN1, mNIP7, Rpl7, Rps16, PTEN, or Bad knockdown, a pool of four
different synthetic siRNA or of the appropriate control siRNA (Dharmacon)
was used as described (Thedieck et al., 2007). All transfections were done
according to the manufacturer’s instructions (Lipofectamine, Invitrogen
transfection).
Protein extracts were prepared as previously described (Jacinto et al., 2004;
Thedieck et al., 2007), resolved on SDS-PAGE, and transferred to nitrocellu-
lose membranes (Protran, Whatman). Immunoprecipitation, immunoblotting,
and mTORC2 kinase assays were performed as previously described (Jacinto
et al., 2004; Thedieck et al., 2007).
Polysome Profiles, Ribosome Purification, and Poly(A) mRNA
Pull-Down
Polysome analysis using sucrose gradients was performed as described previ-
ously (Grosso et al., 2008b; Idol et al., 2007). For ribosome purification by sedi-
mentation through a sucrose cushion, HeLa ormelanoma cells were washed in
PBS, trypsinized, and lysed in buffer A (50mMTris-HCl [pH 7.4], 100mMNaCl,
30 mMMgCl2, 0.3% CHAPS, 100 ug/ml cycloheximide, 40 U/ml RNase inhib-
itor, protease inhibitor cocktail, and 100 ug/ml cycloheximide). Whole-cell
extracts were clarified at 4!C, 10 min at 15,000 3 g. Extracts were loaded
on a 30% sucrose cushion in 50 mM Tris-acetate (pH 7.5), 50 mM NH4Cl,
12 mMMgCl2, and 1 mMDTT and ultracentrifuged for 17 hr in a SW41Ti Beck-
man rotor at 39,000 rpm. For the mTORC2 kinase assay, the ribosomal pellet
was resuspended in mTORC2 kinase buffer (Jacinto et al., 2004; Thedieck
et al., 2007). Ribosome-sucrose gradient fractionation was performed as
previously described (Grosso et al., 2008a). For poly(A) pull-down, HeLa cells
were washed with PBS, trypsinized, and lysed in buffer A. Whole-cell extracts
were clarified at 4!C, 10 min at 8000 3 g. Lysates corresponding to 5 3 107
cells were incubated with oligo(dT) cellulose (Invitrogen) for 1 hr at room
temperature. After incubation, the oligo(dT) cellulose was pelleted andwashed
five times with buffer A. The bound fraction was eluted with elution buffer
(100mMTris [pH 7.4], 500mMNaCl, 10mMEDTA, 1% sodium dodecyl sulfate
(SDS), and 5 mM DTT). Purified ribosome fractions and the bound and
unbound fractions after poly(A) pull-down were concentrated with Vivaspin
500 (Sartorius Stedim) and analyzed by immunoblotting with the indicated
antibodies.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
seven figures, and two tables and can be found with this article online at
doi:10.1016/j.cell.2011.02.014.
ACKNOWLEDGMENTS
We thank Rachel Idol and Stefano Grosso for valuable discussions and
technical assistance and Giulio Spagnoli for the melanoma cell lines. We
acknowledge support from the Swiss National Science Foundation, Sys-
temsX.ch, the Swiss Cancer League, the Louis Jeantet Foundation, and the
Canton of Basel. We declare that no competing interests exist.
Received: July 14, 2010
Revised: October 20, 2010
Accepted: February 7, 2011
Published: March 3, 2011
REFERENCES
Aronova, S., Wedaman, K., Aronov, P.A., Fontes, K., Ramos, K., Hammock,
B.D., and Powers, T. (2008). Regulation of ceramide biosynthesis by TOR
complex 2. Cell Metab. 7, 148–158.
766 Cell 144, 757–768, March 4, 2011 ª2011 Elsevier Inc.
	
  78	
  
Avruch, J., Long, X., Ortiz-Vega, S., Rapley, J., Papageorgiou, A., and Dai, N.
(2009). Amino acid regulation of TOR complex 1. Am. J. Physiol. Endocrinol.
Metab. 296, E592–E602.
Barna, M., Pusic, A., Zollo, O., Costa, M., Kondrashov, N., Rego, E., Rao, P.H.,
and Ruggero, D. (2008). Suppression of Myc oncogenic activity by ribosomal
protein haploinsufficiency. Nature 456, 971–975.
Beeler, T., Bacikova, D., Gable, K., Hopkins, L., Johnson, C., Slife, H., and
Dunn, T. (1998). The Saccharomyces cerevisiae TSC10/YBR265w gene
encoding 3-ketosphinganine reductase is identified in a screen for tempera-
ture-sensitive suppressors of the Ca2+-sensitive csg2Delta mutant. J. Biol.
Chem. 273, 30688–30694.
Boyce, M., Bryant, K.F., Jousse, C., Long, K., Harding, H.P., Scheuner, D.,
Kaufman, R.J., Ma, D., Coen, D.M., Ron, D., and Yuan, J. (2005). A selective
inhibitor of eIF2alpha dephosphorylation protects cells from ER stress.
Science 307, 935–939.
Brazil, D.P., Yang, Z.Z., and Hemmings, B.A. (2004). Advances in protein
kinase B signalling: AKTion on multiple fronts. Trends Biochem. Sci. 29,
233–242.
Casamayor, A., Torrance, P.D., Kobayashi, T., Thorner, J., and Alessi, D.R.
(1999). Functional counterparts of mammalian protein kinases PDK1 and
SGK in budding yeast. Curr. Biol. 9, 186–197.
Ceci, M., Gaviraghi, C., Gorrini, C., Sala, L.A., Offenha¨user, N., Marchisio, P.C.,
and Biffo, S. (2003). Release of eIF6 (p27BBP) from the 60S subunit allows 80S
ribosome assembly. Nature 426, 579–584.
Certa, U., Seiler, M., Padovan, E., and Spagnoli, G.C. (2001). High density
oligonucleotide array analysis of interferon- alpha2a sensitivity and transcrip-
tional response in melanoma cells. Br. J. Cancer 85, 107–114.
Chiocchetti, A., Gibello, L., Carando, A., Aspesi, A., Secco, P., Garelli, E.,
Loreni, F., Angelini, M., Biava, A., Dahl, N., et al. (2005). Interactions between
RPS19, mutated in Diamond-Blackfan anemia, and the PIM-1 oncoprotein.
Haematologica 90, 1453–1462.
Cnop, M., Ladriere, L., Hekerman, P., Ortis, F., Cardozo, A.K., Dogusan, Z.,
Flamez, D., Boyce, M., Yuan, J., and Eizirik, D.L. (2007). Selective inhibition
of eukaryotic translation initiation factor 2 alpha dephosphorylation potentiates
fatty acid-induced endoplasmic reticulum stress and causes pancreatic
beta-cell dysfunction and apoptosis. J. Biol. Chem. 282, 3989–3997.
Cybulski, N., and Hall, M.N. (2009). TOR complex 2: a signaling pathway of its
own. Trends Biochem. Sci. 34, 620–627.
Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg,
M.E. (1997). Akt phosphorylation of BAD couples survival signals to the
cell-intrinsic death machinery. Cell 91, 231–241.
Deschodt-Lanckman, M., Vanneste, Y., Loir, B., Michel, A., Libert, A.,
Ghanem, G., and Lejeune, F. (1990). Degradation of alpha-melanocyte stimu-
lating hormone (alpha-MSH) by CALLA/endopeptidase 24.11 expressed by
human melanoma cells in culture. Int. J. Cancer 46, 1124–1130.
Drenan, R.M., Liu, X., Bertram, P.G., and Zheng, X.F. (2004). FKBP12-rapamy-
cin-associated protein or mammalian target of rapamycin (FRAP/mTOR)
localization in the endoplasmic reticulum and the Golgi apparatus. J. Biol.
Chem. 279, 772–778.
Facchinetti, V., Ouyang,W., Wei, H., Soto, N., Lazorchak, A., Gould, C., Lowry,
C., Newton, A.C., Mao, Y., Miao, R.Q., et al. (2008). The mammalian target of
rapamycin complex 2 controls folding and stability of Akt and protein kinase C.
EMBO J. 27, 1932–1943.
Feldman, M.E., Apsel, B., Uotila, A., Loewith, R., Knight, Z.A., Ruggero, D., and
Shokat, K.M. (2009). Active-site inhibitors of mTOR target rapamycin-resistant
outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38.
Frias, M.A., Thoreen, C.C., Jaffe, J.D., Schroder, W., Sculley, T., Carr, S.A.,
and Sabatini, D.M. (2006). mSin1 is necessary for Akt/PKB phosphorylation,
and its isoforms define three distinct mTORC2s. Curr. Biol. 16, 1865–1870.
Garcı´a-Martı´nez, J.M., and Alessi, D.R. (2008). mTOR complex 2 (mTORC2)
controls hydrophobic motif phosphorylation and activation of serum- and
glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 416, 375–385.
Gervois, N., Guilloux, Y., Diez, E., and Jotereau, F. (1996). Suboptimal activa-
tion of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-
tumor peptide interactions. J. Exp. Med. 183, 2403–2407.
Grosso, S., Volta, V., Sala, L.A., Vietri, M., Marchisio, P.C., Ron, D., and Biffo,
S. (2008a). PKCbetaII modulates translation independently from mTOR and
through RACK1. Biochem. J. 415, 77–85.
Grosso, S., Volta, V., Vietri, M., Gorrini, C., Marchisio, P.C., and Biffo, S.
(2008b). Eukaryotic ribosomes host PKC activity. Biochem. Biophys. Res.
Commun. 376, 65–69.
Guertin, D.A., Stevens, D.M., Saitoh, M., Kinkel, S., Crosby, K., Sheen, J.H.,
Mullholland, D.J., Magnuson, M.A., Wu, H., and Sabatini, D.M. (2009).
mTOR complex 2 is required for the development of prostate cancer induced
by Pten loss in mice. Cancer Cell 15, 148–159.
Gulhati, P., Cai, Q., Li, J., Liu, J., Rychahou, P.G., Qiu, S., Lee, E.Y., Silva, S.R.,
Bowen, K.A., Gao, T., and Evers, B.M. (2009). Targeted inhibition of mamma-
lian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer.
Clin. Cancer Res. 15, 7207–7216.
Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga,
C., Avruch, J., and Yonezawa, K. (2002). Raptor, a binding partner of target of
rapamycin (TOR), mediates TOR action. Cell 110, 177–189.
He, H.N., Wang, X., Zheng, X.L., Sun, H., Shi, X.W., Zhong, Y.J., Huang, B.,
Yang, L., Li, J.K., Liao, L.C., et al. (2010). Concurrent blockade of the
NF-kappaB and Akt pathways potently sensitizes cancer cells to chemother-
apeutic-induced cytotoxicity. Cancer Lett. 295, 38–43.
Helliwell, S.B., Howald, I., Barbet, N., and Hall, M.N. (1998). TOR2 is part of two
related signaling pathways coordinating cell growth in Saccharomyces cerevi-
siae. Genetics 148, 99–112.
Hresko, R.C., andMueckler, M. (2005). mTOR.RICTOR is the Ser473 kinase for
Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 280, 40406–40416.
Hsieh, A.C., Costa, M., Zollo, O., Davis, C., Feldman, M.E., Testa, J.R.,
Meyuhas, O., Shokat, K.M., and Ruggero, D. (2010). Genetic dissection of
the oncogenic mTOR pathway reveals druggable addiction to translational
control via 4EBP-eIF4E. Cancer Cell 17, 249–261.
Idol, R.A., Robledo, S., Du, H.Y., Crimmins, D.L., Wilson, D.B., Ladenson, J.H.,
Bessler, M., and Mason, P.J. (2007). Cells depleted for RPS19, a protein
associated with Diamond Blackfan Anemia, show defects in 18S ribosomal
RNA synthesis and small ribosomal subunit production. Blood Cells Mol.
Dis. 39, 35–43.
Ikenoue, T., Inoki, K., Yang, Q., Zhou, X., and Guan, K.L. (2008). Essential
function of TORC2 in PKC and Akt turn motif phosphorylation, maturation
and signalling. EMBO J. 27, 1919–1931.
Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S.Y., Huang, Q.,
Qin, J., and Su, B. (2006). SIN1/MIP1 maintains rictor-mTOR complex integrity
and regulates Akt phosphorylation and substrate specificity. Cell 127,
125–137.
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Ru¨egg, M.A., Hall, A., and Hall,
M.N. (2004). Mammalian TOR complex 2 controls the actin cytoskeleton and
is rapamycin insensitive. Nat. Cell Biol. 6, 1122–1128.
Jacinto, E., and Lorberg, A. (2008). TOR regulation of AGC kinases in yeast and
mammals. Biochem. J. 410, 19–37.
Kamada, Y., Fujioka, Y., Suzuki, N.N., Inagaki, F., Wullschleger, S., Loewith,
R., Hall, M.N., and Ohsumi, Y. (2005). Tor2 directly phosphorylates the AGC
kinase Ypk2 to regulate actin polarization. Mol. Cell. Biol. 25, 7239–7248.
Kim, A.H., Khursigara, G., Sun, X., Franke, T.F., and Chao, M.V. (2001). Akt
phosphorylates and negatively regulates apoptosis signal-regulating kinase
1. Mol. Cell. Biol. 21, 893–901.
Kim, D.H., Sarbassov, D.D., Ali, S.M., King, J.E., Latek, R.R., Erdjument-
Bromage, H., Tempst, P., and Sabatini, D.M. (2002). mTOR interacts with
raptor to form a nutrient-sensitive complex that signals to the cell growth
machinery. Cell 110, 163–175.
Komili, S., Farny, N.G., Roth, F.P., and Silver, P.A. (2007). Functional specificity
among ribosomal proteins regulates gene expression. Cell 131, 557–571.
Cell 144, 757–768, March 4, 2011 ª2011 Elsevier Inc. 767
	
   79	
  
 
 
  
Laplante, M., and Sabatini, D.M. (2009). mTOR signaling at a glance. J. Cell
Sci. 122, 3589–3594.
Lindstro¨m, M.S. (2009). Emerging functions of ribosomal proteins in gene-
specific transcription and translation. Biochem. Biophys. Res. Commun.
379, 167–170.
Liu, X., and Zheng, X.F. (2007). Endoplasmic reticulum and Golgi localization
sequences for mammalian target of rapamycin. Mol. Biol. Cell 18, 1073–1082.
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J.L., Bonenfant,
D., Oppliger, W., Jenoe, P., and Hall, M.N. (2002). Two TOR complexes, only
one of which is rapamycin sensitive, have distinct roles in cell growth control.
Mol. Cell 10, 457–468.
Madhunapantula, S.V., and Robertson, G.P. (2009). The PTEN-AKT3 signaling
cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res.
22, 400–419.
Manning, B.D., and Cantley, L.C. (2003). Rheb fills a GAP between TSC and
TOR. Trends Biochem. Sci. 28, 573–576.
Masri, J., Bernath, A., Martin, J., Jo, O.D., Vartanian, R., Funk, A., and Gera, J.
(2007). mTORC2 activity is elevated in gliomas and promotes growth and cell
motility via overexpression of rictor. Cancer Res. 67, 11712–11720.
Mulet, J.M., Martin, D.E., Loewith, R., and Hall, M.N. (2006). Mutual antago-
nism of target of rapamycin and calcineurin signaling. J. Biol. Chem. 281,
33000–33007.
Oh, W.J., Wu, C.C., Kim, S.J., Facchinetti, V., Julien, L.A., Finlan, M., Roux,
P.P., Su, B., and Jacinto, E. (2010). mTORC2 can associate with ribosomes
to promote cotranslational phosphorylation and stability of nascent Akt poly-
peptide. EMBO J. 29, 3939–3951.
Pearce, L.R., Huang, X., Boudeau, J., Paw1owski, R., Wullschleger, S., Deak,
M., Ibrahim, A.F., Gourlay, R., Magnuson, M.A., and Alessi, D.R. (2007).
Identification of Protor as a novel Rictor-binding component of mTOR
complex-2. Biochem. J. 405, 513–522.
Robertson, G.P. (2005). Functional and therapeutic significance of Akt dereg-
ulation in malignant melanoma. Cancer Metastasis Rev. 24, 273–285.
Ruggero, D. (2009). The role of Myc-induced protein synthesis in cancer.
Cancer Res. 69, 8839–8843.
Ruggero, D., and Pandolfi, P.P. (2003). Does the ribosome translate cancer?
Nat. Rev. Cancer 3, 179–192.
Sarbassov, D.D., Ali, S.M., Kim, D.H., Guertin, D.A., Latek, R.R., Erdjument-
Bromage, H., Tempst, P., and Sabatini, D.M. (2004). Rictor, a novel binding
partner of mTOR, defines a rapamycin-insensitive and raptor-independent
pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296–1302.
Sarbassov, D.D., Guertin, D.A., Ali, S.M., and Sabatini, D.M. (2005).
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.
Science 307, 1098–1101.
Sarbassov, D.D., Ali, S.M., Sengupta, S., Sheen, J.H., Hsu, P.P., Bagley, A.F.,
Markhard, A.L., and Sabatini, D.M. (2006). Prolonged rapamycin treatment
inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159–168.
Schmidt, A., Bickle, M., Beck, T., and Hall, M.N. (1997). The yeast phosphati-
dylinositol kinase homolog TOR2 activates RHO1 and RHO2 via the exchange
factor ROM2. Cell 88, 531–542.
Schroder, W.A., Buck,M., Cloonan, N., Hancock, J.F., Suhrbier, A., Sculley, T.,
and Bushell, G. (2007). Human Sin1 contains Ras-binding and pleckstrin
homology domains and suppresses Ras signalling. Cell. Signal. 19, 1279–
1289.
Seiser, R.M., and Nicchitta, C.V. (2000). The fate of membrane-bound
ribosomes following the termination of protein synthesis. J. Biol. Chem. 275,
33820–33827.
Sonenberg, N., and Hinnebusch, A.G. (2009). Regulation of translation initia-
tion in eukaryotes: mechanisms and biological targets. Cell 136, 731–745.
Soulard, A., Cohen, A., and Hall, M.N. (2009). TOR signaling in invertebrates.
Curr. Opin. Cell Biol. 21, 825–836.
Sparks, C.A., and Guertin, D.A. (2010). Targeting mTOR: prospects for mTOR
complex 2 inhibitors in cancer therapy. Oncogene 29, 3733–3744.
Stahl, J.M., Cheung, M., Sharma, A., Trivedi, N.R., Shanmugam, S., and
Robertson, G.P. (2003). Loss of PTEN promotes tumor development in
malignant melanoma. Cancer Res. 63, 2881–2890.
Stahl, J.M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J.Q.,
Bosenberg, M.W., Kester, M., Sandirasegarane, L., and Robertson, G.P.
(2004). Deregulated Akt3 activity promotes development of malignant mela-
noma. Cancer Res. 64, 7002–7010.
Sturgill, T.W., Cohen, A., Diefenbacher, M., Trautwein, M., Martin, D.E., and
Hall, M.N. (2008). TOR1 and TOR2 have distinct locations in live cells.
Eukaryot. Cell 7, 1819–1830.
Thedieck, K., Polak, P., Kim, M.L., Molle, K.D., Cohen, A., Jeno¨, P.,
Arrieumerlou, C., and Hall, M.N. (2007). PRAS40 and PRR5-like protein are
new mTOR interactors that regulate apoptosis. PLoS ONE 2, e1217.
Wang, X., McCullough, K.D., Franke, T.F., and Holbrook, N.J. (2000).
Epidermal growth factor receptor-dependent Akt activation by oxidative stress
enhances cell survival. J. Biol. Chem. 275, 14624–14631.
Warner, J.R., and McIntosh, K.B. (2009). How common are extraribosomal
functions of ribosomal proteins? Mol. Cell 34, 3–11.
Wullschleger, S., Loewith, R., Oppliger, W., and Hall, M.N. (2005). Molecular
organization of target of rapamycin complex 2. J. Biol. Chem. 280, 30697–
30704.
Wullschleger, S., Loewith, R., and Hall, M.N. (2006). TOR signaling in growth
and metabolism. Cell 124, 471–484.
Yang, Q., and Guan, K.L. (2007). Expanding mTOR signaling. Cell Res. 17,
666–681.
Yang, Q., Inoki, K., Ikenoue, T., and Guan, K.L. (2006). Identification of Sin1 as
an essential TORC2 component required for complex formation and kinase
activity. Genes Dev. 20, 2820–2832.
Zanchin, N.I., Roberts, P., DeSilva, A., Sherman, F., and Goldfarb, D.S. (1997).
Saccharomyces cerevisiae Nip7p is required for efficient 60S ribosome
subunit biogenesis. Mol. Cell. Biol. 17, 5001–5015.
768 Cell 144, 757–768, March 4, 2011 ª2011 Elsevier Inc.
	
  80	
  
  
	
   81	
  
BIBLIOGRAPHY 
 
Adami, A., García-Alvarez, B., Arias-Palomo, E., Barford, D., and Llorca, O. 
(2007). Structure of TOR and its complex with KOG1. Molecular Cell 27, 509–
516. 
Alayev, A., and Holz, M.K. (2013). mTOR signaling for biological control and 
cancer. J. Cell. Physiol. 228, 1658–1664. 
Andrade, M.A., and Bork, P. (1995). HEAT repeats in the Huntington's disease 
protein. Nat. Genet. 11, 115–116. 
André, B. (1995). An overview of membrane transport proteins in 
Saccharomyces cerevisiae. Yeast 11, 1575–1611. 
Angeles de la Torre-Ruiz, M., Torres, J., Ariño, J., and Herrero, E. (2002). Sit4 
is required for proper modulation of the biological functions mediated by Pkc1 
and the cell integrity pathway in Saccharomyces cerevisiae. J Biol Chem 277, 
33468–33476. 
Arencibia, J.M., Pastor-Flores, D., Bauer, A.F., Schulze, J.O., and Biondi, R.M. 
(2013). Biochimica et Biophysica Acta. BBA - Proteins and Proteomics 1834, 
1302–1321. 
Aronova, S., Wedaman, K., Anderson, S., Yates, J., and Powers, T. (2007). 
Probing the membrane environment of the TOR kinases reveals functional 
interactions between TORC1, actin, and membrane trafficking in 
Saccharomyces cerevisiae. Mol Biol Cell 18, 2779–2794. 
Aronova, S., Wedaman, K., Aronov, P.A., Fontes, K., Ramos, K., Hammock, 
B.D., and Powers, T. (2008). Regulation of ceramide biosynthesis by TOR 
complex 2. Cell Metabolism 7, 148–158. 
Ashe, M., de Bruin, R.A.M., Kalashnikova, T., McDonald, W.H., Yates, J.R., 
and Wittenberg, C. (2008). The SBF- and MBF-associated protein Msa1 is 
required for proper timing of G1-specific transcription in Saccharomyces 
cerevisiae. J Biol Chem 283, 6040–6049. 
Audhya, A., Loewith, R., Parsons, A.B., Gao, L., Tabuchi, M., Zhou, H., Boone, 
C., Hall, M.N., and Emr, S.D. (2004). Genome-wide lethality screen identifies 
new PI4,5P2 effectors that regulate the actin cytoskeleton. Embo J 23, 3747–
3757. 
Banaszynski, L.A., Liu, C.W., and Wandless, T.J. (2005). Characterization of 
the FKBP.rapamycin.FRB ternary complex. J. Am. Chem. Soc. 127, 4715–
4721. 
Bar-Peled, L., Chantranupong, L., Cherniack, A.D., Chen, W.W., Ottina, K.A., 
Grabiner, B.C., Spear, E.D., Carter, S.L., Meyerson, M., and Sabatini, D.M. 
(2013). A Tumor suppressor complex with GAP activity for the Rag GTPases 
	
  82	
  
that signal amino acid sufficiency to mTORC1. Science 340, 1100–1106. 
Bar-Peled, L., Schweitzer, L.D., Zoncu, R., and Sabatini, D.M. (2012). 
Ragulator Is a GEFfor the Rag GTPases that Signal Amino Acid Levels to 
mTORC1. Cell 150, 1196–1208. 
Barbet, N.C., Schneider, U., Helliwell, S.B., Stansfield, I., Tuite, M.F., and Hall, 
M.N. (1996). TOR controls translation initiation and early G1 progression in 
yeast. Mol Biol Cell 7, 25–42. 
Beck, T., and Hall, M.N. (1999). The TOR signalling pathway controls nuclear 
localization of nutrient-regulated transcription factors. Nature 402, 689–692. 
Beck, T., Schmidt, A., and Hall, M.N. (1999). Starvation induces vacuolar 
targeting and degradation of the tryptophan permease in yeast. J Cell Biol 146, 
1227–1238. 
Beeler, T., Bacikova, D., Gable, K., Hopkins, L., Johnson, C., Slife, H., and 
Dunn, T. (1998). The Saccharomyces cerevisiae TSC10/YBR265w gene 
encoding 3-ketosphinganine reductase is identified in a screen for 
temperature-sensitive suppressors of the Ca2+-sensitive csg2Delta mutant. J 
Biol Chem 273, 30688–30694. 
Beeler, T., Gable, K., Zhao, C., and Dunn, T. (1994). A novel protein, CSG2p, 
is required for Ca2+ regulation in Saccharomyces cerevisiae. J Biol Chem 269, 
7279–7284. 
Benjamin, D., Colombi, M., Moroni, C., and Hall, M.N. (2011). Rapamycin 
passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 
10, 868–880. 
Berchtold, D., and Walther, T. (2009). TORC2 Plasma Membrane Localization 
Is Essential for Cell Viability and Restricted to a Distinct Domain. Mol Biol Cell. 
Berchtold, D., Piccolis, M., Chiaruttini, N., Riezman, I., Riezman, H., Roux, A., 
Walther, T.C., and Loewith, R. (2012). Plasma membrane stress induces 
relocalization of Slm proteins and activation of TORC2 to promote sphingolipid 
synthesis. Nat Cell Biol 14, 542–547. 
Berger, A.B., Decourty, L., Badis, G., Nehrbass, U., Jacquier, A., and Gadal, 
O. (2007). Hmo1 is required for TOR-dependent regulation of ribosomal 
protein gene transcription. Mol Cell Biol 27, 8015–8026. 
Betz, C., Stracka, D., Prescianotto-Baschong, C., Frieden, M., Demaurex, N., 
and Hall, M.N. (2013). mTOR complex 2-Akt signaling at mitochondria-
associated endoplasmic reticulum membranes (MAM) regulates mitochondrial 
physiology. Proceedings of the National Academy of Sciences. 
Binda, M., Bonfils, G., Panchaud, N., Péli-Gulli, M.-P., and De Virgilio, C. 
(2010). An EGOcentric view of TORC1 signaling. Cell Cycle 9, 221–222. 
	
   83	
  
Binda, M., Péli-Gulli, M.-P., Bonfils, G., Panchaud, N., Urban, J., Sturgill, T.W., 
Loewith, R., and De Virgilio, C. (2009). The Vam6 GEF controls TORC1 by 
activating the EGO complex. Molecular Cell 35, 563–573. 
Blagosklonny, M.V., and Hall, M.N. (2009). Growth and aging: a common 
molecular mechanism. Aging (Albany NY) 1, 357–362. 
Bonfils, G., Jaquenoud, M., Bontron, S., Ostrowicz, C., Ungermann, C., and 
De Virgilio, C. (2012). Leucyl-tRNA Synthetase Controls TORC1 via the EGO 
Complex. Molecular Cell 46, 105–110. 
Brauer, M.J., Yuan, J., Bennett, B.D., Lu, W., Kimball, E., Botstein, D., and 
Rabinowitz, J.D. (2006). Conservation of the metabolomic response to 
starvation across two divergent microbes. Proc Natl Acad Sci USA 103, 
19302–19307. 
Breitkreutz, A., Choi, H., Sharom, J.R., Boucher, L., Neduva, V., Larsen, B., 
Lin, Z.Y., Breitkreutz, B.J., Stark, C., Liu, G., et al. (2010). A Global Protein 
Kinase and Phosphatase Interaction Network in Yeast. Science 328, 1043–
1046. 
Breslow, D.K., Collins, S.R., Bodenmiller, B., Aebersold, R., Simons, K., 
Shevchenko, A., Ejsing, C.S., and Weissman, J.S. (2010). Orm family proteins 
mediate sphingolipid homeostasis. Nature 463, 1048–1053. 
Broach, J.R. (2012). Nutritional Control of Growth and Development in Yeast. 
Genetics 192, 73–105. 
Brown, E.J., Albers, M.W., Shin, T.B., Ichikawa, K., Keith, C.T., Lane, W.S., 
and Schreiber, S.L. (1994). A mammalian protein targeted by G1-arresting 
rapamycin-receptor complex. Nature 369, 756–758. 
Buerger, C., DeVries, B., and Stambolic, V. (2006). Localization of Rheb to the 
endomembrane is critical for its signaling function. Biochemical and 
Biophysical Research Communications 344, 869–880. 
Buescher, J.M., Moco, S., Sauer, U., and Zamboni, N. (2010). Ultrahigh 
performance liquid chromatography-tandem mass spectrometry method for 
fast and robust quantification of anionic and aromatic metabolites. Anal Chem 
82, 4403–4412. 
Bultynck, G., Heath, V.L., Majeed, A.P., Galan, J.-M., Haguenauer-Tsapis, R., 
and Cyert, M.S. (2006). Slm1 and slm2 are novel substrates of the calcineurin 
phosphatase required for heat stress-induced endocytosis of the yeast uracil 
permease. Mol Cell Biol 26, 4729–4745. 
Butow, R.A., and Avadhani, N.G. (2004). Mitochondrial signaling: the 
retrograde response. Molecular Cell 14, 1–15. 
Büscher, J.M., Czernik, D., Ewald, J.C., Sauer, U., and Zamboni, N. (2009). 
	
  84	
  
Cross-platform comparison of methods for quantitative metabolomics of 
primary metabolism. Anal Chem 81, 2135–2143. 
Cafferkey, R., Young, P.R., McLaughlin, M.M., Bergsma, D.J., Koltin, Y., 
Sathe, G.M., Faucette, L., Eng, W.K., Johnson, R.K., and Livi, G.P. (1993). 
Dominant missense mutations in a novel yeast protein related to mammalian 
phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol 
Cell Biol 13, 6012–6023. 
Calne, R.Y., Collier, D.S., Lim, S., Pollard, S.G., Samaan, A., White, D.J., and 
Thiru, S. (1989). Rapamycin for immunosuppression in organ allografting. 
Lancet 2, 227. 
Canelas, A.B., Harrison, N., Fazio, A., Zhang, J., Pitkänen, J.-P., van den 
Brink, J., Bakker, B.M., Bogner, L., Bouwman, J., Castrillo, J.I., et al. (2010). 
Integrated multilaboratory systems biology reveals differences in protein 
metabolism between two reference yeast strains. Nature Communications 1, 
145–148. 
Cantor, J.R., and Sabatini, D.M. (2012). Cancer cell metabolism: one hallmark, 
many faces. Cancer Discov 2, 881–898. 
Cardenas, M.E., Cutler, N.S., Lorenz, M.C., Di Como, C.J., and Heitman, J. 
(1999). The TOR signaling cascade regulates gene expression in response to 
nutrients. Genes Dev 13, 3271–3279. 
Carobbio, S., Frigerio, F., Rubi, B., Vetterli, L., Bloksgaard, M., Gjinovci, A., 
Pournourmohammadi, S., Herrera, P.L., Reith, W., Mandrup, S., et al. (2009). 
Deletion of glutamate dehydrogenase in beta-cells abolishes part of the insulin 
secretory response not required for glucose homeostasis. J Biol Chem 284, 
921–929. 
Carvalho, J., and Zheng, X.F.S. (2003). Domains of Gln3p interacting with 
karyopherins, Ure2p, and the target of rapamycin protein. J Biol Chem 278, 
16878–16886. 
Chan, T.F., Bertram, P.G., Ai, W., and Zheng, X.F. (2001). Regulation of 
APG14 expression by the GATA-type transcription factor Gln3p. J Biol Chem 
276, 6463–6467. 
Chen, E.J., and Kaiser, C.A. (2003). LST8 negatively regulates amino acid 
biosynthesis as a component of the TOR pathway. J Cell Biol 161, 333–347. 
Cherkasova, V.A. (2003). Translational control by TOR and TAP42 through 
dephosphorylation of eIF2alpha kinase GCN2. Genes Dev 17, 859–872. 
Chiang, G.G., and Abraham, R.T. (2005). Phosphorylation of mammalian 
target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol 
Chem 280, 25485–25490. 
	
   85	
  
Chiu, M.I., Katz, H., and Berlin, V. (1994). RAPT1, a mammalian homolog of 
yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci 
USA 91, 12574–12578. 
Choi, J., Chen, J., Schreiber, S.L., and Clardy, J. (1996). Structure of the 
FKBP12-rapamycin complex interacting with the binding domain of human 
FRAP. Science 273, 239–242. 
Cogoni, C., Valenzuela, L., González-Halphen, D., Olivera, H., Macino, G., 
Ballario, P., and González, A. (1995). Saccharomyces cerevisiae has a single 
glutamate synthase gene coding for a plant-like high-molecular-weight 
polypeptide. J Bacteriol 177, 792–798. 
Collier, S.J. (1989). Immunosuppressive drugs. Curr. Opin. Immunol. 2, 854–
858. 
Cooper, T.G. (1982). Nitrogen Metabolism in  Saccharomyces cerevisiae. Cold 
Spring Harbor Monograph Archive 11B, 39–99. 
Cooper, T.G. (2002). Transmitting the signal of excess nitrogen in 
Saccharomyces cerevisiae from the Tor proteins to the GATA factors: 
connecting the dots. FEMS Microbiology Reviews 26, 223–238. 
Costanzo, M., Nishikawa, J.L., Tang, X., Millman, J.S., Schub, O., Breitkreuz, 
K., Dewar, D., Rupes, I., Andrews, B., and Tyers, M. (2004). CDK activity 
antagonizes Whi5, an inhibitor of G1/S transcription in yeast. Cell 117, 899–
913. 
Crespo, J.L., Powers, T., Fowler, B., and Hall, M.N. (2002). The TOR-
controlled transcription activators GLN3, RTG1, and RTG3 are regulated in 
response to intracellular levels of glutamine. Proc Natl Acad Sci USA 99, 
6784–6789. 
Dames, S.A., Mulet, J.M., Rathgeb-Szabo, K., Hall, M.N., and Grzesiek, S. 
(2005). The solution structure of the FATC domain of the protein kinase target 
of rapamycin suggests a role for redox-dependent structural and cellular 
stability. J Biol Chem 280, 20558–20564. 
Daquinag, A., Fadri, M., Jung, S.Y., Qin, J., and Kunz, J. (2007). The yeast PH 
domain proteins Slm1 and Slm2 are targets of sphingolipid signaling during the 
response to heat stress. Mol Cell Biol 27, 633–650. 
Dazert, E., and Hall, M.N. (2011). mTOR signaling in disease. Curr Opin Cell 
Biol 23, 744–755. 
de Craene, J.O., Soetens, O., and André, B. (2001). The Npr1 kinase controls 
biosynthetic and endocytic sorting of the yeast Gap1 permease. J Biol Chem 
276, 43939–43948. 
De Virgilio, C., and Loewith, R. (2006). Cell growth control: little eukaryotes 
	
  86	
  
make big contributions. Oncogene 25, 6392–6415. 
DeLuna, A. (2001). NADP-Glutamate Dehydrogenase Isoenzymes of 
Saccharomyces cerevisiae. PURIFICATION, KINETIC PROPERTIES, AND 
PHYSIOLOGICAL ROLES. Journal of Biological Chemistry 276, 43775–
43783. 
Di Como, C.J., and Arndt, K.T. (1996). Nutrients, via the Tor proteins, stimulate 
the association of Tap42 with type 2A phosphatases. Genes Dev 10, 1904–
1916. 
Dokudovskaya, S., Waharte, F., Schlessinger, A., Pieper, U., Devos, D.P., 
Cristea, I.M., Williams, R., Salamero, J., Chait, B.T., Sali, A., et al. (2011). A 
conserved coatomer-related complex containing Sec13 and Seh1 dynamically 
associates with the vacuole in Saccharomyces cerevisiae. Mol Cell Proteomics 
10, M110.006478. 
Dong, J., Qiu, H., Garcia-Barrio, M., Anderson, J., and Hinnebusch, A.G. 
(2000). Uncharged tRNA activates GCN2 by displacing the protein kinase 
moiety from a bipartite tRNA-binding domain. Molecular Cell 6, 269–279. 
Dubouloz, F., Deloche, O., Wanke, V., Cameroni, E., and De Virgilio, C. 
(2005). The TOR and EGO protein complexes orchestrate microautophagy in 
yeast. Molecular Cell 19, 15–26. 
Durán, R.V., MacKenzie, E.D., Boulahbel, H., Frezza, C., Heiserich, L., 
Tardito, S., Bussolati, O., Rocha, S., Hall, M.N., and Gottlieb, E. (2013). HIF-
independent role of prolyl hydroxylases in the cellular response to amino acids. 
Oncogene 32, 4549–4556. 
Durán, R.V., Oppliger, W., Robitaille, A.M., Heiserich, L., Skendaj, R., Gottlieb, 
E., and Hall, M.N. (2012). Glutaminolysis Activates Rag-mTORC1 Signaling. 
Molecular Cell 1–10. 
Düvel, K., Santhanam, A., Garrett, S., Schneper, L., and Broach, J.R. (2003). 
Multiple roles of Tap42 in mediating rapamycin-induced transcriptional 
changes in yeast. Molecular Cell 11, 1467–1478. 
Ewald, J.C., Heux, S., and Zamboni, N. (2009). High-throughput quantitative 
metabolomics: workflow for cultivation, quenching, and analysis of yeast in a 
multiwell format. Anal Chem 81, 3623–3629. 
Fabrizio, P., Pozza, F., Pletcher, S.D., Gendron, C.M., and Longo, V.D. (2001). 
Regulation of longevity and stress resistance by Sch9 in yeast. Science 292, 
288–290. 
Fadri, M., Daquinag, A., Wang, S., Xue, T., and Kunz, J. (2005). The pleckstrin 
homology domain proteins Slm1 and Slm2 are required for actin cytoskeleton 
organization in yeast and bind phosphatidylinositol-4,5-bisphosphate and 
TORC2. Mol Biol Cell 16, 1883–1900. 
	
   87	
  
Frias, M.A., Thoreen, C.C., Jaffe, J.D., Schroder, W., Sculley, T., Carr, S.A., 
and Sabatini, D.M. (2006). mSin1 is necessary for Akt/PKB phosphorylation, 
and its isoforms define three distinct mTORC2s. Curr Biol 16, 1865–1870. 
Gallinetti, J., Harputlugil, E., and Mitchell, J.R. (2012). Amino acid sensing in 
dietary-restriction-mediated longevity: roles of signal-transducing kinases 
GCN2 and TOR. Biochem J 449, 1–10. 
Gancedo, J.M. (1998). Yeast carbon catabolite repression. Microbiol Mol Biol 
Rev 62, 334–361. 
Gander, S., Bonenfant, D., Altermatt, P., Martin, D.E., Hauri, S., Moes, S., Hall, 
M.N., and Jenoe, P. (2008). Identification of the rapamycin-sensitive 
phosphorylation sites within the Ser/Thr-rich domain of the yeast Npr1 protein 
kinase. Rapid Commun Mass Spectrom 22, 3743–3753. 
Gao, M., and Kaiser, C.A. (2006). A conserved GTPase-containing complex is 
required for intracellular sorting of the general amino-acid permease in yeast. 
Nat Cell Biol 8, 657–667. 
Gasch, A.P., Spellman, P.T., Kao, C.M., Carmel-Harel, O., Eisen, M.B., Storz, 
G., Botstein, D., and Brown, P.O. (2000). Genomic expression programs in the 
response of yeast cells to environmental changes. Mol Biol Cell 11, 4241–
4257. 
Godard, P., Urrestarazu, A., Vissers, S., Kontos, K., Bontempi, G., van Helden, 
J., and André, B. (2007). Effect of 21 different nitrogen sources on global gene 
expression in the yeast Saccharomyces cerevisiae. Mol Cell Biol 27, 3065–
3086. 
Grenson, M., Dubois, E., Piotrowska, M., Drillien, R., and Aigle, M. (1974). 
Ammonia assimilation in Saccharomyces cerevisiae as mediated by the two 
glutamate dehydrogenases. Evidence for the gdhA locus being a structural 
gene for the NADP-dependent glutamate dehydrogenase. Mol. Gen. Genet. 
128, 73–85. 
Grewal, S.S. (2009). Insulin/TOR signaling in growth and homeostasis: A view 
from the fly world. Int J Biochem Cell Biol 41, 1006–1010. 
Groves, M.R., Hanlon, N., Turowski, P., Hemmings, B.A., and Barford, D. 
(1999). The structure of the protein phosphatase 2A PR65/A subunit reveals 
the conformation of its 15 tandemly repeated HEAT motifs. Cell 96, 99–110. 
Guertin, D.A., Stevens, D.M., Thoreen, C.C., Burds, A.A., Kalaany, N.Y., 
Moffat, J., Brown, M., Fitzgerald, K.J., and Sabatini, D.M. (2006). Ablation in 
mice of the mTORC components raptor, rictor, or mLST8 reveals that 
mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. 
Dev Cell 11, 859–871. 
Hall, M.N., and Tamanoi, F. (2010). Structure, Function and Regulation of TOR 
	
  88	
  
complexes from Yeasts to Mammals - Google Books. 
Han, S., Lone, M.A., Schneiter, R., and Chang, A. (2010). Orm1 and Orm2 are 
conserved endoplasmic reticulum membrane proteins regulating lipid 
homeostasis and protein quality control. Proceedings of the National Academy 
of Sciences 107, 5851–5856. 
Hara, K., Yonezawa, K., Weng, Q.P., Kozlowski, M.T., Belham, C., and 
Avruch, J. (1998). Amino acid sufficiency and mTOR regulate p70 S6 kinase 
and eIF-4E BP1 through a common effector mechanism. J Biol Chem 273, 
14484–14494. 
Hardwick, J.S., Kuruvilla, F.G., Tong, J.K., Shamji, A.F., and Schreiber, S.L. 
(1999). Rapamycin-modulated transcription defines the subset of nutrient-
sensitive signaling pathways directly controlled by the Tor proteins. Proc Natl 
Acad Sci USA 96, 14866–14870. 
Hazelwood, L.A., Daran, J.M., van Maris, A.J.A., Pronk, J.T., and Dickinson, 
J.R. (2008). The Ehrlich Pathway for Fusel Alcohol Production: a Century of 
Research on Saccharomyces cerevisiae Metabolism. Appl Environ Microbiol 
74, 2259–2266. 
Heinisch, J.J., Lorberg, A., Schmitz, H.P., and Jacoby, J.J. (1999). The protein 
kinase C-mediated MAP kinase pathway involved in the maintenance of 
cellular integrity in Saccharomyces cerevisiae. Mol Microbiol 32, 671–680. 
Heitman, J., Movva, N.R., and Hall, M.N. (1991). Targets for cell cycle arrest 
by the immunosuppressant rapamycin in yeast. Science 253, 905–909. 
Helliwell, S.B., Howald, I., Barbet, N., and Hall, M.N. (1998a). TOR2 is part of 
two related signaling pathways coordinating cell growth in Saccharomyces 
cerevisiae. Genetics 148, 99–112. 
Helliwell, S.B., Schmidt, A., Ohya, Y., and Hall, M.N. (1998b). The Rho1 
effector Pkc1, but not Bni1, mediates signalling from Tor2 to the actin 
cytoskeleton. Curr Biol 8, 1211–1214. 
Helliwell, S.B., Wagner, P., Kunz, J., Deuter-Reinhard, M., Henriquez, R., and 
Hall, M.N. (1994). TOR1 and TOR2 are structurally and functionally similar but 
not identical phosphatidylinositol kinase homologues in yeast. Mol Biol Cell 5, 
105–118. 
Hernández-Negrete, I., Carretero-Ortega, J., Rosenfeldt, H., Hernández-
García, R., Calderón-Salinas, J.V., Reyes-Cruz, G., Gutkind, J.S., and 
Vázquez-Prado, J. (2007). P-Rex1 links mammalian target of rapamycin 
signaling to Rac activation and cell migration. J Biol Chem 282, 23708–23715. 
Hofman-Bang, J. (1999). Nitrogen catabolite repression in Saccharomyces 
cerevisiae. Mol. Biotechnol. 12, 35–73. 
	
   89	
  
Holz, M.K., and Blenis, J. (2005). Identification of S6 kinase 1 as a novel 
mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 
280, 26089–26093. 
Huber, A., Bodenmiller, B., Uotila, A., Stahl, M., Wanka, S., Gerrits, B., 
Aebersold, R., and Loewith, R. (2009). Characterization of the rapamycin-
sensitive phosphoproteome reveals that Sch9 is a central coordinator of 
protein synthesis. Genes Dev 23, 1929–1943. 
Huber, A., French, S.L., Tekotte, H., Yerlikaya, S., Stahl, M., Perepelkina, 
M.P., Tyers, M., Rougemont, J., Beyer, A.L., and Loewith, R. (2011). Sch9 
regulates ribosome biogenesis via Stb3, Dot6 and Tod6 and the histone 
deacetylase complex RPD3L. Embo J 30, 3052–3064. 
Jacinto, E., and Hall, M.N. (2003). Tor signalling in bugs, brain and brawn. Nat 
Rev Mol Cell Biol 4, 117–126. 
Jacinto, E., and Lorberg, A. (2008). TOR regulation of AGC kinases in yeast 
and mammals. Biochem J 410, 19–37. 
Jacinto, E., Guo, B., Arndt, K.T., Schmelzle, T., and Hall, M.N. (2001). TIP41 
interacts with TAP42 and negatively regulates the TOR signaling pathway. 
Molecular Cell 8, 1017–1026. 
Jazwinski, S.M., and Kriete, A. (2012). The yeast retrograde response as a 
model of intracellular signaling of mitochondrial dysfunction. Front Physiol 3, 
139. 
Jiang, Y., and Broach, J.R. (1999). Tor proteins and protein phosphatase 2A 
reciprocally regulate Tap42 in controlling cell growth in yeast. Embo J 18, 
2782–2792. 
John, F., Roffler, S., Wicker, T., and Ringli, C. (2011). Plant TOR signaling 
components. Psb 6, 1700–1705. 
Jorgensen, P., Nishikawa, J.L., Breitkreutz, B.-J., and Tyers, M. (2002). 
Systematic identification of pathways that couple cell growth and division in 
yeast. Science 297, 395–400. 
Jorgensen, P., Rupes, I., Sharom, J.R., Schneper, L., Broach, J.R., and Tyers, 
M. (2004). A dynamic transcriptional network communicates growth potential 
to ribosome synthesis and critical cell size. Genes Dev 18, 2491–2505. 
Kaeberlein, M., Powers, R.W., Steffen, K.K., Westman, E.A., Hu, D., Dang, N., 
Kerr, E.O., Kirkland, K.T., Fields, S., and Kennedy, B.K. (2005). Regulation of 
yeast replicative life span by TOR and Sch9 in response to nutrients. Science 
310, 1193–1196. 
Kamada, Y. (2010). Prime-numbered Atg proteins act at the primary step in 
autophagy: unphosphorylatable Atg13 can induce autophagy without TOR 
	
  90	
  
inactivation. Autophagy 6, 415–416. 
Kamada, Y., Fujioka, Y., Suzuki, N.N., Inagaki, F., Wullschleger, S., Loewith, 
R., Hall, M.N., and Ohsumi, Y. (2005). Tor2 directly phosphorylates the AGC 
kinase Ypk2 to regulate actin polarization. Mol Cell Biol 25, 7239–7248. 
Kamada, Y., Yoshino, K.-I., Kondo, C., Kawamata, T., Oshiro, N., Yonezawa, 
K., and Ohsumi, Y. (2010). Tor directly controls the Atg1 kinase complex to 
regulate autophagy. Mol Cell Biol 30, 1049–1058. 
Kim, D.H., and Sabatini, D.M. (2004). Raptor and mTOR: subunits of a 
nutrient-sensitive complex. Curr. Top. Microbiol. Immunol. 279, 259–270. 
Kim, D.-H., Sarbassov, D.D., Ali, S.M., King, J.E., Latek, R.R., Erdjument-
Bromage, H., Tempst, P., and Sabatini, D.M. (2002). mTOR interacts with 
raptor to form a nutrient-sensitive complex that signals to the cell growth 
machinery. Cell 110, 163–175. 
Kim, D.-H., Sarbassov, D.D., Ali, S.M., Latek, R.R., Guntur, K.V.P., Erdjument-
Bromage, H., Tempst, P., and Sabatini, D.M. (2003). GbetaL, a positive 
regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive 
interaction between raptor and mTOR. Molecular Cell 11, 895–904. 
Kim, E., Goraksha-Hicks, P., Li, L., Neufeld, T.P., and Guan, K.-L. (2008). 
Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol 10, 
935–945. 
Klosinska, M.M., Crutchfield, C.A., Bradley, P.H., Rabinowitz, J.D., and 
Broach, J.R. (2011). Yeast cells can access distinct quiescent states. Genes 
Dev 25, 336–349. 
Kogan, K., Spear, E.D., Kaiser, C.A., and Fass, D. (2010). Structural 
Conservation of Components in the Amino Acid Sensing Branch of the TOR 
Pathway in Yeast and Mammals. Journal of Molecular Biology. 
Komeili, A., Wedaman, K.P., O'Shea, E.K., and Powers, T. (2000). Mechanism 
of metabolic control. Target of rapamycin signaling links nitrogen quality to the 
activity of the Rtg1 and Rtg3 transcription factors. J Cell Biol 151, 863–878. 
Kunz, J., Henriquez, R., Schneider, U., Deuter-Reinhard, M., Movva, N.R., and 
Hall, M.N. (1993). Target of rapamycin in yeast, TOR2, is an essential 
phosphatidylinositol kinase homolog required for G1 progression. Cell 73, 
585–596. 
Kunz, J., Schneider, U., Howald, I., Schmidt, A., and Hall, M.N. (2000). HEAT 
repeats mediate plasma membrane localization of Tor2p in yeast. J Biol Chem 
275, 37011–37020. 
Lamming, D.W., Ye, L., Sabatini, D.M., and Baur, J.A. (2013). Rapalogs and 
mTOR inhibitors as anti-aging therapeutics. J Clin Invest 123, 980–989. 
	
   91	
  
Laplante, M., and Sabatini, D.M. (2012). mTOR signaling in growth control and 
disease. Cell 149, 274–293. 
Lee, T.I., Rinaldi, N.J., Robert, F., Odom, D.T., Bar-Joseph, Z., Gerber, G.K., 
Hannett, N.M., Harbison, C.T., Thompson, C.M., Simon, I., et al. (2002). 
Transcriptional regulatory networks in Saccharomyces cerevisiae. Science 
298, 799–804. 
Lempiäinen, H., Uotila, A., Urban, J., Dohnal, I., Ammerer, G., Loewith, R., and 
Shore, D. (2009). Sfp1 interaction with TORC1 and Mrs6 reveals feedback 
regulation on TOR signaling. Molecular Cell 33, 704–716. 
Li, C., Najafi, H., Daikhin, Y., Nissim, I.B., Collins, H.W., Yudkoff, M., 
Matschinsky, F.M., and Stanley, C.A. (2003). Regulation of leucine-stimulated 
insulin secretion and glutamine metabolism in isolated rat islets. J Biol Chem 
278, 2853–2858. 
Li, H., Tsang, C.K., Watkins, M., Bertram, P.G., and Zheng, X.F.S. (2006). 
Nutrient regulates Tor1 nuclear localization and association with rDNA 
promoter. Nature 442, 1058–1061. 
Liu, Z., and Butow, R.A. (1999). A transcriptional switch in the expression of 
yeast tricarboxylic acid cycle genes in response to a reduction or loss of 
respiratory function. Mol Cell Biol 19, 6720–6728. 
Ljungdahl, P.O., and Daignan-Fornier, B. (2012). Regulation of Amino Acid, 
Nucleotide, and Phosphate Metabolism in Saccharomyces cerevisiae. 
Genetics 190, 885–929. 
Ljungdahl, P.O. (2009). Amino-acid-induced signalling via the SPS-sensing 
pathway in yeast. Biochem Soc Trans 37, 242–247. 
Loewith, R., and Hall, M.N. (2011). Target of rapamycin (TOR) in nutrient 
signaling and growth control. Genetics 189, 1177–1201. 
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J.L., Bonenfant, 
D., Oppliger, W., Jenoe, P., and Hall, M.N. (2002). Two TOR complexes, only 
one of which is rapamycin sensitive, have distinct roles in cell growth control. 
Molecular Cell 10, 457–468. 
Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K., and Avruch, J. (2005a). Rheb 
binds and regulates the mTOR kinase. Curr Biol 15, 702–713. 
Long, X., Ortiz-Vega, S., Lin, Y., and Avruch, J. (2005b). Rheb binding to 
mammalian target of rapamycin (mTOR) is regulated by amino acid 
sufficiency. J Biol Chem 280, 23433–23436. 
Luo, B., Groenke, K., Takors, R., Wandrey, C., and Oldiges, M. (2007). 
Simultaneous determination of multiple intracellular metabolites in glycolysis, 
pentose phosphate pathway and tricarboxylic acid cycle by liquid 
	
  92	
  
chromatography-mass spectrometry. J Chromatogr 1147, 153–164. 
Luo, G., Gruhler, A., Liu, Y., Jensen, O.N., and Dickson, R.C. (2008). The 
sphingolipid long-chain base-Pkh1/2-Ypk1/2 signaling pathway regulates 
eisosome assembly and turnover. J Biol Chem 283, 10433–10444. 
Luo, X., Talarek, N., and De Virgilio, C. (2011). Initiation of the yeast G0 
program requires Igo1 and Igo2, which antagonize activation of decapping of 
specific nutrient-regulated mRNAs. RNA Biol 8, 14–17. 
Magasanik, B. (1992). 6 Regulation of Nitrogen Utilization. Cold Spring Harbor 
Monograph Archive 21B, 283–317. 
Magasanik, B., and Kaiser, C.A. (2002). Nitrogen regulation in Saccharomyces 
cerevisiae. Gene 290, 1–18. 
Marini, A.M., Soussi-Boudekou, S., Vissers, S., and André, B. (1997). A family 
of ammonium transporters in Saccharomyces cerevisiae. Mol Cell Biol 17, 
4282–4293. 
Martin, D.E., Soulard, A., and Hall, M.N. (2004). TOR regulates ribosomal 
protein gene expression via PKA and the Forkhead transcription factor FHL1. 
Cell 119, 969–979. 
Matheos, D.P., Kingsbury, T.J., Ahsan, U.S., and Cunningham, K.W. (1997). 
Tcn1p/Crz1p, a calcineurin-dependent transcription factor that differentially 
regulates gene expression in Saccharomyces cerevisiae. Genes Dev 11, 
3445–3458. 
Miller, S.M., and Magasanik, B. (1990). Role of NAD-linked glutamate 
dehydrogenase in nitrogen metabolism in Saccharomyces cerevisiae. J 
Bacteriol 172, 4927–4935. 
Mitchell, A.P. (1985). The GLN1 locus of Saccharomyces cerevisiae encodes 
glutamine synthetase. Genetics 111, 243–258. 
Mitchell, A.P., and Magasanik, B. (1983). Purification and properties of 
glutamine synthetase from Saccharomyces cerevisiae. J Biol Chem 258, 119–
124. 
Mueller, P.P., and Hinnebusch, A.G. (1986). Multiple upstream AUG codons 
mediate translational control of GCN4. Cell 45, 201–207. 
Mulet, J.M., Martin, D.E., Loewith, R., and Hall, M.N. (2006). Mutual 
antagonism of target of rapamycin and calcineurin signaling. J Biol Chem 281, 
33000–33007. 
Murguía, J.R., and Serrano, R. (2012). New functions of protein kinase Gcn2 
in yeast and mammals. IUBMB Life. 
	
   93	
  
Nakashima, A., Maruki, Y., Imamura, Y., Kondo, C., Kawamata, T., Kawanishi, 
I., Takata, H., Matsuura, A., Lee, K.S., Kikkawa, U., et al. (2008). The yeast 
Tor signaling pathway is involved in G2/M transition via polo-kinase. PLoS 
ONE 3, e2223. 
Neklesa, T.K., and Davis, R.W. (2009). A genome-wide screen for regulators 
of TORC1 in response to amino acid starvation reveals a conserved Npr2/3 
complex. PLoS Genet 5, e1000515. 
Nelissen, B., De Wachter, R., and Goffeau, A. (1997). Classification of all 
putative permeases and other membrane plurispanners of the major facilitator 
superfamily encoded by the complete genome of Saccharomyces cerevisiae. 
FEMS Microbiology Reviews 21, 113–134. 
Niles, B.J., Mogri, H., Hill, A., Vlahakis, A., and Powers, T. (2012). Plasma 
membrane recruitment and activation of the AGC kinase Ypk1 is mediated by 
target of rapamycin complex 2 (TORC2) and its effector proteins Slm1 and 
Slm2. Proceedings of the National Academy of Sciences 109, 1536–1541. 
Nobukuni, T., Joaquin, M., Roccio, M., Dann, S.G., Kim, S.Y., Gulati, P., 
Byfield, M.P., Backer, J.M., Natt, F., Bos, J.L., et al. (2005). Amino acids 
mediate mTOR/raptor signaling through activation of class 3 
phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci USA 102, 14238–14243. 
Noda, T., and Ohsumi, Y. (1998). Tor, a phosphatidylinositol kinase 
homologue, controls autophagy in yeast. J Biol Chem 273, 3963–3966. 
Nojima, H., Tokunaga, C., Eguchi, S., Oshiro, N., Hidayat, S., Yoshino, K.-I., 
Hara, K., Tanaka, N., Avruch, J., and Yonezawa, K. (2003). The mammalian 
target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 
S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 
278, 15461–15464. 
Oka, M., Maruyama, J.-I., Arioka, M., Nakajima, H., and Kitamoto, K. (2004). 
Molecular cloning and functional characterization of avaB, a gene encoding 
Vam6p/Vps39p-like protein in Aspergillus nidulans. FEMS Microbiology Letters 
232, 113–121. 
Panchaud, N., Péli-Gulli, M.-P., and De Virgilio, C. (2013). Amino acid 
deprivation inhibits TORC1 through a GTPase-activating protein complex for 
the Rag family GTPase Gtr1. Science Signaling 6, ra42. 
Pearce, L.R., Komander, D., and Alessi, D.R. (2010). The nuts and bolts of 
AGC protein kinases. Nat Rev Mol Cell Biol 11, 9–22. 
Peterson, R.T., Beal, P.A., Comb, M.J., and Schreiber, S.L. (2000). FKBP12-
rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 
under translationally repressive conditions. J Biol Chem 275, 7416–7423. 
Peterson, T.R., Laplante, M., Thoreen, C.C., Sancak, Y., Kang, S.A., Kuehl, 
	
  94	
  
W.M., Gray, N.S., and Sabatini, D.M. (2009). DEPTOR is an mTOR inhibitor 
frequently overexpressed in multiple myeloma cells and required for their 
survival. Cell 137, 873–886. 
Powers, T., and Walter, P. (1999). Regulation of ribosome biogenesis by the 
rapamycin-sensitive TOR-signaling pathway in Saccharomyces cerevisiae. Mol 
Biol Cell 10, 987–1000. 
Raymond, C.K., Howald-Stevenson, I., Vater, C.A., and Stevens, T.H. (1992). 
Morphological classification of the yeast vacuolar protein sorting mutants: 
evidence for a prevacuolar compartment in class E vps mutants. Mol Biol Cell 
3, 1389–1402. 
Regenberg, B., Düring-Olsen, L., Kielland-Brandt, M.C., and Holmberg, S. 
(1999). Substrate specificity and gene expression of the amino-acid 
permeases in Saccharomyces cerevisiae. Curr Genet 36, 317–328. 
Reinke, A., Anderson, S., McCaffery, J.M., Yates, J., Aronova, S., Chu, S., 
Fairclough, S., Iverson, C., Wedaman, K.P., and Powers, T. (2004). TOR 
complex 1 includes a novel component, Tco89p (YPL180w), and cooperates 
with Ssd1p to maintain cellular integrity in Saccharomyces cerevisiae. J Biol 
Chem 279, 14752–14762. 
Reinke, A., Chen, J.C.-Y., Aronova, S., and Powers, T. (2006). Caffeine 
targets TOR complex I and provides evidence for a regulatory link between the 
FRB and kinase domains of Tor1p. J Biol Chem 281, 31616–31626. 
Reiter, A., Steinbauer, R., Philippi, A., Gerber, J., Tschochner, H., Milkereit, P., 
and Griesenbeck, J. (2011). Reduction in ribosomal protein synthesis is 
sufficient to explain major effects on ribosome production after short-term TOR 
inactivation in Saccharomyces cerevisiae. Mol Cell Biol 31, 803–817. 
Robaglia, C., Thomas, M., and Meyer, C. (2012). Sensing nutrient and energy 
status by SnRK1 and TOR kinases. Curr Opin Plant Biol 15, 301–307. 
Robinson, J.S., Klionsky, D.J., Banta, L.M., and Emr, S.D. (1988). Protein 
sorting in Saccharomyces cerevisiae: isolation of mutants defective in the 
delivery and processing of multiple vacuolar hydrolases. Mol Cell Biol 8, 4936–
4948. 
Roelants, F.M., Breslow, D.K., Muir, A., Weissman, J.S., and Thorner, J. 
(2011). Protein kinase Ypk1 phosphorylates regulatory proteins Orm1 and 
Orm2 to control sphingolipid homeostasis in Saccharomyces cerevisiae. 
Proceedings of the National Academy of Sciences 108, 19222–19227. 
Rothman, J.H., Howald, I., and Stevens, T.H. (1989). Characterization of 
genes required for protein sorting and vacuolar function in the yeast 
Saccharomyces cerevisiae. Embo J 8, 2057–2065. 
Rudra, D., Zhao, Y., and Warner, J.R. (2005). Central role of Ifh1p-Fhl1p 
	
   95	
  
interaction in the synthesis of yeast ribosomal proteins. Embo J 24, 533–542. 
Sabatini, D.M., Erdjument-Bromage, H., Lui, M., Tempst, P., and Snyder, S.H. 
(1994). RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-
dependent fashion and is homologous to yeast TORs. Cell 78, 35–43. 
Sabers, C.J., Martin, M.M., Brunn, G.J., Williams, J.M., Dumont, F.J., 
Wiederrecht, G., and Abraham, R.T. (1995). Isolation of a protein target of the 
FKBP12-rapamycin complex in mammalian cells. J Biol Chem 270, 815–822. 
Saito, K., Araki, Y., Kontani, K., Nishina, H., and Katada, T. (2005). Novel role 
of the small GTPase Rheb: its implication in endocytic pathway independent of 
the activation of mammalian target of rapamycin. J. Biochem. 137, 423–430. 
Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A.L., Nada, S., and Sabatini, 
D.M. (2010). Ragulator-Rag complex targets mTORC1 to the lysosomal 
surface and is necessary for its activation by amino acids. Cell 141, 290–303. 
Sancak, Y., Peterson, T.R., Shaul, Y.D., Lindquist, R.A., Thoreen, C.C., Bar-
Peled, L., and Sabatini, D.M. (2008). The Rag GTPases bind raptor and 
mediate amino acid signaling to mTORC1. Science 320, 1496–1501. 
Sancak, Y., Thoreen, C.C., Peterson, T.R., Lindquist, R.A., Kang, S.A., 
Spooner, E., Carr, S.A., and Sabatini, D.M. (2007). PRAS40 is an insulin-
regulated inhibitor of the mTORC1 protein kinase. Molecular Cell 25, 903–915. 
Sato, T., Nakashima, A., Guo, L., and Tamanoi, F. (2009). Specific activation 
of mTORC1 by RHEB G-protein in vitro involves enhanced recruitment of its 
substrate protein. J Biol Chem. 
Schalm, S.S., Fingar, D.C., Sabatini, D.M., and Blenis, J. (2003). TOS motif-
mediated raptor binding regulates 4E-BP1 multisite phosphorylation and 
function. Curr Biol 13, 797–806. 
Schawalder, S.B., Kabani, M., Howald, I., Choudhury, U., Werner, M., and 
Shore, D. (2004). Growth-regulated recruitment of the essential yeast 
ribosomal protein gene activator Ifh1. Nature 432, 1058–1061. 
Schmidt, A., Beck, T., Koller, A., Kunz, J., and Hall, M.N. (1998). The TOR 
nutrient signalling pathway phosphorylates NPR1 and inhibits turnover of the 
tryptophan permease. Embo J 17, 6924–6931. 
Schmidt, A., Bickle, M., Beck, T., and Hall, M.N. (1997). The yeast 
phosphatidylinositol kinase homolog TOR2 activates RHO1 and RHO2 via the 
exchange factor ROM2. Cell 88, 531–542. 
Schmidt, A., Kunz, J., and Hall, M.N. (1996). TOR2 is required for organization 
of the actin cytoskeleton in yeast. Proc Natl Acad Sci USA 93, 13780–13785. 
Schneider, C.A., Rasband, W.S., and Eliceiri, K.W. (2012). NIH Image to 
	
  96	
  
ImageJ: 25 years of image analysis. Nat Methods 9, 671–675. 
Schreiber, S.L. (1991). Chemistry and biology of the immunophilins and their 
immunosuppressive ligands. Science 251, 283–287. 
Schure, ter, E.G., Silljé, H.H., Verkleij, A.J., Boonstra, J., and Verrips, C.T. 
(1995). The concentration of ammonia regulates nitrogen metabolism in 
Saccharomyces cerevisiae. J Bacteriol 177, 6672–6675. 
Schure, ter, E.G., van Riel, N.A., and Verrips, C.T. (2000). The role of 
ammonia metabolism in nitrogen catabolite repression in Saccharomyces 
cerevisiae. FEMS Microbiology Reviews 24, 67–83. 
Sehgal, S.N., Baker, H., and Vézina, C. (1975). Rapamycin (AY-22,989), a 
new antifungal antibiotic. II. Fermentation, isolation and characterization. J. 
Antibiot. 28, 727–732. 
Shamji, A.F., Kuruvilla, F.G., and Schreiber, S.L. (2000). Partitioning the 
transcriptional program induced by rapamycin among the effectors of the Tor 
proteins. Curr Biol 10, 1574–1581. 
Shimobayashi, M., Oppliger, W., Moes, S., Jenö, P., and Hall, M.N. (2013). 
TORC1-regulated protein kinase Npr1 phosphorylates Orm to stimulate 
complex sphingolipid synthesis. Mol Biol Cell 24, 870–881. 
Shin, C.-S., Kim, S.Y., and Huh, W.-K. (2009). TORC1 controls degradation of 
the transcription factor Stp1, a key effector of the SPS amino-acid-sensing 
pathway in Saccharomyces cerevisiae. J Cell Sci 122, 2089–2099. 
Smets, B., Ghillebert, R., De Snijder, P., Binda, M., Swinnen, E., De Virgilio, 
C., and Winderickx, J. (2010). Life in the midst of scarcity: adaptations to 
nutrient availability in Saccharomyces cerevisiae. Curr Genet 56, 1–32. 
Soetens, O., de Craene, J.O., and André, B. (2001). Ubiquitin is required for 
sorting to the vacuole of the yeast general amino acid permease, Gap1. J Biol 
Chem 276, 43949–43957. 
Soulard, A., Cohen, A., and Hall, M.N. (2009). TOR signaling in invertebrates. 
Curr Opin Cell Biol 21, 825–836. 
Soulard, A., Cremonesi, A., Moes, S., Schütz, F., Jenö, P., and Hall, M.N. 
(2010). The rapamycin-sensitive phosphoproteome reveals that TOR controls 
protein kinase A toward some but not all substrates. Mol Biol Cell 21, 3475–
3486. 
Staschke, K.A., Dey, S., Zaborske, J.M., Palam, L.R., McClintick, J.N., Pan, T., 
Edenberg, H.J., and Wek, R.C. (2010). Integration of general amino acid 
control and target of rapamycin (TOR) regulatory pathways in nitrogen 
assimilation in yeast. Journal of Biological Chemistry 285, 16893–16911. 
	
   97	
  
Sturgill, T.W., and Hall, M.N. (2009). Activating mutations in TOR are in similar 
structures as oncogenic mutations in PI3KCalpha. ACS Chem. Biol. 4, 999–
1015. 
Sturgill, T.W., Cohen, A., Diefenbacher, M., Trautwein, M., Martin, D.E., and 
Hall, M.N. (2008). TOR1 and TOR2 have distinct locations in live cells. 
Eukaryotic Cell 7, 1819–1830. 
Sun, Y., Miao, Y., Yamane, Y., Zhang, C., Shokat, K.M., Takematsu, H., 
Kozutsumi, Y., and Drubin, D.G. (2012). Orm protein phosphoregulation 
mediates transient sphingolipid biosynthesis response to heat stress via the 
Pkh-Ypk and Cdc55-PP2A pathways. Mol Biol Cell 23, 2388–2398. 
Takahara, T., Hara, K., Yonezawa, K., Sorimachi, H., and Maeda, T. (2006). 
Nutrient-dependent multimerization of the mammalian target of rapamycin 
through the N-terminal HEAT repeat region. J Biol Chem 281, 28605–28614. 
Takahashi, K., Nakagawa, M., Young, S.G., and Yamanaka, S. (2005). 
Differential membrane localization of ERas and Rheb, two Ras-related proteins 
involved in the phosphatidylinositol 3-kinase/mTOR pathway. J Biol Chem 280, 
32768–32774. 
Talarek, N., Cameroni, E., Jaquenoud, M., Luo, X., Bontron, S., Lippman, S., 
Devgan, G., Snyder, M., Broach, J.R., and De Virgilio, C. (2010). Initiation of 
the TORC1-regulated G0 program requires Igo1/2, which license specific 
mRNAs to evade degradation via the 5“-3” mRNA decay pathway. Molecular 
Cell 38, 345–355. 
Tate, J.J., and Cooper, T.G. (2003). Tor1/2 regulation of retrograde gene 
expression in Saccharomyces cerevisiae derives indirectly as a consequence 
of alterations in ammonia metabolism. J Biol Chem 278, 36924–36933. 
Tate, J.J., Georis, I., Dubois, E., and Cooper, T.G. (2010). Distinct 
phosphatase requirements and GATA factor responses to nitrogen catabolite 
repression and rapamycin treatment in Saccharomyces cerevisiae. J Biol 
Chem 285, 17880–17895. 
Tate, J.J., Georis, I., Feller, A., Dubois, E., and Cooper, T.G. (2009). 
Rapamycin-induced Gln3 dephosphorylation is insufficient for nuclear 
localization: Sit4 and PP2A phosphatases are regulated and function 
differently. J Biol Chem 284, 2522–2534. 
Tato, I., Bartrons, R., Ventura, F., and Rosa, J.L. (2011). Amino Acids Activate 
Mammalian Target of Rapamycin Complex 2 (mTORC2) via PI3K/Akt 
Signaling. J Biol Chem 286, 6128–6142. 
Tennant, D.A., Durán, R.V., Boulahbel, H., and Gottlieb, E. (2009). Metabolic 
transformation in cancer. Carcinogenesis 30, 1269–1280. 
Thevelein, J.M., and De Winde, J.H. (1999). Novel sensing mechanisms and 
	
  98	
  
targets for the cAMP-protein kinase A pathway in the yeast Saccharomyces 
cerevisiae. Mol Microbiol 33, 904–918. 
Thomson, A.W., and Woo, J. (1989). Immunosuppressive properties of FK-506 
and rapamycin. Lancet 2, 443–444. 
Tocci, M.J., Matkovich, D.A., Collier, K.A., Kwok, P., Dumont, F., Lin, S., 
Degudicibus, S., Siekierka, J.J., Chin, J., and Hutchinson, N.I. (1989). The 
immunosuppressant FK506 selectively inhibits expression of early T cell 
activation genes. J Immunol 143, 718–726. 
Toda, T., Cameron, S., Sass, P., and Wigler, M. (1988). SCH9, a gene of 
Saccharomyces cerevisiae that encodes a protein distinct from, but 
functionally and structurally related to, cAMP-dependent protein kinase 
catalytic subunits. Genes Dev 2, 517–527. 
Torres, J., Di Como, C.J., Herrero, E., and La Torre-Ruiz, De, M.A. (2002). 
Regulation of the cell integrity pathway by rapamycin-sensitive TOR function in 
budding yeast. J Biol Chem 277, 43495–43504. 
Tschochner, H., and Hurt, E. (2003). Pre-ribosomes on the road from the 
nucleolus to the cytoplasm. Trends in Cell Biology 13, 255–263. 
Umekawa, M., and Klionsky, D.J. (2012). Ksp1 kinase regulates autophagy via 
the target of rapamycin complex 1 (TORC1) pathway. Journal of Biological 
Chemistry 287, 16300–16310. 
Urban, J., Soulard, A., Huber, A., Lippman, S., Mukhopadhyay, D., Deloche, 
O., Wanke, V., Anrather, D., Ammerer, G., Riezman, H., et al. (2007). Sch9 is 
a major target of TORC1 in Saccharomyces cerevisiae. Molecular Cell 26, 
663–674. 
van der Plaat, J.B. (1974). Cyclic 3',5‘-adenosine monophosphate stimulates 
trehalose degradation in baker’s yeast. Biochemical and Biophysical Research 
Communications 56, 580–587. 
Vander Haar, E., Lee, S.-I., Bandhakavi, S., Griffin, T.J., and Kim, D.-H. 
(2007). Insulin signalling to mTOR mediated by the Akt/PKB substrate 
PRAS40. Nat Cell Biol 9, 316–323. 
Vézina, C., Kudelski, A., and Sehgal, S.N. (1975). Rapamycin (AY-22,989), a 
new antifungal antibiotic. I. Taxonomy of the producing streptomycete and 
isolation of the active principle. J. Antibiot. 28, 721–726. 
Vinayak, S., and Carlson, R.W. (2013). mTOR inhibitors in the treatment of 
breast cancer. Oncology (Williston Park, N.Y.) 27, 38–44–46–48passim. 
Wade, J.T., Hall, D.B., and Struhl, K. (2004). The transcription factor Ifh1 is a 
key regulator of yeast ribosomal protein genes. Nature 432, 1054–1058. 
	
   99	
  
Walther, T.C., Aguilar, P.S., Fröhlich, F., Chu, F., Moreira, K., Burlingame, 
A.L., and Walter, P. (2007). Pkh-kinases control eisosome assembly and 
organization. Embo J 26, 4946–4955. 
Walther, T.C., Brickner, J.H., Aguilar, P.S., Bernales, S., Pantoja, C., and 
Walter, P. (2006). Eisosomes mark static sites of endocytosis. Nature 439, 
998–1003. 
Wang, H., and Jiang, Y. (2003). The Tap42-protein phosphatase type 2A 
catalytic subunit complex is required for cell cycle-dependent distribution of 
actin in yeast. Mol Cell Biol 23, 3116–3125. 
Wang, L., Rhodes, C.J., and Lawrence, J.C. (2006). Activation of mammalian 
target of rapamycin (mTOR) by insulin is associated with stimulation of 4EBP1 
binding to dimeric mTOR complex 1. J Biol Chem 281, 24293–24303. 
Wang, X., Campbell, L.E., Miller, C.M., and Proud, C.G. (1998). Amino acid 
availability regulates p70 S6 kinase and multiple translation factors. Biochem J 
334 ( Pt 1), 261–267. 
Wanke, V., Cameroni, E., Uotila, A., Piccolis, M., Urban, J., Loewith, R., and 
De Virgilio, C. (2008). Caffeine extends yeast lifespan by targeting TORC1. 
Mol Microbiol 69, 277–285. 
Wanke, V., Pedruzzi, I., Cameroni, E., Dubouloz, F., and De Virgilio, C. (2005). 
Regulation of G0 entry by the Pho80-Pho85 cyclin-CDK complex. Embo J 24, 
4271–4278. 
Warner, J.R. (1999). The economics of ribosome biosynthesis in yeast. Trends 
in Biochemical Sciences 24, 437–440. 
Wedaman, K.P., Reinke, A., Anderson, S., Yates, J., McCaffery, J.M., and 
Powers, T. (2003). Tor kinases are in distinct membrane-associated protein 
complexes in Saccharomyces cerevisiae. Mol Biol Cell 14, 1204–1220. 
Wei, Y., and Zheng, X.F.S. (2011). Nutritional control of cell growth via TOR 
signaling in budding yeast. Methods Mol Biol 759, 307–319. 
Wek, R.C., Jackson, B.M., and Hinnebusch, A.G. (1989). Juxtaposition of 
domains homologous to protein kinases and histidyl-tRNA synthetases in 
GCN2 protein suggests a mechanism for coupling GCN4 expression to amino 
acid availability. Proc Natl Acad Sci USA 86, 4579–4583. 
Wolfe, K.H., and Shields, D.C. (1997). Molecular evidence for an ancient 
duplication of the entire yeast genome. Nature 387, 708–713. 
Wong, K.H., Hynes, M.J., and Davis, M.A. (2008). Recent advances in 
nitrogen regulation: a comparison between Saccharomyces cerevisiae and 
filamentous fungi. Eukaryotic Cell 7, 917–925. 
	
  100	
  
Wu, L., Mashego, M.R., van Dam, J.C., Proell, A.M., Vinke, J.L., Ras, C., van 
Winden, W.A., van Gulik, W.M., and Heijnen, J.J. (2005). Quantitative analysis 
of the microbial metabolome by isotope dilution mass spectrometry using 
uniformly 13C-labeled cell extracts as internal standards. Anal Biochem 336, 
164–171. 
Wu, X., and Tu, B.P. (2011). Selective regulation of autophagy by the Iml1-
Npr2-Npr3 complex in the absence of nitrogen starvation. Mol Biol Cell 22, 
4124–4133. 
Wullschleger, S., Loewith, R., and Hall, M.N. (2006). TOR signaling in growth 
and metabolism. Cell 124, 471–484. 
Wullschleger, S., Loewith, R., Oppliger, W., and Hall, M.N. (2005). Molecular 
organization of target of rapamycin complex 2. J Biol Chem 280, 30697–
30704. 
Wurmser, A.E., Sato, T.K., and Emr, S.D. (2000). New component of the 
vacuolar class C-Vps complex couples nucleotide exchange on the Ypt7 
GTPase to SNARE-dependent docking and fusion. J Cell Biol 151, 551–562. 
Yan, G., Shen, X., and Jiang, Y. (2006). Rapamycin activates Tap42-
associated phosphatases by abrogating their association with Tor complex 1. 
Embo J 25, 3546–3555. 
Yip, C.K., Murata, K., Walz, T., Sabatini, D.M., and Kang, S.A. (2010). 
Structure of the human mTOR complex I and its implications for rapamycin 
inhibition. Molecular Cell 38, 768–774. 
Yonezawa, K., Tokunaga, C., Oshiro, N., and Yoshino, K.-I. (2004). Raptor, a 
binding partner of target of rapamycin. Biochemical and Biophysical Research 
Communications 313, 437–441. 
Zaborske, J.M., Narasimhan, J., Jiang, L., Wek, S.A., Dittmar, K.A., Freimoser, 
F., Pan, T., and Wek, R.C. (2009). Genome-wide analysis of tRNA charging 
and activation of the eIF2 kinase Gcn2p. Journal of Biological Chemistry 284, 
25254–25267. 
Zaborske, J.M., Wu, X., Wek, R.C., and Pan, T. (2010). Selective control of 
amino acid metabolism by the GCN2 eIF2 kinase pathway in Saccharomyces 
cerevisiae. BMC Biochem. 11, 29. 
Zaman, S., Lippman, S.I., Schneper, L., Slonim, N., and Broach, J.R. (2009). 
Glucose regulates transcription in yeast through a network of signaling 
pathways. Mol Syst Biol 5, 245. 
Zaragoza, D., Ghavidel, A., Heitman, J., and Schultz, M.C. (1998). Rapamycin 
induces the G0 program of transcriptional repression in yeast by interfering 
with the TOR signaling pathway. Mol Cell Biol 18, 4463–4470. 
	
   101	
  
Zhang, G., Yang, P., Guo, P., Miele, L., Sarkar, F.H., Wang, Z., and Zhou, Q. 
(2013). Biochimica et Biophysica Acta. BBA - Reviews on Cancer 1836, 49–
59. 
Zhang, Y., Billington, C.J., Pan, D., and Neufeld, T.P. (2006). Drosophila target 
of rapamycin kinase functions as a multimer. Genetics 172, 355–362. 
Zheng, L., Baumann, U., and Reymond, J.-L. (2004). An efficient one-step site-
directed and site-saturation mutagenesis protocol. Nucleic Acids Res 32, e115. 
Zheng, X.F., Florentino, D., Chen, J., Crabtree, G.R., and Schreiber, S.L. 
(1995). TOR kinase domains are required for two distinct functions, only one of 
which is inhibited by rapamycin. Cell 82, 121–130. 
Zheng, Y., and Jiang, Y. (2005). The yeast phosphotyrosyl phosphatase 
activator is part of the Tap42-phosphatase complexes. Mol Biol Cell 16, 2119–
2127. 
Zinzalla, V., Graziola, M., Mastriani, A., Vanoni, M., and Alberghina, L. (2007). 
Rapamycin-mediated G1 arrest involves regulation of the Cdk inhibitor Sic1 in 
Saccharomyces cerevisiae. Mol Microbiol 63, 1482–1494. 
Zinzalla, V., Stracka, D., Oppliger, W., and Hall, M.N. (2011). Activation of 
mTORC2 by association with the ribosome. Cell 144, 757–768. 
Zoncu, R., Bar-Peled, L., Efeyan, A., Wang, S., Sancak, Y., and Sabatini, D.M. 
(2011). mTORC1 senses lysosomal amino acids through an inside-out 
mechanism that requires the vacuolar H⁷-ATPase. Science 334, 678–683. 
 
  
	
  102	
  
  
	
   103	
  
Daniele Stracka 
 
 	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
WORK EXPERIENCE 
January 2015 
Present 
Healthcare Consultant by Executive Insight 
• Focus Area: Market Access, Customer & Market Insights 
• Experience: Value Story development, payor testing and objection 
handling for a pre-launch biologic in the dermatology area 
 
November 2008 
July 2014 
Researcher (PhD and 9 months Postdoctoral Fellow) 
University of Basel, Biozentrum: Laboratory of Professor Michael N Hall  
• Fields of research: broad range of molecular biology, yeast genetics and 
biochemistry approaches to understanding cell growth regulatory 
mechanisms, essential processes deregulated in tumors, with a particular 
focus on TOR (target of rapamycin) pathway. 
• Experienced with mammalian and budding yeast tissue cultures; cloning; 
protein expression and purification; subcellular fractionation; ribosome 
profiling; kinase assay.  
• Extensive computer experience with: Microsoft Office tools; Adobe 
Illustrator and Photoshop; Graphpad Prism; Bioinformatic tools. 
• Teamwork skills developed through successful scientific collaborations 
leading to three publications.  
• Project management: completed Basic Project Management Training 
(SPOL) in January 2014.  
• Participated with oral and written presentations at various scientific 
conferences. 
• Mentor and lecturer for undergraduate students. 
• Theses’ Supervisor: Bachelor (2007) and Master (2011-2012). 
• Member of the PhD Students’ Representatives: Biozentrum PhD Students. 
Representative (2011-2012) with specific responsibilities as Treasurer and 
Yearly PhD Student Retreat Organizer. 
• Transferable skills: logical & innovative entrepreneurial attitudes; quick to 
grasp new concepts; hypothesis driven problem solving; data analysis, 
evaluation & synthesis; planning & organization; attention to relevant 
detail; collaborative teamwork & leadership; communication and internal & 
external presentation skills; mentoring; ability to work under pressure; 
comfortable with ambiguity. 
 
 
 
Date of Birth 11 December 1982 
Nationality Italian 
Address Rotfluhstrasse 63 
 8702 Zollikon, Switzerland  
Email danyk_82@libero.it 
Phone +41 78 656 10 54 
LinkedIn ch.linkedin.com/in/danielestracka/ 
Languages Italian (mother tongue) 
English (fluent) 
German (sound knowledge) 
	
  104	
  
May 2008  
September 2008  
Research Fellow (Postgraduate)  
University of Milano, Bicocca: Laboratory of Professor Massimo Labra 
• Project Title: “Development of DNA molecular markers for varietal 
characterization and traceability of food”.  
• Field of research: plant biology, DNA barcoding.  
• Developed expertise in following areas:  DNA extraction, amplification & 
sequencing; bioinformatics tools for DNA analysis, comparison & 
phylogenesis.  	
  
EDUCATION 
November 2008  
October 2013  
Philosophiæ Doctor in Biochemistry 
University of Basel, Biozentrum: Laboratory of Professor Michael N 
Hall 
Thesis Title: “Upstream regulation of yeast TOR complexes”. 
 
January 2006  
April 2008  
Master of Science in Industrial Biotechnology, major 
Pharmacogenomics  
University of Milano, Bicocca: Laboratory of Professor Marina Vai  
Thesis Title: “Gene expression and histone code in nitrogen starvation in 
Saccharomyces cerevisiae”.  
 
September 2001  
December 2005 
Bachelor of Science in Biotechnology, major Molecular Biotechnology  
University of Milano, Bicocca: Laboratory of Professor Maurizio 
Casiraghi  
Thesis Title: “Bioinformatic tools applied to the analysis of the secretion 
system’s proteins of wolbachia, symbiont of the filarial nematode Dirofilaria 
immitis”.  
 
OTHER ACHIEVEMENTS 
Presentations and 
Publications 
• Oral presentation at the Swiss Yeast Meeting (SYM) 2010. 
• Poster presentations at the Biozentrum Symposium 2013, and 
Biozentrum PhD Students’ Retreat 2009-2012.  
• Stracka D, Jozefczuk S, Rudroff F, Sauer U, Hall MN.  Nitrogen source 
activates TOR (Target Of Rapamycin) complex 1 via glutamine and 
independently of Gtr/Rag proteins. J Biol Chem. 2014 Sep 
5;289(36):25010-20. 
• Betz C, Stracka D, Prescianotto-Baschong C, Frieden M, Demaurex N, 
Hall MN. mTOR complex 2-Akt signaling at mitochondria-associated 
endoplasmic reticulum membranes (MAM) regulates mitochondrial 
physiology. Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12526-34. 
• Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation of mTORC2 by 
association with the ribosome. Cell. 2011 Mar 4;144(5):757-68. 
Awards and 
Honors 
• Research Fellowship, May - September 2008, Einap Regione Lombardia, 
Italy.  
Hobbies and 
Passions 
• Dancing, fitness, squash, travelling, and wine tasting. 
 RECENT INDUSTRY MEMBERSHIPS 
 
• TriNations BioValley 
• Life Science Network Basel 
• Swiss Academy of Pharmaceutical Sciences 	
  
	
   105	
  
	
  
REFEREES 
 
 
 wProf. Dr. Michael Hall, Biozentrum,  
Universitaet Basel, Klingelbergstrasse 50/70 CH-4056 Basel 
Switzerland  
Phone: 0041 61 267 21 50, Fax: 0041 61 267 21 49  
Email: m.hall@unibas.ch 
 
 wProf. Dr. Markus Affolter, Biozentrum,  
Universitaet Basel, Klingelbergstrasse 50/70 CH-4056 Basel 
Switzerland  
Phone: 0041 61 267 20 72, Fax: 0041 61 267 20 78 
Email: markus.affolter@unibas.ch 
  
 wProf. Dr. Uwe Sauer, Institute of Molecular Systems Biology,  
ETH Zurich, Wolfgang-Pauli Str. 16  
CH-8093 Zurich Switzerland 
Phone: 0041 44 633 36 72, Fax: 0041 44 633 10 51 
Email: sauer@imsb.biol.ethz.ch 
 
 wDr. Paul Jenö, Biozentrum Proteomics Core Facility 
Universitaet Basel, Klingelbergstrasse 50/70  
CH-4056 Basel Switzerland  
Phone: 0041 61 267 21 56 
Email: paul.jenoe@unibas.ch 
 
 wProf. Dr. Marina Vai, Dipartimento di Biotecnologie e Bioscienze, 
Univesità degli Studi di Milano-Bicocca, Piazza della Scienza, 2  
MI 20126 Milano Italy  
Phone: 0039 02 6448 3531 
Email: marina.vai@unimib.it 
 
